

PARADIGM MEDICAL INDUSTRIES INC
Form PRE 14A
November 20, 2002

PARADIGM MEDICAL INDUSTRIES, INC.
2355 South 1070 West
Salt Lake City, Utah 84119

PROXY STATEMENT

INFORMATION CONCERNING SOLICITATION AND VOTING

General

The enclosed Proxy is solicited on behalf of the Board of Directors of Paradigm Medical Industries, Inc., a Delaware corporation (the "Company") for use at the Annual Meeting of Shareholders (the "Annual Meeting") to be held on Friday, December 27, 2002, beginning at 10:00 a.m., local time (MST), or at any adjournment(s) thereof. The purposes of the meeting are set forth herein and in the accompanying Notice of Annual Meeting of Shareholders. The Annual Meeting will be held at the Company's corporate headquarters at 2355 South 1070 West, Salt Lake City, Utah. This Proxy Statement and accompanying materials are being mailed on or about November 30, 2002. The Company will bear the cost of this solicitation.

Record Date

Shareholders of record of the Company's Common Stock at the close of business on November 20, 2002 are entitled to notice of and to vote at the meeting. At the record date, 21,948,208 shares of the Company's Common Stock, \$.001 par value, 5,627 shares of the Series A Preferred Stock, 8,986 shares of Series B Preferred Stock, no shares of Series C Convertible Preferred Stock, 5,000 shares of Series D Convertible Preferred Stock, 1,500 shares of Series E Convertible Preferred Stock and 6,273.75 shares of Series F Preferred Stock were issued and outstanding. Shareholders of Series A Series B, Series C, Series D, Series E and Series F Preferred Stock are not entitled to vote at the Annual Meeting. Shareholders holding at least one-third of the outstanding shares of Common Stock represented in person or by proxy, shall constitute a quorum for the transaction of business at the Annual Meeting.

Revocability of Proxies

Shareholders may revoke any appointment of proxy given pursuant to this solicitation by delivering the Company a written notice of revocation or a duly executed proxy bearing a later date or by attending the meeting and voting in person. An appointment of proxy is revoked upon the death or incapacity of the shareholder if the Secretary or other officer of the Company authorized to tabulate votes receives notice of such death or incapacity before the proxy exercises its authority under the appointment.

Voting and Solicitation

Each shareholder will be entitled to one vote for each share of Common Stock held at the record date. Assuming a quorum is present, a plurality of votes cast by the shares entitled to vote in the election of directors will be required to elect each director. Because the shares of Series A, Series B, Series C, Series D, Series E and Series F Preferred Stock are non-voting securities, the holders thereof will not be entitled to vote at the Annual Meeting. To approve the granting of the stock options to the outside directors of the Company, holders of a majority of the shares entitled to vote at the Annual Meeting must vote in favor of the stock options. The principal executive offices of the Company are located at 2355 South 1070 West, Salt Lake City,

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Utah. In addition to the use of the mails, proxies may be solicited personally, by telephone, or by facsimile, and the Company may reimburse brokerage firms and other persons holding shares in the Company in their names or those of their nominees for their reasonable expenses in forwarding soliciting materials to the beneficial owners.

1

ELECTION OF DIRECTORS

Proposal 1

Nominees

The Company's Bylaws do not limit the number of persons serving on the Company's Board of Directors, and it is contemplated that a board of three directors will be elected at the Annual Meeting. The Board of Directors recommends that the shareholders vote "FOR" the election of the three director nominees listed below. Assuming a quorum is present, a plurality of votes cast by the shares entitled to vote in the election of directors will be required to elect each director. Unless otherwise instructed, the proxy holders will vote the proxies received by them for management's four nominees named below, all of whom are presently directors of the Company.

In the event that any management nominee is unable or declines to serve as a director at the time of the Annual Meeting, the proxies will be voted for any nominee who shall be designated by the present Board of Directors to fill the vacancy. In the event that additional persons are nominated as directors, the proxy holders intend to vote all proxies received by them in such a manner as will ensure the election of as many of the nominees listed below as possible. It is not expected that any nominee will be unable or will decline to serve as a director. The term of office of each person elected as a director will continue until the next annual meeting of shareholders and until such person's successor has been elected and qualified. Officers are appointed by the Board of Directors and serve at the discretion of the board.

The name and certain information regarding each nominee as set forth below. See also "Certain Relationships and Related Transactions."

Name	Age	Director Since	Position with the Com
----	---	-----	-----
Randall A. Mackey, Esq.	56	January 2000	Chairman of the Board
Dr. David M. Silver	61	January 2000	Director
Keith D. Ignatz	54	November 2000	Director

The following biographical information is furnished with respect to the three director nominees:

Randall A. Mackey, Esq. has served as Chairman of the Board of the Company since August 30, 2002 and as a director of the Company since January 2000. He had previously served as a director of the Company from November 1995

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

to September 1998. Mr. Mackey has been President of the Salt Lake City law firm of Mackey Price & Thompson since 1992 and a shareholder and a director of the firm and its predecessor firms since 1989. From 1979 to 1989, he practiced law with the Salt Lake City firm of Fabian & Clendenin, where he was a shareholder and a director of the firm from 1982 to 1989. From 1977 to 1979, Mr. Mackey was associated with the Washington D.C. law firm of Hogan & Hartson. Mr. Mackey received a B.S. degree in Economics from the University of Utah in 1968, an M.B.A. degree from Harvard University in 1970, a J.D. degree from Columbia University in 1975, and a B.C.L. degree from Oxford University in 1977. Mr. Mackey has served as Chairman of the Board since June 2001 and a director since 1998 of Cimatrix, Incorporated, a software development company. Mr. Mackey has also served as a Chairman of the Board since July 2000 and a trustee since 1993 of Salt Lake Community College.

David M. Silver, Ph.D. has served as a director of the Company since January 2000. He had previously served as a director of the Company from November 1995 to September 1998. Dr. Silver is a Principal Senior Scientist in the Milton S. Eisenhower Research and Technology Development Center at the Johns Hopkins University Applied Physics Laboratory, where he has been employed since 1970. He served as the J.H. Fitzgerald Dunning Professor of Ophthalmology in the Johns Hopkins Wilmer Eye Institute in Baltimore during 1998-99. He received a B.S. degree from Illinois Institute of Technology, an M.A. degree from Johns Hopkins University, and a Ph.D. degree from Iowa State University before holding a postdoctoral fellowship at Harvard University and a visiting scientist position at the University of Paris.

Keith D. Ignatz has served as a director of the Company since November 2000. Mr. Ignatz is President and Chief Operating Officer of SpectRx, Inc., a medical technology company that he founded in 1992, which develops, manufactures and markets alternatives to traditional blood-based medical tests. From 1986 to 1992, Mr. Ignatz was Senior Vice President of Allergan Humphrey, Inc., a medical electronics company. From 1985 to 1986, he was President of Humphrey Instruments Limited - SKB, a medical electronics company, and from 1980 to 1985, Mr. Ignatz

2

was President of Humphrey Instruments GMBH, also a medical electronics company. Mr. Ignatz also served on the Board of Directors of Vismed, Inc., d/b/a Dicon from 1992 to June 2000. Mr. Ignatz received a B.A. degree in Sociology and Political Science from San Jose University and an M.B.A. degree from Pepperdine University. He has served as a trustee of Pennsylvania College of Optometry since 1990, as a director of FluorX, Inc. since 1997, and as a member of the American Marketing Association of the American Association of Diabetes Education.

Board Meetings and Committees Board Meetings and Committees

The Board of Directors held a total of six meetings during the fiscal year ended December 31, 2001. The Audit Committee of the Board of Directors currently consists of directors Randall A. Mackey, Dr. David M. Silver and Keith D. Ignatz. The Audit Committee is primarily responsible for reviewing the services performed by the Company's independent public accountants and internal audit department and evaluating the Company's accounting practices and procedures and its system of internal accounting controls. The Compensation Committee of the Board of Directors currently consists of directors Randall A. Mackey, Dr. David M. Silver and Keith D. Ignatz. The Compensation Committee is primarily responsible for reviewing compensation of executive officers and overseeing the granting of stock options. No director attended fewer than 75% of all meetings of the Board of Directors during the 2001 fiscal year.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Pursuant to the Nasdaq corporate governance requirements recently made applicable to Nasdaq SmallCap Market companies, the Company must have (i) a minimum of two independent directors; (ii) an audit committee with a majority of independent directors; and (iii) an annual shareholders meeting. The Company has and can presently satisfy each of these requirements. Messrs. Silver and Ignatz qualify as independent directors.

Executive Officers

The following sets forth certain information with respect to the executive officers of the Company:

Name ----	Age ---	Title -----
Heber C. Maughan	50	Interim Chief Executive Officer, Vice President Treasurer and Chief Financial Officer
Aziz A. Mohabbat	42	Interim Chief Operating Officer and Vice President Operations

Heber C. Maughan has served as Interim Chief Executive Officer of the Company since August 30, 2002 and Vice President of Finance, Treasurer and Chief Financial Officer of the Company since October 2001. From July 1997 to October 2001, Mr. Maughan served as Controller for Peterbilt of Utah, which sells and services heavy duty trucks. From 1989 to 1997, he was employed by First Health Strategies, Inc., where he served as Vice President of Finance from 1995 to 1997. From 1987 to 1989, Mr. Maughan was the Chief Financial Officer at Standard Optical Company, a regional retail eye care chain. Mr. Maughan received a B.S. degree in Accounting from Oklahoma State University in 1976 and an M.A. degree in Accounting from Brigham Young University in 1977.

Aziz A. Mohabbat has served as Interim Chief Operating Officer of the Company since August 30, 2002 and Vice President of Operations since 2001. From 2000 to 2001, he served as Managing Director of the San Diego Division of the Company and from 1999 to 2000 as its Regulatory Affairs and Quality Assurance Manager. From 1997 to 1999, Mr. Mohabbat served as Operations and Regulatory Affairs and Quality Assurance Manager of Invacare Infusion Systems. From 1989 to 1997, he was Regulatory Affairs and Quality Assurance Manager of Codan U.S., a subsidiary of Codan GmbH, a manufacturer of disposable sterile and non-sterile medical devices. Prior to 1989, Mr. Mohabbat held various management and bioengineering positions in the medical laboratory and diagnostics field in the Eye Care Clinic of the University Hospital - Eppendorf and the General Hospital of Barmbek in Hamburg, Germany. Mr. Mohabbat received a B.S. degree in Medical Laboratory Technology in 1986 from St. George Hospital College in Hamburg, Germany. He is a member of the American Society for Quality.

Executive Compensation

The following table sets forth, for each of the last three fiscal years, the compensation received by Thomas F. Motter, the Company's former Chairman and Chief Executive Officer, and all other executive officers (collectively, the "Named Executive Officers") at December 31, 2001, whose salary and bonus for all services in all capacities exceed \$100,000 for the fiscal year ended December 31, 2001.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

3

Name and Principal Position	Period	Annual Compensation			Awards			Long-Term Com
		Salary (\$)	Bonus (\$)	Other Annual Compensation (\$)	Restricted Stock Awards (\$)	Securities Underlying Options/ SARs (#)	In	
Thomas F. Motter, Chairman of the Board and Chief Executive Officer	2001(1)	\$200,000	\$ 22,380(6)	0	0	925,000(9)		
	2000(2)	178,357	486,113(7)	0	0	0		
	1999(3)	141,208	0	0	0	50,000(10)		
Mark R. Miehle, President and Chief Operating Officer(8)	2001(1)	\$150,000	0	0	0	110,000(8)		
	2000(2)	\$235,201	\$194,000(9)	0	0	150,000(9)		

-
- (1) For the fiscal year ended December 31, 2001.
 - (2) For the fiscal year ended December 31, 2000.
 - (3) For the fiscal year ended December 31, 1999.
 - (4) The amounts under "Other Annual Compensation" for 2001, 2000 and 1999 consist of payments related to the operation of automobiles and/or automobiles and insurance by the named executives.
 - (5) The amounts under "Other Annual Compensation" for 2000 consist of payments related to the residential housing accommodations for the Company's employees, living outside of Utah while they were working at the Company's Corporate headquarters in Salt Lake City, leased from Mr. Motter at \$2,500 per month.
 - (6) The Company awarded Mr. Motter a cash bonus in June 2001.
 - (7) On January 21, 2000, the Board of Directors approved a bonus to Mr. Motter in the form of 38,889 shares of the Company's Common Stock. The bonus was valued at \$486,113 on the basis of the closing bid price of the Company's Common Stock of \$12.50 per share on January 21, 2000, the date the board approved the bonus.
 - (8) On September 11, 2001, the Company granted options to purchase the respective number of shares of the Company's Common Stock at an exercise price of \$2.75 per share.
 - (9) On June 5, 2000, the Board of Directors issued Mr. Miehle 28,500 shares of the Company's Common Stock as a initial bonus as part of his employment agreement. The market price on the date of grant was \$6.8125 per share, and compensation expense in the amount of \$194,000 was recognized. Mr. Miehle was also granted options to purchase 150,000 shares of the Company's Common Stock at an exercise price of \$6.00 per share.
 - (10) On September 10, 1999, the Company granted Mr. Motter options to purchase 50,000 shares of the Company's Common Stock at an exercise price of \$4.00 per share.

The following table sets forth information concerning the exercise of

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

options to acquire shares of the Company's Common Stock by the Named Executive Officers during the fiscal year ended December 31, 2001, as well as the aggregate number and value of unexercised options held by the Named Executive Officers on December 31, 2001.

Aggregated Option/SAR Exercises in Last Fiscal Year and Fiscal Year-End Option/SAR Values

Name	Shares Acquired On Exercise (#)	Value Realized (\$)	Number of Securities Underlying Unexercised Options/SARs At December 31, 2001 (#)		Value of Un- In-the-Money Op- December 31
			Exercisable	Unexercisable	Exercisable
Thomas F. Motter	0	0	787,450	225,000	0
Mark R. Miehle	0	0	62,500	342,000	0

4

Director Compensation

On September 11, 2001, Dr. David M. Silver, Randall A. Mackey and Keith D. Ignatz were each granted options to purchase 125,000 shares of the Company's Common Stock at an exercise price of \$2.75 per share, of which options to purchase 31,250 shares of Common Stock were vested on September 11, 2001, with options to purchase 31,250 shares of Common Stock to be vested at the end of each three month period thereafter until all such options are vested. On September 11, 2001, Dr. David M. Silver and Randall A. Mackey also were each granted options to purchase 200,000 shares of the Company's Common Stock at an exercise price of \$2.75 per share in consideration for past services as directors of the Company from November 1995 to September 1998 and since January 2000. In addition, outside directors are also reimbursed for their expenses in attending board and committee meetings. Directors are not precluded from serving the Company in any other capacity and receiving compensation therefor. The options were not issued at a discount to the then market price.

Employee 401(k) Plan

In October 1996, the Company's Board of Directors adopted a 401(k) Retirement Savings Plan. Under the terms of the 401(k) plan, effective as of November 1, 1996, the Company may make discretionary employer matching contributions to its employees who choose to participate in the plan. The plan allows the board to determine the amount of the contribution at the beginning of each year. The board adopted a contribution formula specifying that such discretionary employer matching contributions would equal 100% of the participating employee's contribution to the plan up to a maximum discretionary employee contribution of 3% of a participating employee's compensation, as defined by the plan. All persons who have completed at least six months' service with the Company and satisfy other plan requirements are eligible to participate in the 401(k) plan.

1995 Stock Option Plan

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

The Company adopted a 1995 Stock Option Plan (the "Plan") for officers, employees, and consultants of the Company on November 7, 1995. The Plan authorized the granting of stock options ("Plan Options") to purchase an aggregate of not more than 300,000 shares of the Company's Common Stock. On February 16, 1996, options for all 300,000 shares were granted. On June 9, 1997, the Company's shareholders approved an amendment to the Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 300,000 shares to 600,000 shares. On September 3, 1998, the Company's shareholders approved an amendment to the Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 600,000 shares to 1,200,000 shares. On November 29, 2000, the Company's shareholders approved an amendment to the Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 1,200,000 shares to 1,700,000 shares. On September 11, 2001, the Company's shareholders approved an amendment to the Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 1,700,000 shares to 2,700,000 shares.

The Plan is administered by the Compensation Committee. In general, the Compensation Committee will select the person to whom options will be granted and will determine, subject to the terms of the Plan, the number, exercise, and other provisions of such options. Options granted under the Plan will become exercisable at such times as may be determined by the Compensation Committee. Plan Options granted may be either incentive stock options ("ISOs"), as such term is defined in the Internal Revenue Code, or non-ISOs. ISOs may only be granted to persons who are employees of the Company. Non-ISOs may be granted to any person, including, but not limited to, employees of the Company, independent agents, consultants, as the Compensation Committee believes has contributed, or will contribute, to the success of the Company. The Compensation Committee shall determine the exercise price of options granted under the Plan, provided that, in the case of ISOs, such price may not be less than 100% (110% in the case of ISOs granted to holders of 10% of voting power of the Company's stock) of the fair market value (as defined in the Plan) of the Common Stock on the date of grant. The aggregate fair market value (determined at the time of option grant) of stock with respect to which ISOs become exercisable for the first time in any year cannot exceed \$100,000.

The term of each Option shall not be more than 10 years (five years in the case of ISOs granted to holders of 10% of the voting power of the Company's stock) from the date of grant. The Board of Directors has a right to amend, suspend or terminate the Plan at any time; provided, however, that unless ratified by the Company's shareholders, no amendment or change in the Plan will be effective which would increase the total number of shares which may be issued under the Plan, materially increase the benefits accruing to persons granted under the Plan or materially modify the requirements as to eligibility and participation in the Plan. No amendment, supervision or termination of the Plan

5

shall, without the consent of an employee to whom an option shall heretofore have been granted, affect the rights of such employee under such option.

Employment Agreements

The Company entered into an employment agreement with Thomas F. Motter which commenced on January 1, 1998 and will expire on December 31, 2003. The agreement requires Mr. Motter to devote substantially all of his working time to the Company, provided that he may be terminated for "cause" (as provided in the

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

agreement) and prohibits him from competing with the Company for two years following the termination of his employment agreement. The agreement provides for the payment of an initial annual base salary of \$135,000, effective as of January 1, 1998. The agreement also provides for salary increases and bonuses as shall be determined at the discretion of the Board of Directors. Effective as of October 1, 1999, the Board of Directors approved an increase in Mr. Motter's annual base salary to \$160,000, and effective as of July 1, 2000, the board approved an increase in his annual base salary to \$200,000.

The Company entered into an employment agreement with Mark R. Miehle, which commenced on June 5, 2000 and will expire on June 4, 2003. The agreement requires Mr. Miehle to devote substantially all of his working time to the Company, provided that he may be terminated for "cause" (as provided in the agreement) and prohibits him from competing with the Company for two years following the termination of his employment agreement. The agreement provides for the payment of an initial annual base salary of \$150,000, effective as of June 5, 2000, and the issuance of stock options to purchase 150,000 shares of the Company's Common Stock at \$6.00 per share, to be vested in equal annual amounts over a three year period. The agreement also provides for salary increases and bonuses as shall be determined at the discretion of the Board of Directors. On August 30, 2002, the Board of Directors terminated the employment agreement with Mr. Miehle, effective as of that date, and entered into a consulting agreement with Mr. Miehle.

Limitation of Liability and Indemnification

The Company reincorporated in Delaware in February 1996, in part, to take advantage of certain provisions in Delaware's corporate law relating to limitations on liability of corporate officers and directors. The Company believes that the reincorporation into Delaware, the provisions of its Certificate of Incorporation and Bylaws and the separate indemnification agreements outlined below are necessary to attract and retain qualified persons as directors and officers. The Company's Certificate of Incorporation limits the liability of directors to the maximum extent permitted by Delaware law. This provision is intended to allow the directors the benefit of Delaware General Corporation Law which provides that directors of Delaware corporations may be relieved of monetary liabilities for breach of their fiduciary duties as directors, except under certain circumstances, including breach of their duty of loyalty, acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, unlawful payments of dividends or unlawful stock repurchases or redemptions or any transaction from which the director derived an improper personal benefit. The Company's Bylaws provide that it shall indemnify its officers and directors to the fullest extent provided by Delaware law. The Bylaws authorize the use of indemnification agreements and the Company has entered into such agreements with each of its directors and executive officers.

Certain Relationships and Related Transactions

The information set forth herein describes certain transactions between the Company and certain affiliated parties. Future transactions, if any, will be approved by a majority of the disinterested members of the Company and will be on terms no less favorable to the Company than those that could be obtained from unaffiliated parties.

Patrick M. Kolenik, a director of the Company from November 1997 to January 21, 2000, is President, a director and a 25% shareholder of Win Capital Corp ("Win Capital"), the placement agent for the Company's Series C Convertible Preferred Stock offering, and Steven J. Bayern, a director of the Company from July 26, 1999 to January 21, 2000, is Chairman, a director and a 25% shareholder of Win Capital. Under the terms of an agency agreement with Win Capital, the Company agreed to pay to Win Capital a commission equal to 9% of the aggregate purchase price of the shares sold, or \$269,820. Win Capital was also paid a

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

nonaccountable expense allowance equal to 3% of the aggregate purchase price of the shares sold.

6

The Company has also entered into an agreement with Win Capital dated August 20, 1997, wherein Win Capital agreed to perform unspecified investment banking services for the Company for a two year period, for which the Company agreed to pay Win Capital a monthly retainer of \$2,000 for the first six months of the agreement, \$4,000 per month for the second six months, and \$6,000 per month for the remainder of the agreement. In an agreement entered into in February 1999, Win Capital agreed to accept \$7,500 in cash plus \$60,500 in Common Stock valued at the close of business the day prior to the initial close of the Company's Series D Convertible Preferred stock offering in addition to a \$50,000 finders fee as it related to that offering. In addition, the Company issued warrants to Win Capital to purchase 191,000 shares of Common Stock at an exercise price of \$3.00 per share in connection with the investment banking agreement and additional warrants to purchase 100,000 shares of common stock at \$3.00 per share for services rendered in the private placement of Series C Convertible Preferred Stock.

Prior to the initial closing of the Series D preferred stock offering, the Company borrowed \$75,000 from Cyndel & Co., Inc. ("Cyndel"), of which Messrs. Kolenik and Bayern are each an officer, a director and a 50% shareholder of Cyndel, and \$25,000 from Win Capital. The combined \$100,000 loan bore interest at a rate of 10% per annum, and was paid back at the end of six months. The Company issued warrants to Cyndel to purchase 105,000 shares of Common Stock and warrants to Win Capital to purchase 35,000 shares of Common Stock, both at an exercise price equal to the closing price of the Common Stock on the business day immediately prior to the issuance date of the warrants, or \$2.30 per share, the closing price of the Company's Common Stock on the business day immediately prior to the issue date of the warrants. The Company also entered into a one-year consulting agreement dated January 19, 1999, with Win Capital to provide financial consulting services to the Company in consideration for a fee of \$5,000 per month for the term of the agreement.

In addition, on April 23, 1999, the Company agreed to issue warrants to Cyndel to purchase 75,000 shares of Common Stock at an exercise price equal to \$4.00 per share, upon the condition that Cyndel exercises its warrants to purchase 105,000 shares of Common Stock at \$2.30 per share within 72 hours after receiving notice that a registration statement has become effective registering the shares issuable upon the exercise of the warrants to purchase 105,000 shares of Common Stock at \$2.30 per share. On April 23, 1999, the Company also agreed to issue warrants to Win Capital to purchase 25,000 shares of Common Stock at an exercise price equal to \$4.00 per share, upon the condition that Win Capital exercise its warrants to purchase 35,000 shares of Common Stock at \$2.30 per share within 72 hours after receiving notice that a Registration Statement has become effective registering the shares issuable upon the exercise of the warrants to purchase 35,000 shares of Common Stock at \$2.30 per share.

On October 1, 1999, the Company entered into a consulting agreement with Cyndel, in which Cyndel agreed to perform unspecified investment banking services for the Company for a one-year period, for which the Company agreed to pay Cyndel a monthly retainer of \$8,333.33, plus reimburse Cyndel for any expenses incurred in connection with such investment banking services. The October 1, 1999 consulting agreement was terminated when the Company entered into a new consulting agreement with Cyndel on April 1, 2000. Under the terms of

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

the April 1, 2000 consulting agreement, Cyndel has agreed to perform unspecified investment banking services for the Company for a one-year period, for which the Company agreed to pay Cyndel a monthly retainer of \$16,666.66, plus reimburse Cyndel for any expenses incurred in connection with such investment banking services.

Besides a monthly retainer, the Company has agreed in the April 1, 2000 consulting agreement to pay Cyndel additional compensation of an unspecified amount to be mutually agreed upon if Cyndel brings to the Company a candidate for merger, acquisition, joint venture or other combination or relationship, and the Company enters into a business relationship with such entity. The April 1, 2000 consulting agreement is automatically renewable for additional, successive one-year periods through March 31, 2003, unless either party delivers to the other party on or before January 1 of the contract year written notice of its intent not to renew the agreement.

Randall A. Mackey, Chairman of the Board of the Company since August 30, 2002, and a director of the Company since January 21, 2000, and a former director of the Company from September 1995 to September 3, 1998, is President and a shareholder of the law firm of Mackey Price & Thompson, which rendered legal services to the Company in connection with the Company's public offering and other corporate matters. Legal fees and expenses paid to Mackey Price & Thompson for the fiscal years ended December 31, 2000 and 2001 totaled \$167,022 and \$158,990, respectively.

Thomas F. Motter, Chairman of the Board and Chief Executive Officer of the Company from 1993 to August 30, 2002, leased his former residence, which he still owns, to the Company for \$2,500 per month. The primary use of the residential property was for housing accommodations for the Company's employees

7

living outside of Utah while they were working at the Company's corporate headquarters in Salt Lake City. The Company obtained an appraisal from an independent appraiser which has concluded that the monthly rate of \$2,500 represented the fair market rate for leasing the residential property. The lease agreement was terminated on October 31, 2000.

Report of the Audit Committee

The Company has an Audit Committee consisting of three non-management directors, Randall A. Mackey, Keith D. Ignatz, and Dr. David M. Silver. Each member of the audit committee is considered independent and qualified in accordance with applicable independent director and audit committee listing standards. The Company's Board of Directors has adopted a written charter for the Audit Committee.

During the year 2001, the Audit Committee met two times. The Audit Committee has met with management and discussed the Company's internal controls, the quality of the Company's financial reporting, the results of internal and external audit examinations, and the audited financial statements. In addition, the Audit Committee has met with the Company's independent auditors, Tanner & Co., and discussed all matters required to be discussed by the auditors with the Audit Committee under Statement on Auditing Standards No. 61 (communication with audit committees). The Audit Committee received and discussed with the auditors their annual written report on their independence from the Company and its

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

management, which is made under Independence Standards Board Standard No. 1 (independence discussions with audit committees), and considered with the auditors whether the provision of financial information systems design and implementation and other non-audit services provided by them to the Company during 2001 was compatible with the auditors' independence.

In performing these functions, the Audit Committee acts only in an oversight capacity. In its oversight role, the Audit Committee relies on the work and assurances of the Company's management, which is responsible for the integrity of the Company's internal controls and its financial statements and reports, and the Company's independent auditors, who are responsible for performing an independent audit of the Company's financial statements in accordance with generally accepted auditing standards and for issuing a report on these financial statements.

Pursuant to the reviews and discussions described above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2001, for filing with the Securities and Exchange Commission.

Compliance with Section 16(a) of the Securities and Exchange Act of 1934

Section 16(a) of the Securities Exchange Act of 1934 requires the Company's executive officers, directors and persons who own more than 10% of any class of the Company's Common Stock to file initial reports of ownership and reports of changes of ownership of the Company's Common Stock. Such persons are also required to furnish the Company with copies of all Section 16(a) reports they file.

Based solely on its review of the copies of such reports received by it with respect to fiscal 2001, or written representations from certain reporting persons, the Company believes that all filing requirements applicable to its directors, officers and greater than 10% beneficial owners were complied with, except that Thomas F. Motter, Chairman and Chief Executive Officer from 1993 to August 30, 2002, through an oversight, filed one late stock transaction report covering one transaction, and Dr. David M. Silver, a director of the Company, through an oversight, filed one late stock transaction report covering two transactions. No other late filings occurred during 2001.

Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information with respect to beneficial ownership of the Company's Common Stock as of October 31, 2002 for (i) each executive officer of the Company, (ii) each director, (iii) each person known to the Company to be the beneficial owner of more than 5% of the outstanding shares, and (iv) all directors and officers as a group.

8

Name and Address(1)	Number of Shares	Percent of Ownership(2)
-----	-----	-----
Dr. David M. Silver (3)	505,666	*

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Randall A. Mackey (3)	495,000	*
Keith D. Ignatz (4)	204,560	*
Heber C. Maughan (5)	30,000	*
Aziz Mohabbat (6)	60,000	*
Executive officers and director as a group (5 persons)	1,295,226	6.2%

* Less than 1%.

- (1) The address for Dr. Silver is 17 Avalon Court, Bethesda, Maryland 20816. The address for Mr. Mackey is 1474 Harvard Avenue, Salt Lake City, Utah 84105. The address for Mr. Ignatz is 5597 Fitzpatrick Trace, Norcross, Georgia 30092. The address for Messrs. Maughan and Mohabbat is c/o Paradigm Medical Industries, Inc., 2355 South 1070 West, Salt Lake City, Utah 84119.
- (2) Assumes no exercise of the options described in this Proxy Statement or any other options or any warrants that the Company may have issued and no conversion of outstanding shares of the Company's Series A, Series B, Series C, Series D, Series E and Series F Preferred Stock into shares of Common Stock.
- (3) Includes options granted to each of Dr. Silver and Mr. Mackey to purchase 495,000 shares of Common Stock.
- (4) Includes options granted to Mr. Ignatz to purchase 203,851 shares of Common Stock.
- (5) Includes options granted to Mr. Maughan to purchase 30,000 shares of Common Stock.
- (6) Includes options granted to Mr. Mohabbat to purchase 60,000 shares of Common Stock.

APPROVAL OF INCREASE IN THE NUMBER OF AUTHORIZED SHARES

Proposal 2

The Certificate of Incorporation currently authorizes the issuance of 40,000,000 shares of Common Stock. As of the record date, approximately 21,948,208 shares were issued and outstanding. There have been 6,753 shares of Common Stock set aside and reserved in the event that holders of shares of Series A Preferred Stock elect to convert those shares into shares of Common Stock, 10,783 shares of Common Stock set aside and reserved in the event that holders of shares of Series B Preferred Stock elect to convert those shares into shares of Common Stock, 8,750 shares of Common Stock set aside and reserved in the event that holders of shares of Series D Preferred Stock elect to convert those shares into shares of Common Stock, 80,000 shares of Common Stock set aside and reserved in the event that holders of shares of Series E Preferred Stock elect to convert those shares into shares of Common Stock, and 334,600 shares of Common Stock set aside and reserved in the event that holders of shares of Series F Preferred Stock elect to convert those shares into shares of Common Stock. An additional 2,683,882 shares are available for issuance to officers and employees under the 1995 Stock Option Plan.

As a result of our prior financings, acquisitions and efforts to provide incentives to employees, officers and directors, the Company has issued or reserved for issuance a sufficient amount of its authorized Common Stock. The Board of Directors has determined that it is in the best interest of the Company and its shareholders to amend Article III of the Company's Certificate of Incorporation (the "Amendment") to increase the number of authorized shares of Common Stock of the Company from 40,000,000 to 80,000,000 shares, and hereby solicits the approval of the shareholders of the Amendment. If the shareholders approve the Amendment, the Board of Directors currently intends to file an Amendment to the Company's Certificate of Incorporation reflecting the Amendment

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

with the Secretary of State of the State of Delaware as soon as practicable following such stockholder approval. If Amendment is not approved by the shareholders, Article III of the existing Certificate of Incorporation will continue in effect.

The objective of the increase in the authorized number of shares of Common Stock is to ensure that the Company will have sufficient shares available for future issuances. The Board of Directors believes that it is prudent to increase the authorized number of shares of Common Stock to the proposed levels in order to provide a reserve of shares available for issuance to meet the Company's business needs as they arise. Though the Board of Directors has no immediate plans to issue a significant number of additional shares of Common Stock, such future business needs may include, without limitation, funding future financings and acquisitions and providing equity incentives to the Company's officers and employees.

9

Possible Effects of Proposed Amendment to Certificate of Incorporation

All authorized but unissued shares of Common Stock will be available for issuance from time to time for any proper purpose approved by the Board of Directors. There are currently no arrangements, agreements or understandings for the issuance or use of the additional shares of the authorized Common Stock. The Board of Directors does not presently intend to seek further shareholder approval of any particular issuance of shares unless such approval is required by law or the rules of The Nasdaq Stock Market.

The Company's shareholders do not currently have any preemptive or similar rights to subscribe for or purchase any additional shares of Common Stock that may be issued in the future, and therefore, future issuances of Common Stock may, depending on the circumstances, have a diluted effect on the earnings per share, voting power and other interest of the existing shareholders.

Vote Required and Recommendation of the Board of Directors

The affirmative vote of the holders of a majority of the outstanding shares of the Company's Common Stock entitled to vote at the Special Meeting will be required to approve the proposed Amendment, assuming a quorum is present.

The Board of Directors recommends that shareholders vote "FOR" approval of the amendment to increase the number of authorized shares of Common Stock from 40,000,000 to 80,000,000 shares

APPROVAL OF AMENDMENT TO THE 1995 STOCK OPTION PLAN

Proposal 3

The Board of Directors adopted on November 18, 2002, subject to the approval by the stockholders, an amendment (the "2002 Amendment") to the Company's 1995 Stock Option Plan. The 2002 Amendment increases from 2,700,000 to 3,700,000 the number of shares of the Company's Common Stock available for issuance under the 1995 Stock Option Plan. The Company has in the past used, and intends in the future to use, stock options as incentive devices to motivate and

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

compensate its salaried officers and other key employees, and believes that equity incentives represented by stock options enhances the Company's ability in attracting and retaining the best possible persons for positions of significant responsibility by providing its officers and other key employees with additional incentives to contribute to the Company's success.

Management further believes that the availability of such equity incentives has served, and will continue to serve, an important part in the implementation of the Company's acquisition strategy. As of October 31, 2002, options to purchase an aggregate of 85,300 shares of Common Stock have been exercised under the 1995 Plan; as of such date, options to purchase 2,683,882 shares of Common Stock were outstanding under the 1995 Stock Option Plan. Accordingly, options to purchase only 16,118 shares of Common Stock remain available for future grants under the 1995 Stock Option Plan as of such date.

The Board of Directors recommends that the shareholders vote "FOR" approval of the 2002 Amendment.

10

RATIFICATION OF THE GRANTING OF STOCK OPTIONS TO OUTSIDE DIRECTORS

Proposal 4

The proposal would ratify the granting of stock options on September 11, 2001 to purchase 125,000 shares of Common Stock at an exercise price of \$2.75 per share to each of Dr. David M. Silver, Randall A. Mackey and Keith D. Ignatz, outside directors of the Company, of which options to purchase 31,250 shares of Common Stock were fully vested as of September 11, 2001, the date of grant, with options to purchase 31,250 shares of Common Stock to be vested at the end of each three month period thereafter until all such options are vested. These options granted to Messrs. Silver, Mackey and Ignatz may be exercised at any time not later than September 11, 2008. The proposal would also approve the granting of stock options to purchase 250,000 shares of Common Stock at an exercise price of \$2.75 per share to each of Messrs. Silver and Mackey, of which options to purchase 250,000 shares of Common Stock were fully vested as of September 11, 2001, in consideration for past services to the Company by Messrs. Silver and Mackey. The Company is required to register the shares of Common Stock issuable upon the exercise of the options.

The options contain provisions that protect the holders against dilution by adjustment of the exercise price per share and the number of shares issuable upon exercise thereof upon the occurrence of certain events, including stock dividends, stock splits, mergers and the sale of substantially all of the Company's assets. The options are to be exercised by delivering to the Company payment of the purchase price of the shares to be purchased or by delivering shares of the Company's stock already owned by the holder and having a fair market value on the date of exercise equal to the exercise price of the option, or a combination of such shares and cash.

The Board of Directors recommends that shareholders vote "FOR" ratification of the granting of stock options to the outside directors.

RATIFICATION OF APPOINTMENT OF INDEPENDENT PUBLIC ACCOUNTANTS

Proposal 5

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

The independent public accounting firm of Tanner & Co. has been the Company's independent accountants since fiscal year 1998. The Audit Committee has recommended and the Board of Directors has appointed Tanner & Co. for purposes of auditing the consolidated financial statements of the Company for the fiscal year ending December 31, 2002. It is anticipated that representatives of Tanner & Co. will be present at the Annual Meeting and will be provided an opportunity to make a statement if they desire, and to be available to respond to appropriate questions.

The Board of Directors recommends that shareholders vote "FOR" ratification of the appointment of Tanner & Co. as the Company's independent accountants for fiscal 2002.

AUDIT FEES, FINANCIAL INFORMATION SYSTEMS DESIGN AND IMPLEMENTATION FEES AND ALL OTHER FEES

Fees for the year 2001 annual audit and related quarterly reviews were approximately \$38,500, and all other fees were approximately \$17,000. Other fees consisted of assistance in filing of reports on the EDGAR system of the Securities and Exchange Commission, and assistance with other filings made with the Securities and Exchange Commission.

ADDITIONAL INFORMATION

The Company will provide without charge to any person from whom a Proxy is solicited by the Board of Directors, upon the written request of such person, a copy of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 excluding certain exhibits thereto, as filed with the Securities and Exchange Commission. Written requests for such information should

11

be directed to Heber C. Maughan, Interim Chief Executive Officer, Paradigm Medical Industries, Inc., 2355 South 1070 West, Salt Lake City, Utah 84119.

OTHER MATTERS

As of the date of this Proxy Statement, the Company knows of no business that will be presented for consideration at the Annual Meeting other than the items referred to above. However, if any other matters are properly brought before the meeting, it is the intention of the persons named as proxies in the accompanying Proxy to vote the shares they represent on such business in accordance with their best judgment. In order to assure the presence of the necessary quorum and to vote on the matters to come before the Annual Meeting, please indicate your choices on the enclosed Proxy and date, sign and return it promptly in the postage pre-paid envelope provided. The signing and delivery of a Proxy by no means prevents you from attending the Annual Meeting.

By order of the Board of Directors,

Randall A. Mackey
Chairman of the Board

November 27, 2002.

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD DECEMBER 27, 2002

To our Shareholders:

You are cordially invited to attend the Annual Meeting of Shareholders (the "Annual Meeting") of Paradigm Medical Industries, Inc. (the "Company") to be held on Friday, December 27, 2002, beginning at 10:00 a.m. local time (MST) at the Company's corporate headquarters at 2355 South 1070 West, Salt Lake City, Utah. At the Annual Meeting, shareholders will act on the following matters:

1. To elect three directors to serve until the next annual meeting of the shareholders and until their respective successors are elected and qualified.
2. To approve the proposed Amendment to the Company's Certification of Incorporation to increase the number of authorized shares of Common Stock from 40,000,000 to 80,000,000 shares.
3. To amend the Company's 1995 Stock Option Plan to authorize an additional 1,000,000 shares of Common Stock to be made available for issuance under the Plan.
4. To ratify the granting of stock options to purchase shares of Common Stock at \$2.75 per share to each of Dr. David Silver, Randall A. Mackey and Keith D. Ignatz, outside directors of the Company.
5. To ratify the appointment of Tanner & Co. as the Company's independent accountants for the fiscal year ending December 31, 2002.
6. To transact such other business as may properly come before the meeting or any adjournment thereof.

The foregoing items of business are more fully described in the Proxy Statement accompanying this Notice. Also included is a single-page Proxy/Voting Instruction Form and a postage prepaid return envelope. Only shareholders of record at the close of business on November 20, 2002 are entitled to notice of, and to vote at, the Annual Meeting or any adjournment thereof.

It is important that your shares be represented at the Annual Meeting. Whether or not you plan to attend, we hope that you will complete and return your Proxy/Voting Instruction Form in the postage prepaid envelope as promptly as possible.

Sincerely yours,

Randall A. Mackey
Chairman of the Board

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

November 27, 2002
Salt Lake City, Utah

PARADIGM MEDICAL INDUSTRIES, INC.

PROXY FOR ANNUAL MEETING OF SHAREHOLDERS
December 27, 2002

THIS PROXY SOLICITED ON BEHALF OF THE
BOARD OF DIRECTORS OF
PARADIGM MEDICAL INDUSTRIES, INC.

The undersigned hereby appoints Randall A. Mackey and Heber C. Maughan or either of them, each with full power of substitution, as proxies to vote at the Annual Meeting of Shareholders to be held on Friday, December 27, 2002, beginning at 10:00 a.m., local time, at the corporate headquarters of Paradigm Medical Industries, Inc. at 2355 South 1070 West, Salt Lake City, Utah, and at all adjournments thereof, all shares of common stock which the undersigned would be entitled to vote on matters set forth below, if personally present:

1. ELECTION OF DIRECTORS, NOMINEES: RANDALL A. MACKEY, DR. DAVID M. SILVER AND KEITH D. IGNOTZ.

FOR all nominees listed (except as indicated in writing to the contrary below)

WITHHOLD AUTHORITY to vote for all nominees listed below

Instruction: To withhold authority to vote for any individual nominee, write that nominee's name here:

-
2. APPROVAL OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 40,000,000 TO 80,000,000 SHARES.

FOR AGAINST ABSTAIN

3. APPROVAL OF AMENDMENT TO THE 1995 STOCK OPTION PLAN TO AUTHORIZE AN ADDITIONAL 1,000,000 SHARES OF COMMON STOCK

FOR AGAINST ABSTAIN

4. RATIFICATION OF THE GRANTING OF STOCK OPTIONS TO THE OUTSIDE DIRECTORS.

FOR AGAINST ABSTAIN

5. RATIFICATION OF APPOINTMENT OF TANNER & CO. AS THE COMPANY'S INDEPENDENT ACCOUNTANTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2002.

FOR AGAINST ABSTAIN

6. IN THEIR DISCRETION, ON SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING.

THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

DIRECTION IS INDICATED, WILL BE VOTED FOR PROPOSALS 1, 2, 3, 4 AND 5. In their discretion, the proxies are authorized to vote upon such other matters as may properly come before the meeting or any adjournment(s) thereof.

DATED _____, 2002.

SIGNATURE: _____

(This proxy should be marked, dated and signed by each shareholder exactly as such shareholder's name appears hereon and returned promptly. Persons signing in a fiduciary capacity should so indicate. If shares are held by joint tenants or as community property, both should sign. If a corporation, please sign in full corporation name by the President or by an authorized corporate officer. If a partnership, please sign in partnership name by an authorized person).

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-KSB/A

(Mark One)

- Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the year ended December 31, 2001
- Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File No. 0-28498

PARADIGM MEDICAL INDUSTRIES, INC.
(Name of small business issuer in its charter)

DELAWARE
(State or other jurisdiction of incorporation or organization)

87-0459536
IRS Identification Number

2355 South 1070 West, Salt Lake City, Utah 84119
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including Area Code (801) 977-8970

Securities registered under Section 12(b) of the Exchange Act:

Name of each exchange on Title of each class	which registered
_____	_____
(None)	(None)

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, par value \$.001 per share
(Title of class)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

requirements for the past 90 days.

Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-B is not contained in herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB.

Registrant's revenues for the fiscal year ended December 31, 2001 were \$7,919,000.

The aggregate market value of the voting stock held by non-affiliates of the Registrant as of March 31, 2002 was approximately \$48,425,223 based on the closing price on that date on the Nasdaq SmallCap Market.

As of March 31, 2002 Registrant had outstanding 17,017,129, shares of Common Stock, 5,757 shares of Series A Preferred Stock, 8,986 shares of Series B Preferred Stock, no shares of Series C Preferred Stock and 10,000 shares of Series D Preferred Stock, 13,050 shares of Series E Preferred Stock and 39,866 shares of Series F Preferred Stock.

1

DOCUMENTS INCORPORATED BY REFERENCE:

Additional documents set forth in Part IV hereof are incorporated by reference.

Transitional Small Business Disclosure Format (check one): Yes No

PART I

Item 1. Description of Business

General

The Company develops, manufactures, sources, markets and sells ophthalmic surgical and diagnostic instrumentation and related accessories, including disposable products. The Company's surgical equipment is designed for minimally invasive cataract treatment. The Company markets three cataract surgery systems with related accessories and disposable products. The Company's flagship cataract removal system, the Photon(TM) laser system, is a laser cataract surgery system marketed as the next generation of cataract removal. The Photon(TM) product is currently under review by the Food Drug and Administration ("FDA"). The Photon(TM) is available for sale in many markets outside of the United States. Both the Photon(TM) and the Precisionist ThirtyThousand (TM) are manufactured as an Ocular Surgery Workstation(TM). The Company plans to market the Ocular Surgery Workstation(TM) as a plug-in module for the Photon(TM) and other lasers for use in eye care and other medical specialties. The Company also offers the SIStem(TM), a mid-range priced ultrasonic phaco, and competes in the market segment that only desires an ultrasonic phaco.

The Company's diagnostic products include a pachymeter, an A-Scan, an A/B Scan, an UBM biomicroscope, a perimeter, a corneal topographer and the Blood flow Analyzer(TM). The diagnostic ultrasonic products including the pachymeter, the A-Scan, the A/B Scan and the UBM biomicroscope were acquired from Humphrey

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Systems a division of Carl Zeiss in 1998. The Company developed and offered for sale in the fall of 2000 the P45 which combines the A/B Scan and the UBM in one machine. The perimeter and the corneal topographer were added when the company acquired the outstanding shares of the stock of Vismed, Inc. d/b/a/ Dicon(TM) in June 2000. The Company purchased Ocular Blood Flow, Ltd. ("OBF") in June 2000 whose principal product is the Blood Flow Analyzer(TM). This product is designed for the measurement of intraocular pressure and pulsatile ocular blood flow volume for detection and treatment of glaucoma. The Company is currently developing additional applications for all of its diagnostic products.

A cataract is a condition, which largely affects the elderly population, in which the natural lens of the eye hardens and becomes cloudy, thereby reducing visual acuity. Treatment consists of removal of the cloudy lens and replacement with a synthetic lens implant, which restores visual acuity. Cataract surgery is the single largest volume and revenue producing outpatient surgical procedure for ophthalmologists worldwide. The Health Care Finance Administration reports that in the United States approximately two million cataract removal procedures are performed annually, making this the largest outpatient procedure reimbursed by Medicare. Most cataract procedures are performed using a method called phacoemulsification or "phaco", which employs a high frequency (40 kHz to 60 kHz) ultrasonic probe needle device to fragment the cataract while still in the eye and remove it in pieces by suction through a small incision.

2

In June 1997, the Company received FDA clearance to market the Blood Flow Analyzer(TM) for measurement of intraocular pressure and pulsatile ocular blood flow for the detection of glaucoma and other retina related diseases. Ocular blood flow is critical, the reduction of which may cause nerve fiber bundle death through oxygen deprivation thus resulting in visual field loss associated with glaucoma. The Company's Blood Flow Analyzer(TM) is a portable automated in-office system that presents an affordable method for ocular blood flow testing for the ophthalmic and optometric practitioner. In June 2000 the company purchased OBF, the manufacturer of the Blood Flow Analyzer(TM). The terms and conditions of the sale were \$100,000 in cash and 100,000 shares of common stock. In April 2001, the Company received authorization to use a CPT code for procedures performed with the Blood Flow Analyzer(TM) which provides for a reimbursement to doctors using the device. In the fall of 2001, the manufacturing of the Blood Flow Analyzer(TM) was moved to the Company's San Diego facility from an outsourced facility in England.

On June 26, 1998, the Company entered into a Co-Distribution Agreement with Pharmacia & Upjohn Company ("Pharmacia") and MAXXIM Corporation, which provided for the marketing and sale of a range of ophthalmic products. The contract was renewable for one-year periods. The companies do not intend to renew the agreement upon expiration in 2002. Under the terms of the Co-Distribution Agreement, the Company, Pharmacia and MAXXIM will offer a comprehensive package of products to cataract surgeons, including cataract surgical equipment, intraocular lens implants, intraocular pharmaceuticals, surgical instruments and sterile procedural packs. The Company will provide the Precisionist(TM) for distribution and sale under the Co-Distribution Agreement. The Pharmacia products to be distributed as part of the Co-Distribution Agreement include the Healon(R) and Healon-GV(R), and Healon V, the new visco-elastic solution. Pharmacia also manufactures the CeeOn line of foldable, small intraocular lens implants, designed to replace the natural lens removed during cataract surgery.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

On July 23, 1998, the Company entered into an Agreement for Purchase and Sale of Assets with the Humphrey Systems Division of Carl Zeiss, Inc. to acquire the ownership and manufacturing rights to certain assets of Humphrey Systems that are used in the manufacturing and marketing of an ultrasonic microprocessor-based line of ophthalmic diagnostic instruments, including the Ultrasonic Biometer Model 820, the A/B Scan System Model 837, the Ultrasound Pachymeter Model 855, and the Ultrasound Biomicroscope Model 840, and all accessories, packaging and end-user collateral materials for each of the product lines for the sum of \$500,000, payable in the form of 78,947 shares of Common Stock which were issued to Humphrey Systems and 26,316 shares of Common Stock which were issued to business broker Douglas Adams. If the net proceeds received by Humphrey Systems from the sale of the shares issued pursuant to the Agreement was less than \$375,000, after payment of commissions, transfer taxes and other expenses relating to the sale of such shares, the Company would be required to issue additional shares of Common Stock, or pay additional funds to Humphrey Systems as would be necessary to increase the net proceeds from the sale of the assets to \$375,000. Since Humphrey Systems realized only \$162,818 from the sale of 78,947 shares of the Company's common stock, The Company issued 80,000 additional shares in January 1999, to enable Humphrey Systems to receive its guaranteed amount. The amount of \$21,431 was paid to the Company as excess proceeds from the sale of this additional stock.

The rights to the ophthalmic diagnostic instruments which have been purchased from Humphrey Systems complement both the Company's cataract surgical equipment and its ocular Blood Flow Analyzer(TM). The Ultrasonic Biometer calculates the prescription for the intraocular lens to be implanted during cataract surgery. The Ultrasound Pachymeter measures corneal thickness for the new refractive surgical applications that eliminate the need for eyeglasses and for optometric applications including contact lens fitting. The A/B Scan System combines the Ultrasonic Biometer and ultrasound imaging for advanced diagnostic testing throughout the eye and is a viable tool for retinal specialists. The Ultrasound Biomicroscope utilizes microscopic digital ultrasound resolution for detection of tumors and improved glaucoma management. The Company introduced the

3

P45 in the fall of 2000 which combines the A/B Scan and the Ultrasonic Biometer in one machine.

On October 21, 1999, the Company purchased Mentor's surgical product line, consisting of the Phaco SIStem(TM), the Odyssey(TM) and the Surg-E-Trol(TM). This acquisition rounds out the Company's cataract surgery product line by adding entry-level, moderately priced cataract surgery products. The transaction was paid for with \$1.5 million worth of Paradigm common stock.

On June 5, 2000, the Company purchased Vismed Inc. d/b/a Dicon(TM) under a pooling of interest accounting treatment. The purchase included the Dicon(TM) perimeter product line consisting of the LD 400, the TKS 4000, the SST(TM), FieldLink(TM), FieldView(TM) and Advanced FieldView and the corneal topographer product line the CT 200(TM), the CT 50 and an ongoing service and software business. Perimeters are used to determine retinal sensitivity testing the visual pathway. Corneal topographers are used to determine the shape and integrity of the cornea, the anterior surface of the eye. Corneal topographers are used for the refractive surgical applications that eliminate the need for eyeglasses and for optometric applications including contact lens fitting.

Background

Corporate History: The Company's business originated with Paradigm Medical, Inc. ("PMI"), a California corporation formed in October 1989. PMI developed the Company's present ophthalmic business and was operated by its

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

founders Thomas F. Motter and Robert W. Millar. In May 1993, PMI merged with and into the Company. At the time of the merger, the Company was a dormant public shell existing under the name French Bar Industries, Inc. ("French Bar"). French Bar had operated a mining and tourist business in Montana. Prior to its merger with PMI in 1993, French Bar had disposed of its mineral and mining assets in a settlement of outstanding debt and had returned to the status of a dormant entity. Pursuant to the merger, the Company caused a 1-for-7.96 reverse stock split of its shares of Common Stock. The Company then acquired all of the issued and outstanding shares of Common Stock of PMI using shares of its own Common Stock as consideration. As part of the merger, the Company changed its name from French Bar Industries, Inc. to Paradigm Medical Industries, Inc. and the management of PMI assumed control of the Company. In April 1994, the Company caused a 1-for-5 reverse stock split of its shares of Common Stock. In February 1996, the Company re-domesticated to Delaware pursuant to a reorganization.

Overview

Disorders of the Eye: The human eye is a complex organ which functions much like a camera, with a lens in front and a light-sensitive screen, the retina, in the rear. The intervening space contains a transparent jelly-like substance, the vitreous, which together with the outer layer, the sclera and cornea, helps the eyeball to maintain its shape. Light enters through the cornea, a transparent domed window at the front of the eye. The size of the pupil, an aperture in the center of the iris, controls the amount of light that is then focused by the lens onto the retina as an upside-down image. The lens is the internal optical component of the eye and is responsible for adjusting focus. The lens is enclosed in a capsule. The retina is believed to contain more than 130 million light-receptor cells. These cells convert light into nerve impulses that are transmitted right-side up by the optic nerve to the brain, where they are interpreted. Muscles attached to the eye control its movements.

Birth defects, trauma from accidents, disease and age related deterioration of the components of the eye can all contribute to eye disorders. The most common eye disorders are either pathological or refractive. Many pathological disorders of the eye can be corrected by surgery. These include cataracts (clouded lenses), glaucoma (elevated pressure in the eye), corneal disorders such as scars, defects and irregular surfaces and vitreoretinal disorders such as the attachment of membrane growths to the retina causing blood leakage within the eye. All of these disorders can impair vision. Many

4

refractive disorders can be corrected through the use of eyeglasses and contact lenses. Myopia (nearsightedness), hyperopia (farsightedness) and presbyopia (inability to focus) are three of the most common refractive disorders.

Ultrasound Technology: Ultrasound devices have been used in ophthalmology since the late 1960's for diagnostic and surgical applications when treating or correcting eye disorders. In diagnostics, ultrasound instruments are used to measure distances and shapes of various parts of the eye for prescription of eyeglasses and contact lenses and for calculation of lens implant prescriptions for cataract surgery treatment. These devices emit sound waves through a hand-held probe that is placed onto or near the eye with the sound waves emitted being reflected by the targeted tissue. The reflection "echo" is computed into a distance value that is presented as a visual image, or cross-section of the eye, with precise measurements displayed and printed for diagnostic use by the surgeon.

Surgical use of ultrasound in ophthalmology is limited to treatment of cataractous lenses in the eye through a procedure called phacoemulsification or "phaco." A primary objective of cataract surgeries is the removal of the

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

opacified (cataractous) lens through an incision that is as small as possible. The opacified lens is then replaced by a new synthetic lens intraocular implant ("IOL"). Phaco technology involves a process by which a cataract is broken into small pieces using ultrasonic shock waves delivered through a hollow, open-ended metal needle attached to a hand-held probe. The fragments of cataractous tissue are then removed through aspiration. Phaco systems were first designed in the late 1960's after various attempts by surgeons to use other techniques to remove opacified lens, including crushing, cutting, freezing, drilling and applying chemicals to the cataract. By the mid-1970's, ultrasound had proven to be the most effective technology to fragment cataracts. Market Scope's (Manchester, Missouri), "The 2001 Report on the Worldwide Cataract Market", January 2001 indicates that phaco cataract treatment is the technology for cataract removal used in over 80% of surgeries in the United States and over 20% of all foreign surgeries.

Laser Technology: The term "laser" is an acronym for Light Amplification by Stimulated Emission of Radiation. Lasers have been commonly used for a variety of medical and ophthalmic procedures since the 1960's. Lasers emit photons into a highly intense beam of energy that typically radiates at a single wavelength or color. Laser energy is generated and intensified in a laser tube or solid-state cavity by charging and exciting photons of energy contained within material called the lasing medium. This stored light energy is then delivered to targeted tissue through focusing lenses by means of optical mirrors or fiber optics. Most laser systems use solid state crystals or gases as their lasing medium. Differing wavelengths of laser light are produced by the selection of the lasing medium. The medium selected determines the laser wavelength emitted, which in turn is absorbed by the targeted tissue in the body. Different tissues absorb different wavelengths or colors of laser light. The degree of absorption by the tissue also varies with the choice of wavelength and is an important variable in treating various tissue. In a surgical laser, light is emitted in either a continuous stream or in a series of short duration "pulses", thus interacting with the tissue through heat and shock waves, respectively. Several factors, including the wavelength of the laser and the frequency and duration of the pulse or exposure, determine the amount of energy that interacts with the targeted tissue and, thus, the amount of surgical effect on the tissue.

Lasers are widely accepted in the ophthalmic community for treatment of certain eye disorders and are popular for surgical applications because of their relatively non-invasive nature. In general, ophthalmic lasers, such as argon, Nd:YAG and excimer (argon-fluoride) are used to coagulate, cut or ablate targeted tissue. The argon laser is used to treat leaking blood vessels on the retina (retinopathy) and retinal detachment. The excimer laser is used in corneal refractive surgery. The Nd:YAG pulsed laser is used to perforate clouded posterior capsules (posterior capsulotomy) and to relieve glaucoma-induced elevated pressure in the eye (iridotomy, trabeculoplasty, transcleral cyclophotocoagulation). Argon, Nd:YAG and excimer lasers are primarily used for

5

one or two clinical applications each. In contrast to these conventional laser systems, the Company's Photon(TM) laser cataract system is designed to be used for multiple ophthalmic applications, including certain new applications that may be made possible with the Company's proprietary technology. Such new applications, however, must be tested in clinical trials and be approved by the FDA.

Products

The Company's principal proprietary surgical products are systems for

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

use by ophthalmologists to perform surgical treatment procedures to remove cataracts. The Company has complete ownership of each product with no technological licensing limitations.

The SIStem(TM): The SIStem(TM) is the Company's state-of-the-art, entry-level phacoemulsification system. The SIStem(TM) is designed to be a full-featured, cost-effective, reliable phaco machine. The competitive feature package includes automated priming and tuning, error detection, audible feedback, patented fluidics system, pneumatic vitrectomy and bipolar electro-surgical coagulation. With both reusable and single-use consumables, the SIStem(TM) is positioned for the world's primary ultrasonic phaco markets, including the United States, Europe and Asia. Fiscal years 2001 and 2000 sales of the SIStem(TM) represented approximately 3% and 9% of total revenues, respectively.

Precisionist ThirtyThousand(TM): The Precisionist ThirtyThousand(TM) (the "Precisionist(TM)") is the Company's core phaco surgical technology. The Precisionist(TM) was placed into production and offered for sale in 1997. As a phaco cataract surgery system, the Company believes the Precisionist(TM) with its new fluidics panel is equal or superior to the present competitive systems in the United States. The system features a graphic color display and unique proprietary on-board computer and graphic user interface linked to soft-key membrane panel for flexible programmable operation. The system provides real-time "on-the-fly" adjustment capabilities for each surgical parameter during the surgical procedure for high-volume applications. In addition, the Precisionist(TM) provides one hundred pre-programmable surgery set-ups, with a second level of sub-programmed custom modes within each major surgical screen (i.e., ultrasound phaco and irrigation/aspiration modes). The Precisionist(TM) features the Company's newly developed proprietary fluidics panel which is completely non-invasive for improved sterility and to provide a surgical environment in the eye that virtually eliminates fluidic surge and solves chamber maintenance problems normally associated with phaco cataract surgery. This new fluidics system provides greater control for the surgeon and allows the safe operation at much higher vacuum settings by sampling changes in aspiration 100 times per second. Greater vacuum in phaco surgery means less use of ultrasound or laser energy to fragment the cataract and less chance for surrounding tissue damage. In addition to the full complement of surgical modalities (e.g., irrigation, aspiration, bipolar coagulation and anterior vitrectomy), system automation includes "dimensional" audio feedback of vacuum levels and voice confirmation for major system functions, providing an intuitive environment in which the advanced phaco surgeon can concentrate on the surgical technique rather than the equipment. Sales of the Precisionist(TM) were not significant in the fiscal years 2001 or 2000.

Ocular Surgery Workstation(TM): The Ocular Surgery Workstation(TM) (the Workstation(TM)) comprises the base system of the Precisionist(TM) ThirtyThousand(TM) and is the first system to the knowledge of the Company which uses the expansive capabilities of today's advanced computer technology to offer seamless open architecture expandability of the system hardware and software modules. The Workstation(TM) utilizes an embedded open architecture computer developed for the Company and controlled by a proprietary software system

6

developed by the Company that interfaces with all components of the system. Ultrasound, fluidics (irrigation), aspiration, venting, coagulation and anterior vitrectomy (pneumatic) are all included in the base model. Each component is controlled as a peripheral module within this fully integrated system. This approach allows for seamless expansion and refinement of the Workstation(TM) with the ability to add other hardware and software features. Expansion such as the Company's Photon(TM) laser system, when approved by the FDA, and hardware

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

for additional surgical applications are easily implemented by means of a pre-existing expansion rack which resides in the base of the Workstation(TM). These expanded capabilities could include, but would not be limited to laser systems, video surgical fiber optic imaging, cutting and electrosurgery equipment. However, there is no guarantee that the Workstation(TM) will be accepted in the market place. Upon approval from the FDA for the Photon(TM), the Company will refer to the Workstation(TM) as the Photon(TM) Ocular Surgery Workstation(TM). To date, the Company has not commercially developed or offered for sale any other added hardware or software features to its Workstation (TM).

Photon(TM) Laser System: The Photon(TM) laser cataract system, which is still subject to FDA approval, is designed to be installed as a seamless plug-in upgrade or add-on to the Company's Precisionist(TM) Ocular Surgery Workstation(TM). The plug-in platform concept is unique in the ophthalmic surgical market for systems of this magnitude and presents a unique market opportunity for the Company. The main elements of the laser system are the Nd:YAG laser module, Photon(TM) laser software package and interchangeable disposable hand-held fiber optic laser cataract probe. The Photon(TM) laser utilizes the on-board microprocessor computer of the Workstation(TM) to generate short pulse laser energy developed through the patented LCP(TM) to targeted cataract tissue inside the eye, while simultaneously irrigating the eye and aspirating the diseased cataract tissue from the eye. The probe is smaller in diameter than conventional ultrasound phaco needles and presents no damaging vibration or heat build-up in the eye. The Company's Phase I clinical trials demonstrated that this probe can easily reduce the size of the cataract incision from 3.0 mm to under 2.0 mm thereby reducing surgical trauma and complementing current foldable intraocular implant technology. The laser probe may also eliminate any possibility for burns around the incision or at the cornea and may therefore be used with cataract surgery techniques which utilize a more delicate clear cornea incision which can eliminate sutures and be conducted with topical anesthesia. However, this system may not effectively remove harder grade cataracts. Harder grade cataracts can be removed using the already existing ultrasound capability of the Precisionist(TM).

The Company intends to refine the laser delivery system and laser cataract surgical technique used on soft cataracts through expanded research and clinical studies. As far as the Company can determine, no integrated single laser photofragmenting probe is presently available on the market that uses laser energy directly, contained in an enclosed probe, to denature cataract tissue at a precise location inside the eye while simultaneously irrigating and aspirating the site.

The Company's laser system is based upon the concept that pulsed laser energy produced with the micro-processor controlled Nd:YAG laser system provides ophthalmic surgeons with a more precise and less traumatic alternative in cataract surgery. Although conventional ultrasonic surgical systems have proven effective and reliable in clinical use for many years, their use of high frequency shock waves and vibration to fragment the cataract can make the procedure difficult and can present risk of complication both during and after surgery. In contrast, the Company's laser system, which utilizes short centralized energy bursts, should permit the delivery of the laser beam with less trauma to adjacent tissue. Therefore, unlike ultrasonic systems, whose vibrations and shock waves affect (and can damage) non-cataractous tissues within the eye, the Company's Photon(TM) laser cataract system should only affect tissues it comes into direct contact with.

In addition to cataract surgery, the Company believes that its Photon(TM) laser system is capable of being configured with specialty probes for use in other ophthalmic surgical and other medical procedures. In October of 2000, the Company received FDA approval for the Photon(TM) Workstation(TM) to be

used with a 532nm green laser which is effective for medical procedures other than cataract removal, such as, photocoagulation of retinal and venous anomalies within or outside the eye, pigmented lesions around the orbital socket, posterior or anterior procedures associated with glaucoma or diabetes and general photocoagulation for various dermatological venous anomalies including telangiectasia (surface veins), or commonly referred to as "spider veins". The goal is to be able to integrate multiple laser wavelengths into one system or workstation that can be used for multiple medical specialties. This approval represents only one of the potential applications that could represent substantial growth opportunities including additional sales of equipment, instruments, accessories and disposables. The Photon(TM) Ocular Surgery Workstation(TM) has not been commercially developed with any other added hardware or software features. There is no guarantee that the laser will be accepted by the ophthalmic surgery market in this capacity or that the FDA will grant approval.

Surgical Instruments, Accessories and Disposables: In addition to the cataract surgery equipment, the Company's surgical systems utilize or will utilize accessory instruments and disposables, some of which are proprietary to the Company. These include replacement ultrasound tips, sleeves, tubing sets and fluidics packs, instrument drapes and laser cataract probes. The Company intends to expand its disposable accessories as it further penetrates the cataract surgery market and expands the treatment applications for its Workstation(TM). These products contributed approximately 8% and 14% of total revenues for 2001 and 2000, respectively.

Diagnostic Eye Care Products: Glaucoma is a second leading cause of adult blindness in the world. Glaucoma is described as a partial or total loss of visual field resulting from certain progressive disease or degeneration of the retina, macula or nerve fiber bundle. The cause and mechanism of the glaucoma pathology is not completely understood. Present detection methods focus on the measurement of intraocular pressure in the eye, visual field and observation of the optic nerve head to determine the possibility of pressure being exerted upon the retina, and optic nerve fiber bundle, which can diminish visual field. Recently, retinal blood circulation has been indicated as a key component in the presence of glaucoma. Some companies produce color Doppler equipment in the \$80,000 price range intended to provide measurement of ocular blood flow activity in order to diagnose and treat glaucoma at an earlier stage.

Blood Flow Analyzer(TM): In June 1997, the Company received FDA clearance to market the Blood Flow Analyzer(TM) for early detection and treatment management of glaucoma and other retina related diseases. The device measures not only intraocular pressure but also pulsatile ocular blood flow, the reduction of which may cause nerve fiber bundle death through oxygen deprivation thus resulting in visual field loss associated with glaucoma. The Company's Blood Flow Analyzer(TM) is a portable automated in-office system that presents an affordable method for ocular blood flow testing for the ophthalmic and optometric practitioner. This was the Company's first diagnostic eye care device. The device is a portable desktop system that utilizes a proprietary and patented pneumatic Air Membrane Applanation Probe(TM) (the "AMAP TM") which can be attached to any model of standard examination slitlamp which is then placed on the cornea of the patient's eye to measure the intraocular pressure within the eye. The device is unique in that it reads a series of intraocular pressure pulses over a short period of time (approximately five to ten seconds) and generates a wave form profile which can be correlated to blood flow volume within the eye. The blood flow volume is calculated by a proprietary software algorithm developed by David M. Silver, Ph.D., at Johns Hopkins. The device presents a numerical intraocular pressure reading and blood flow analysis rating

in a concise printout which is affixed to the patient history file. In addition, the data generated by the device can be downloaded to a personal computer system for advanced database development and management. The Company markets the Blood Flow Analyzer(TM) as a stand-alone model packaged with a custom built computer system. The Blood Flow Analyzer(TM) utilizes a single-use disposable cover for its AMAP(TM) corneal probe which is shipped in sterile packages. The AMAP (TM) probe tip cover provides accurate readings and acts as a prophylactic barrier for the patient. The device has been issued a patent in the European Economic Community and the United States and has a patent pending in Japan. The FDA cleared the Blood Flow Analyzer(TM) for marketing in June 1997 and the Company commenced selling the system in September 1997. In addition to the Humphrey products, this diagnostic product allowed the Company to expand its market to approximately 35,000 optometry practitioners in the United States in addition to the approximately 18,000 ophthalmic practitioners who currently perform eye surgeries and are candidates for the Company's surgical systems. In April 2001, the Company received authorization from the CPT Code Research and Development Division of the American Medical Association to use a common procedure terminology (CPT) code for its Blood Flow Analyzer(TM) which provides for a reimbursement to doctors. In the fall of 2001, the manufacturing activities for the Blood Flow Analyzer(TM) were moved to the San Diego facility from the outsourced plant located in England. The revenues from sales of the Blood Flow Analyzer(TM) represented approximately 25% of total 2001 revenues and were not significant in 2000 due to the fact that major sales efforts for the product commenced in 2001.

Dicon(TM) perimeters consist of the LD 400, the TKS 4000, the SST(TM), FieldLink(TM), FieldView(TM) and Advanced FieldView. Perimeters are used to determine retinal sensitivity testing the visual pathway. Perimeters have become standard of care in the detection and monitoring of glaucoma worldwide. Perimetry is reimbursable worldwide. The Dicon(TM) perimeters feature patented kinetic fixation and voice synthesis now in 27 different languages. Software programs are sold to assist in the analysis of the test results. Sales of the perimeters generated approximately 15% and 26% of the 2001 and 2000 total revenues, respectively.

Dicon(TM) corneal topographers include the CT 200(TM) and the CT 50. Corneal topographers are used to determine the shape and integrity of the cornea, the anterior surface of the eye. Clinical applications for corneal topographers include refractive surgery that eliminates the need for eyeglasses and optometric applications including contact lens fitting. Revenues from the topographer were slightly less than 12% and 17% of the total revenues for 2001 and 2000, respectively.

Pachymetric Analyzer: The ultrasonic pachymeter is used for measurement of corneal thickness. The Model P55 is positioned as a standard office pachymeter. This device is targeted to the refractive surgery market and contributed approximately 1% and 2% to the total revenues for 2001 and 2000, respectively.

Ultrasonic A-Scan: The Ultrasonic A-Scan was and remains the industry standard for axial length eye measurement, which is a prerequisite procedure reimbursed by Medicare and is performed before every cataract surgery. Over 5,000 A-Scan systems have been installed in the worldwide market, representing a substantial market opportunity for software upgrades and extended warranty contract sales. A-Scan sales were approximately 2% and 4% of the total 2001 and 2000 revenues, respectively.

Ultrasonic A/B Scan: The A/B Scan is used by retinal sub-specialists to identify foreign bodies in the posterior chamber of the eye and to evaluate the structural integrity of the retina. The A/B Scan is attractive to the general

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

ophthalmic community at large because of its lower price point. Sales from this product were approximately 5% of the total 2001 and 2000 revenues.

Ultrasonic Biomicroscope ("UBM"): The UBM was developed by Humphrey Systems in conjunction with the New York Eye and Ear Infirmary in Manhattan and the University of Toronto. The UBM and its intellectual property were included in the purchase from Humphrey Systems and gives the Company the proprietary rights to this device. The UBM creates a high-resolution computer image of the

9

unseen parts of the eye that is a "map" for the glaucoma surgeon. The UBM is an "enabling technology" for the ophthalmologist, one that the Company has repositioned for broader market sales penetration. Formerly sold only to glaucoma sub-specialty practitioners, the Company reintroduced the UBM at a price-point targeted for the average practitioner seeking to add glaucoma filtering surgical procedures and income to his/her cataract surgical practice.

The UBM related surgical filtering procedures are fully reimbursable by Medicare and insurance providers. This untapped new market positions the Company with its proprietary UBM and to its knowledge, the only commercially viable product of this type on the market, as a leader in the rapidly expanding glaucoma imaging and treatment segment. In the fall of 2000 the company introduced the P45 which combines the UBM and the A/B Scan in one instrument. The Company believes that by combining functions the P45 will appeal to a broader market. UBM sales were approximately 11% and 14% of total revenues for the years ended December 31, 2001 and 2000, respectively. The P45 which was available for sale for all of 2001, contributed approximately 9% of total revenues for 2001 and approximately 3% of total 2000 revenues.

In July of 2000, the Company received ISO 9001 and EN 46001 certification using TUV Essen as the notified body. Under ISO 9001 certification, all of the Companies products are now CE marked. The CE mark allows the Company to ship product for revenue into the European Community. The Company successfully retained its certification in 2001.

Marketing and Sales

Ophthalmologists are mainly office-based and perform their surgeries in local hospitals or surgical centers that provide the necessary surgical equipment and supplies. Ophthalmologists are generally involved in decisions relating to the purchase of equipment and accessories for their independent ambulatory surgical centers and for the hospitals with which they are affiliated. This provides the opportunity for direct, targeted, personal selling, responsive high quality customer service and short buying cycles to achieve a product sale in the office or hospital. Hospitals also comprise a significant market as recent demand for ultrasonic surgery technology has put pressure on the ophthalmologist, who in turn persuades the hospital to install the latest technology system so that they can offer this procedure to their patients and the community.

Industry analysts report that the United States ophthalmic surgical device market has been characterized by slower growth in recent years. This has apparently been caused by the potential reforms associated with the health care industry. Further, hospitals have been inclined to keep their older phaco machines longer than expected as they have been forced to mind budgets more carefully and have become less willing to invest in capital equipment until more information on health care reform becomes available. However, analysts predict that the ophthalmic surgical device market will see renewed growth in the coming years as the health care environment stabilizes and as the growing elderly population produces an increased number of cataract surgeries. As a consequence

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

of these factors, the market should see a greater rate of replacement of older machines that hospitals and surgeons have been postponing for longer than usual.

Current Market Acceptance and Potential: The principal purchasers of the Company's products have been ophthalmologists, optometrists and clinics in many countries throughout the world. The Company believes that the market for its products is being driven by: (i) the aging of the population, which is evidenced by the domestic and international cataract surgery volume growth trend over the past ten years, (The National Eye Institute reported in March 2002 that the number of blind or visually impaired Americans is likely to double over the next 30 years.) (ii) the entry by emerging countries (including China, Russia, and other countries in Asia, Eastern Europe and Africa) into advanced technology medical care for their populations, (iii) increased awareness worldwide of the benefits of the minimally invasive phaco cataract procedure and (iv) the introduction of technology improvements such as the Company's laser system. The Secretary of Health and Human Services, Tommy Thompson, stated in March 2002

10

that early detection and treatment can reduce blindness and visual impairment from most eye diseases and disorders.

Marketing Organization: The Company markets its products internationally through a network of dealers and domestically through direct sales representatives. As of December 31, 2001, the Company had fourteen direct domestic sales representatives in the United States and sixty-six foreign dealers. These sales representatives are assigned exclusive territories and have entered into contracts with the Company that contain performance quotas. The Company also plans to continue to market its products by identifying customers through internal market research, trade shows and direct marketing programs. The Company also utilizes a Clinical Advisory Board comprised of leading ophthalmic surgeons in the United States and Europe who speak at conventions, train ophthalmologists and visit foreign doctors and dealers to promote the Company's products.

The Company, when marketing its Ocular Surgery Workstation(TM), will emphasize the expandable features of the Workstation(TM). The Company's marketing approach will be to focus on the upgradeability of the Workstation(TM) and to develop the image of the Workstation(TM) as the most versatile, upgradeable and cost effective surgical equipment available. The Company will continue to focus its sales efforts towards ophthalmic hospital and surgical center facilities specializing in cataract surgery. However, as systems are installed, the Company will expand its focus to provide additional ophthalmic and non-ophthalmic surgical applications as part of its Workstation(TM). Additional surgical applications will expand the market for the Workstation(TM) as well as associated sales of disposable surgical products.

Product advertising is focused in the major industry trade newspapers. Most of the ophthalmologists or optometrists in the United States receive one or more of these magazines through professional subscription programs. The media has shown strong interest in the Company's technology and products, as evidenced by several recent front-page articles in these publications.

Manufacturing and Raw Materials: Currently, the Company maintains a 29,000 square foot facility in Salt Lake City and a 26,000 square foot facility in San Diego. The Company transferred the manufacturing activities for the Blood Flow Analyzer(TM) to San Diego from OBF in England during 2001. These facilities accommodate the Company's expanded manufacturing, marketing and engineering capabilities. The Company manufactures under systems of quality control and testing, which complies with the Quality System Requirements (QSR) established by the FDA, as well as similar guidelines established by foreign governments,

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

including the CE Mark and ISO-9001.

The Company subcontracts the manufacturing of some of its ancillary instruments, accessories and disposables through specified vendors in the United States. These products are contracted in quantities and at costs consistent with the Company's financial purchasing capabilities and pricing needs. The Company manufactures the LCP (TM) laser cataract probe and some of its surgical instruments, accessories and fluidics surgical tubing sets at its facility in Salt Lake City.

Product Service and Support: Service for the Company's products is overseen from its Salt Lake City and San Diego locations and is augmented by its international dealer network who provide technical service and repair. Installation, on-site training and a limited product warranty are included as the standard terms of sale. The Company provides distributors with replacement parts at no charge during the warranty period. To date, the Company has incurred minimal expenses under this warranty program. International distributors are responsible for installation, repair and other customer service to installed systems in their territory. All systems parts are modular sub-components that are easily removed and replaced. The Company maintains adequate parts inventory and provides overnight replacement parts shipment to its dealers. After the warranty period expires, the Company offers one year and three year service contracts to its domestic customers and will continue to sell parts to

11

international dealers who in turn create their own service plans with their customers.

Research and Development

The Company's primary market for its surgical products is the cataract surgery market. However, the Company believes that its laser systems may potentially have broader ophthalmic applications. Consequently, the Company believes that a strong research and development capability is important for the Company's future. In addition to the Company's expanded in-house R&D capabilities, it has enlisted several recognized and respected consultants and other technical personnel to act in technical and medical advisory capacities. Several of these consultants serve on the Company's clinical Advisory Board to provide expert and technical support for current and proposed products, programs and services of the Company.

The Company believes its research and development capabilities provide it with the ability to respond to regulatory developments, including new products, new product features devised from its users and new applications for its products on a timely and proprietary basis. The Company intends to continue investing in research and development and to strengthen its ability to enhance existing products and develop new products.

Competition

General. The Company is subject to competition in the cataract surgery and the glaucoma diagnostic markets from two principal sources: (i) manufacturers of competing ultrasound systems used when performing cataract treatments and (ii) developers of technologies for ophthalmic diagnostic and surgical instruments used for treatment. The surgical equipment industry is dominated by a few large companies that are well established in the marketplace, have experienced management, are well financed and have well recognized trade names and product lines. The Company believes that the combined sales of five entities account for over 90% of the cataract surgery market. The remaining

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

market is fragmented among emerging smaller companies, some of which are foreign. The ophthalmic diagnostic market has a similar composition.

Most major competitors either entered or expanded into the cataract or glaucoma markets through the acquisition of smaller, entrepreneurial high-technology manufacturing companies. Therefore, because existing competitors or other entities desiring to enter the market could conceivably acquire current entrepreneurial enterprises with small market activity, any and all competitors must be considered to be formidable.

The Cataract Surgical System Industry: Presently, products currently in use are offered by the major manufacturers utilizing ultrasonic technology. Those systems rely on accessories including single-use cassette packs and other ancillary surgical disposables such as saline solution, sutures and intraocular lenses for their profits. The cassette packs are required for fluid and tissue collection during the surgical procedure. The cassette packs are generally unique and proprietary to their respective systems and represent a barrier to entry for third-party, lower-cost after-market suppliers. While there is growing market resistance in the United States and internationally to single-use cassettes, the Company anticipates that manufacturers of ultrasound equipment will continue to develop and enhance their present ultrasound products in order to protect their investments in system and cassette technology and to protect their profits from sales of these cassettes and accessories. The Company's Precisionist Thirty Thousand(TM) ultrasonic phaco system has the ability to use either reusable or single-use disposable components. The Photon(TM) laser cataract system will utilize probes and cassette packs designed for single-use and semi-disposable instruments priced at a level consistent with the demands of health care cost containment. This will allow the health care providers a

12

substantial measure of cost containment, while providing the Company with the quality control and income capability of cassette sales.

The international market, with significantly lower medical budgets, has not been able to justify the expense of using disposable components. Budgetary constraints have limited current manufacturers from gaining a significant share of the international ultrasound equipment market, and have provided a niche for the emerging smaller companies discussed above.

Ultrasound Equipment Manufacturers. As a relatively recent entrant into the cataract surgical equipment market with a newer equipment line, the Company is establishing itself and, as yet, does not hold a significant share of the market. The Company currently recognizes Bausch & Lomb, Alcon Laboratories, and Allergan Medical Optics as its primary competitors in the ultrasound phaco cataract equipment market.

Laser Equipment Manufacturers. To the Company's knowledge, there are several other companies attempting to develop laser equipment for cataract surgery. These companies can be differentiated by the laser wavelength employed for the cataract surgery. Based on the information currently available to the Company, Er:YAG laser wavelength appears to offer a less viable means of removing cataracts than the Nd:Yag wavelength used by the Photon(TM). One competitor uses a Nd:YAG wavelength, however the laser is used only to vibrate an ultrasonic needle. Thus the device remains an ultrasonic system subject to same risk factors of phaco, thereby eliminating the benefits of using a laser to remove the cataract. The Company also believes that its product is sufficiently distinctive and, if properly marketed, can capture a significant share of the cataract surgical device market. However, there are substantial risks in undertaking a new venture in an established and already highly competitive industry. In the short-term, the Company is seeking to exploit these

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

opportunities. Depending upon further developments, the Company may ultimately exploit those opportunities through a merger with a stronger entity already established or one that desires to enter the medical industry.

The Company believes that its ability to compete successfully will depend on its capability to create and maintain advanced technology, develop proprietary products, attract and retain scientific personnel, obtain patent or other proprietary protection for its products and technologies, obtain required regulatory approvals and manufacture, assemble and successfully market products either alone or through third parties.

The Retinal Diagnostic Market. The Glaucoma Research Foundation suggests that with the aging of the so-called baby boom generation, there will be an increase of macular degeneration and glaucoma in the United States, the leading causes of adult blindness worldwide. The National Eye Institute stated in 2002 that the number of visually impaired Americans is likely to double over the next three decades. Their report estimated that 2.4 million people suffer some vision impairment in the country. The damage caused by these diseases is irreversible. The preconditions for the onset of macular degeneration or glaucoma are low ocular blood flow and/or high intraocular pressure. Diagnostic screening is important for individuals susceptible to these diseases. People in high-risk categories include: African Americans over 40 years of age, all persons over 60 years of age, persons with a family history of glaucoma or diabetes, and the very near-sighted. The glaucoma Research Foundation recommends that these high-risk individuals be tested regularly for glaucoma. According to the U.S. Census Bureau, in 1995 there were over 30 million adults 65 years of age and older and 8 million African Americans 45 years of age and older. The Glaucoma Research Foundation reports that glaucoma currently accounts for more than 7 million visits to physicians annually.

The Company is subject to intense competition in the ophthalmic diagnostic market from well-financed, established companies with recognizable

13

trade names and product lines and new and developing technologies. The industry is dominated by several large entities which the Company believes account for the majority of diagnostic equipment sales. The Company to continues to derive revenues from the sale of its ultrasound diagnostic equipment and blood flow analyzer. The blood flow analyzer is designed to detect glaucoma in an earlier stage than is presently possible. In addition, the device performs tonometry and blood flow analysis. Other ophthalmic diagnostic devices that do not detect glaucoma in the early stages of the disease as does the Company's analyzer retail at comparable prices. The Company thus believes that it can compete in the diagnostic market place based upon the lower price and improved diagnostic functions of the analyzer.

Intellectual Property Protection

The Company's cataract surgical products are proprietary in design, engineering and performance. The Company's surgical ultrasonic products have not been patented to date because the primary technology for ultrasonic tissue fragmentation, as available to all competitors in the market, is mainly in the public domain.

The Company did acquire proprietary intellectual property in the transaction with Humphrey Systems when it purchased the diagnostic ultrasonic product line in 1999. This technology uses ultrasound to create a high-resolution computer image of the unseen parts of the eye that is a "map" for the practitioner.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

The Photon(TM) laser cataract probe is protected under a United States patent issued in 1987 to Daniel M. Eichenbaum, M.D. and subsequently assigned to Photomed International, Inc. ("Photomed") and a Japanese patent issued in 1997 to the Company for the utility and methods of laser ablation, aspiration and irrigation of tissue through a hand-held probe of a unique design. The Company secured the exclusive worldwide right to this patent shortly after its issue, and to the international patents pending, from Photomed by means of a license agreement (the "License Agreement"). The License Agreement was amended on December 5, 1997 to allow Photomed the right to conduct research, development and marketing utilizing the patent in certain medical sub-specialties other than ophthalmology for which the Company would receive royalty payments equal to 1% of the proceeds from the net sales of products utilizing the patent. See "Management" and "Certain Relationships and Related Transactions."

The Blood Flow Analyzer(TM) has been granted a patent in the European Economic Community and the United States and has a patent pending in Japan.

The Dicon(TM) Perimeter and the Dicon(TM) Corneal Topographer each have a U.S. patent with a wide scope of claims.

The Company's trademarks are important to its business. It is the Company's policy to pursue trademark registrations for its trademarks associated with its products as appropriate. Also, the Company relies on common law trademark rights to protect its unregistered trademarks, although common law trademark rights do not provide the Company with the same level of protection as would U.S. federal registered trademarks. Common law trademark rights only extend to the geographical area in which the trademark is actually used while U.S. federal registration prohibits the use of the trademark by any party anywhere in the United States.

The Company also relies on trade secret law to protect some aspects of its intellectual property. All of the Company's key employees, consultants and advisors are required to enter into a confidentiality agreement with the Company. Most of the Company's third-party manufacturers and formulators are also bound by confidentiality agreements with the Company.

Regulation

The Company's surgical and diagnostic systems are regulated as medical devices by the FDA under the FD&C Act. As such, these devices require Premarket clearance or approval by the FDA prior to their marketing and sale. Such clearance or approval is premised on the production of evidence sufficient for the Company to show reasonable assurance of safety and effectiveness regarding its products. Pursuant to the FD&C Act, the FDA regulates the manufacture, distribution and production of medical devices in the United States and the export of medical devices from the United States. Noncompliance with applicable requirements can result in fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, denial of Premarket clearance or approval for devices. Recommendations by the FDA that the Company not be allowed to enter into government contracts and criminal prosecution may also be made.

Following the enactment of the Medical Device Amendments to the FD&C Act in May 1976, the FDA began classifying medical devices in commercial distribution into one of three classes: Class I, II or III. This classification is based on the controls that are perceived to be necessary to reasonably ensure the safety and effectiveness of medical devices. Class I devices are those devices, the safety and effectiveness of which can reasonably be ensured through general controls, such as adequate labeling, advertising, Premarket notification

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

and adherence to the FDA's Quality System Requirements (QSR) regulations. Some Class I devices are exempt from some of the general controls. Class II devices are those devices the safety and effectiveness of which can reasonably be assured through the use of special controls, such as performance standards, postmarket surveillance, patient registries and FDA guidelines. Class III devices are devices that must receive Premarket approval by the FDA to ensure their safety and effectiveness. Generally, Class III devices are limited to life-sustaining, life-supporting or implantable devices, or to new devices that have been found not to be substantially equivalent to legally marketed devices.

There are two principal methods by which FDA approval may be obtained. One method is to seek FDA approval through a Premarket notification filing under Section 510(k) of the FD&C Act. If a manufacturer or distributor of a medical device can establish that a proposed device is "substantially equivalent" to a legally marketed Class I or Class II medical device or to a pre-1976 Class III medical device for which the FDA has not called for a PMA, the manufacturer or distributor may seek FDA Section 510(k) Premarket clearance for the device by filing a Section 510(k) Premarket notification. The Section 510(k) notification and the claim of substantial equivalence will likely have to be supported by various types of data and materials, possibly including clinical testing results, obtained under an IDE granted by the FDA. The manufacturer or distributor may not place the device into interstate commerce until an order is issued by the FDA granting Premarket clearance for the device. There can be no assurance that the Company will obtain Section 510(k) Premarket clearance for any of the future devices for which the Company seeks such clearance including the Photon(TM) Laser.

The FDA may determine that the device is "substantially equivalent" to another legally marketed Class I, Class II or pre-1976 Class III device for which the FDA has not called for a PMA, and allow the proposed device to be marketed in the United States. The FDA may determine, however, that the proposed device is not substantially equivalent, or may require further information, such as additional test data, before the FDA is able to make a determination regarding substantial equivalence. A "not substantially equivalent" determination or a request for additional information could delay the Company's market introduction of its products and could have a material adverse effect on the Company's business, operating results and financial condition.

The alternate method to seek approval is to obtain Premarket approval from the FDA. If a manufacturer or distributor of a medical device cannot establish that a proposed device is substantially equivalent to another legally marketed device, whether or not the FDA has made a determination in response to a Section 510(k) notification, the manufacturer or distributor will have to seek

Premarket approval for the proposed device. A PMA application would have to be submitted and be supported by extensive data, including preclinical and clinical trial data to prove the safety and efficacy of the device. If human clinical trials of a proposed device are required and the device presents a "significant risk," the manufacturer or the distributor of the device will have to file an IDE application with the FDA prior to commencing human clinical trials. The IDE application must be supported by data, typically including the results of animal and mechanical testing. If the IDE application is approved, human clinical trials may begin at a specific number of investigational sites, and the approval letter could include the number of patients approved by the FDA. An IDE clinical trial can be divided into several parts or Phases. Sometimes, a company will conduct a feasibility study (Phase I) to confirm that a device functions according to its design and operating parameters. This is usual clinical trial site. If the Phase I results are promising, the applicant may, with the FDA's permission, expand the number of clinical trial sites and the number of patients

to be treated to assure reasonable stability of clinical results. Phase II studies are performed to confirm predictability of results and the absence of adverse reactions. The applicant may, upon receipt of the FDA's authorization, subsequently expand the study to a third phase with a larger number of clinical trial sites and a greater number of patients. This involves longer patient follow-up times and the collection of more patient data. Product claims, labeling and core data for the PMA are derived primarily from this portion of the clinical trial. The applicant may also, upon receipt of the FDA's permission, consolidate one or more of such portions of the study. Sponsors of clinical trials are permitted to sell those devices distributed in the course of the study, provided such compensation does not exceed recovery of the costs of manufacture, research, development and handling. Although both approval methods may require clinical testing of the device in question under an approved IDE, the Premarket approval procedure is more complex and time consuming.

Upon receipt of the PMA application, the FDA makes a threshold determination whether the application is sufficiently complete to permit a substantive review. If the FDA determines that the PMA is sufficiently complete to permit a substantive review, the FDA will "file" the application. Once the submission is filed, the FDA has by regulation 90 days to review it; however, the review time is often extended significantly by the FDA asking for more information or clarification of information already provided in the submission. During the review period, an advisory committee may also evaluate the application and provide recommendations to the FDA as to whether the device should be approved. In addition, the FDA will inspect the manufacturing facility to ensure compliance with the FDA's QSR requirements prior to approval of a PMA. While the FDA has responded to PMA applications within the allotted time period, PMA reviews generally take approximately 12 to 18 months or more from the date of filing to approval. The PMA process is lengthy and expensive, and there can be no assurance that such approval will be obtained for any of the Company's products determined to be subject to such requirements. A number of devices for which PMA approval has been sought by other companies have never been approved for marketing.

Any products manufactured or distributed by the Company pursuant to a premarket clearance notification or PMA are or will be subject to pervasive and continuing regulation by the FDA. The FD&C Act also requires that the Company's products be manufactured in registered establishments and in accordance with QSR regulations. Labeling, advertising and promotional activities are subject to scrutiny by the FDA and, in certain instances, by the Federal Trade Commission. The export of medical devices is also subject to regulation in certain instances. In addition, the use of the Company's products may be regulated by various state agencies.

All lasers manufactured for the Company are subject to the Radiation Control for Health and Safety Act administered by the Center for Devices and Radiological Health of the FDA. The law requires laser manufacturers to file new product and annual reports and to maintain quality control, product testing and sales records, to incorporate certain design and operating features in lasers sold to end users pursuant to specific performance standards, and to comply with

labeling and certification requirements. Various warning labels must be affixed to the laser, depending on the class of the product, as established by the performance standards.

Although the Company believes that it currently complies and will continue to comply with all applicable regulations regarding the manufacture and sale of medical devices, such regulations are always subject to change and depend heavily on administrative interpretations. There can be no assurance that

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

future changes in review guidelines, regulations or administrative interpretations by the FDA or other regulatory bodies, with possible retroactive effect, will not materially adversely affect the Company. In addition to the foregoing, the Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of potentially hazardous substance. There can be no assurance that the Company will not be required to incur significant costs to comply with such laws and regulations and that such compliance will not have a material adverse effect upon the Company's ability to conduct business.

The Company and the manufacturers of the Company's products may be inspected on a routine basis by both the FDA and individual states for compliance with current QSR regulations and other requirements.

Congress has considered several comprehensive federal health care programs designed to broaden coverage and reduce the costs of existing government and private insurance programs. These programs have been the subject of criticism within Congress and the health care industry, and many alternative programs and features of programs have been proposed and discussed. Therefore, the Company cannot predict the content of any federal health care program, if any is passed by Congress, or its effect on Company and its business. Some measures that have been suggested as possible elements of a new program, such as government price ceilings on non-reimbursable procedures and spending limitations on hospitals and other healthcare providers for new equipment, could have an adverse effect on the Company's business, operating results or financial condition. Uncertainty concerning the features of any health care program considered by the Congress, its adoption by the Congress and the effect of the program on the Company's business could result in volatility of the market price of the Company's Common Stock.

Furthermore, the introduction of the Company's products in foreign countries may require the Company to obtain foreign regulatory clearances. The Company believes that only a limited number of foreign countries have extensive regulatory requirements, including France, Germany, Korea, China and Japan. The time involved for regulatory approval in foreign countries varies and can take a number of years. A number of European and other economically advanced countries, including Italy, Norway, Spain and Sweden, have not developed regulatory agencies for intensive supervision of such devices. Instead, they generally have been willing to accept the approval of the FDA. Therefore, a PMA, Section 510(k) or approved IDE from the FDA is tantamount to approval in those countries. These countries and most developing countries have simply deferred direct discretion to licensed practicing surgeons to determine the nature of devices that they will use in medical procedures. The Company's two ultrasound systems, the Photon(TM) laser cataract system the Company is developing and the ocular blood flow analyzer are all devices, which require FDA approval. Therefore, a significant aspect of the acceptance of the devices in the market is the effectiveness of the Company in obtaining the necessary approvals. Having an approved IDE allows the Company to export a product to qualified investigational sites.

Regulatory Status of Products

All of the Company's products, with the exception of the Photon(TM) are approved for sale in the U. S. by the FDA under a 510(k). All of the Companies products have been accepted for import into CE countries and various non-CE countries.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Laser Cataract System outside the United States under an open IDE granted by the FDA in September 1994. Although the Photon(TM) laser cataract system is uniquely configured in an original and proprietary manner, the laser system, a Nd:YAG laser, is not proprietary to the device or the Company and is widely used in the medical industry and other industries as well. Of particular significance is the fact that this particular component has received previous market clearance from the FDA for other ophthalmic and medical applications. Also of significance is the Company's belief that the surgical treatment method used with the Photon(TM) laser is similar to the current ultrasound cataract treatment employed by ophthalmologists.

The Company submitted a Premarket Notification 510(k) application to the FDA for the Photon(TM) laser cataract system in September 1993. The FDA requested clinical support data for claims made in the 510(k), and in October 1994 the Company submitted an IDE application to provide for a "modest clinical study" in order to collect the data required by the FDA for clearance of the Photon(TM) laser cataract system. The FDA granted this IDE in May 1995 for a Phase I Feasibility Study. The Company began human clinical trials in April 1996 and completed the Phase I study in November 1997. The Company started Phase II trials in September 1998 and completed numerous cases of treatment group and control group patients which were included in the Company's submission to the FDA. The Company received a warning letter dated August 30, 2000, from the Office of Compliance, Center for Devices and Radiological Health of the Food and Drug Administration ("FDA") relating to the human clinical trials for its Photon(TM) Laser Cataract System. The warning letter concerns the conditions found by the FDA during several audits at Company's clinical sites. The FDA's comments were isolated to the administrative procedures of compiling data from the clinical sites. The Company responded to the warning letter in a submission dated September 27, 2000. In the submission the Company took corrective action that included submitting a revised clinical protocol and case report forms and procedures for the collection and control of data. In a subsequent letter dated November 2, 2000 to the Company, the FDA requested clarification of two issues.

Subsequent to the warning letter, the Company received approval to continue its clinical trials, the results of which were included in its supplemental submission to the FDA for the existing (510)(k) predicate device application for the Photon(TM) laser system. In December 2001, the Company received a preliminary review from the FDA regarding the supplemental submission. As a result of that preliminary review, the Company submitted additional clinical information to the FDA on February 6, 2002. The application is receiving on-going review by the FDA. The Company believes all items in the warning letter have been satisfied and the clinical trials and their data are in good standing.

Employees

As of December 31, 2001, the Company had 88 full-time employees. This number does not include the Company's manufacturer's representatives who are independent contractors rather than employees of the Company. The Company also utilizes several consultants and advisors. There can be no assurance that the Company will be successful in recruiting or retaining key personnel. None of the Company's employees is a member of a labor union and the Company has never experienced any business interruption as a result of any labor disputes.

Item 2. Description of Property

The Company's executive offices are currently located at 2355 South 1070 West, Salt Lake City, Utah. This facility consists of approximately 29,088

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

square feet of leased office space under a three-year lease that will expire on March 1, 2003 with an additional three-year renewal option. These facilities are leased from Eden Roc, a California partnership, at a base monthly rate of \$15,999 plus a \$2,356 monthly common area maintenance fee. The base monthly rent increases to \$16,479 and \$16,973 for the second and third years of the lease, respectively. Pursuant to the lease, the Company pays all real estate and personal property taxes and the insurance costs on the premises.

The Company maintains a facility located at 10373 Roselle Street, San Diego, California. This facility consists of approximately 25,952 square feet of leased office space under a five-year lease that will expire on August 1, 2002. These facilities are leased from Torrey Sorrento Associates, Ltd., a California limited partnership, at a gross monthly rate of \$17,544. The Company is currently looking at various alternatives to securing suitable facilities by the end of the lease term.

The Company believes that these facilities are adequate and satisfy its needs for the foreseeable future.

Item 3. Legal Proceedings

An action was brought against the Company in March 2000 by George Wiseman, a former employee, in the Third District Court of Salt Lake County, State of Utah. The complaint alleges that the Company owes Mr. Wiseman 6,370 shares of its common stock plus costs, attorney's fees and a wage penalty (Equal to 1,960 additional shares of Paradigm common stock) pursuant to Utah law. The action is based upon an extension of a written employment agreement. The Company believes the complaint is without merit and intends to vigorously defend against the action.

An action was brought against the Company in September 2000 by PhotoMed International, Inc. and Daniel M. Eichenbaum in the Third District Court of Salt Lake County, State of Utah. The action involves an amount of royalties that are allegedly due and owing to PhotoMed International, Inc. and Dr. Eichenbaum with respect to the sales of certain equipment plus attorney's fees. Discovery has taken place and the Company has paid royalties of \$15,000 to bring all payments up to date through June 30, 2001. However, the legal action has not been dismissed as a result of the payments. The Company is in the process of working with Photomed International and Dr. Eichenbaum to ensure that the calculations have been correctly made on the royalties paid as well as the proper method of calculation for the future. It is anticipated that once the parties can agree on the correct calculations on the royalties, the legal action will be dismissed.

An Action was brought against the Company on March 7, 2000 in the Third District Court of Salt Lake County, State of Utah, by Merrill Corporation that alleges that the Company owes the plaintiff approximately \$20,000 together with interest thereon at the rate of 10% per annum from August 30, 1999, plus costs and attorney's fees. The complaint alleges a breach of contract relative to printing services. The Company has filed an answer to the complaint and discovery is proceeding. The Company believes that the complaint against the Company is without merit and intends to vigorously defend against the action.

The Company is not a party to any other material legal proceedings outside the ordinary course of its business or to any other legal proceedings which, if adversely determined, would have a material adverse effect on the Company's financial condition or results of operations.

Item 4. Submission of Matters to a Vote of Security Holders

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

At a special meeting of the shareholders held on December 28, 2001 to approve the proposed amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 20,000,000 to 40,000,000 shares, it was determined to adjourn the meeting until January 28, 2002 because the shares entitled to vote, which were present in person or represented by proxy, did not constitute a quorum at the meeting. At the January 28, 2002 special meeting of the shareholders, the proposed amendment to the

19

Certificate of Incorporation was approved (with votes cast of 10,474,115 for, 1,076,070 votes against and 39,740 votes abstaining).

PART II

Item 5. Market for Common Equity and related Stockholder Matters

The Authorized capital stock of the Company consists of 20,000,000 shares of Common Stock, \$.001 par value per share, and 5,000,000 shares of Preferred Stock, \$.001 par value per share. The Company has created six classes of Preferred Stock, designated as Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock.

The Company's Common Stock and Class A Warrants trade on The Nasdaq SmallCap Market under the respective symbols of "PMED" and "PMEDW." Prior to July 22, 1996, there was no public market for the Common Stock. As of March 31, 2002 the closing sale prices of the Common Stock and Class A Warrants were \$2.93 per share and \$0.19 per warrant, respectively. The following are the high and low sales prices for the Common Stock and Class A Warrants by quarter as reported by Nasdaq since January 1, 2000.

Period (Calendar Year)	Common Stock Price Range		Class P
	High	Low	High
2000			

First Quarter	14.500	6.880	6.500
Second Quarter	10.500	4.190	3.630
Third Quarter	6.190	3.380	2.000
Fourth Quarter	4.940	1.310	1.250
2001			

First Quarter	4.130	1.500	1.000
Second Quarter	3.540	1.610	0.740
Third Quarter	2.750	1.860	0.450
Fourth Quarter	3.080	1.940	0.390
2002			

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

First Quarter

3.310

2.210

0.380

The Company's Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock are not publicly traded. As of March 31, 2002, there were 717 record holders of Common Stock, five record holders of Series A Preferred Stock, three record holders of Series B Preferred Stock, no record holders of Series C Preferred Stock, two record holders of Series D Preferred Stock, 17 holders of Series E Preferred Stock and 56 holders of Series F Preferred Stock.

20

The Company has never paid any cash dividends on its Common Stock and does not anticipate paying any cash dividends on its Common Stock in the foreseeable future. The Company must pay cash dividends to holders of its Series A Preferred, Series B Preferred, Series C Preferred, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock before it can pay any cash dividend to holders of its Common Stock. Dividends paid in cash pursuant to outstanding shares of the Company's Series A, Series B, Series C, Series D, Series E and Series F Preferred Stock are only payable from surplus earnings of the Company and are non-cumulative and therefore, no deficiencies in dividend payments from one year will be carried forward to the next. The Company currently intends to retain future earnings, if any, to fund the development and growth of the Company's proposed business and operations. Any payment of cash dividends in the future on the Common Stock will be dependent upon the Company's financial condition, results of operations, current and anticipated cash requirements, plans for expansion, restrictions, if any, under any debt obligations, as well as other factors that the Company's Board of Directors deems relevant. The Company issued 6,764 shares of its Series A Preferred and 6,017 shares of its Series B Preferred on January 8, 1996 as a stock dividend to Series A and Series B shareholders of record as of December 31, 1994.

Item 6. Management's Discussion and Analysis or Plan of Operation

This report contains forward-looking statements and information relating to the Company that is based on beliefs of management as well as assumptions made by, and information currently available to management. These statements reflect the current view of the Company respecting future events are subject to risks, uncertainties and assumptions, including the risks and uncertainties noted throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward-looking statements not to come true as anticipated, believed, projected, expected or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended.

General

The following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements which involve risks and uncertainty. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors discussed in this section. The Company's fiscal year is from January 1 through December 31.

The Company's ultrasound diagnostic products include a pachymeter, an A-Scan, an A/B Scan and a biomicroscope, the technology for which was acquired

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

from Humphrey Systems in 1998. The Company introduced the P45 in the fall of 2000 which combines the A/B Scan and the biomicroscope in one machine. In addition, the Company markets its Blood Flow Analyzer(TM) acquired in the purchase of Ocular Blood Flow Ltd. in June 2000. Other diagnostic products are the Dicon (TM) Perimeter and the Dicon (TM) Corneal Topographer which were acquired in the acquisition of Vismed d/b/a Dicon in June 2000. The Company purchased the inventory and design and production rights of the SIStem(TM) from Mentor Corporation in October 1999 which was designed to perform minimally invasive cataract surgery. In November 1999, the Company entered into a Mutual Release and Settlement Agreement with the manufacturer of the Precisionist ThirtyThousand(TM) in which the Company purchased the raw material and finished goods inventory to bring the manufacturing of this product in-house. FDA approval for the Company's Photon(TM) laser system for cataract removal is in process.

21

Activities for the twelve months ended December 31, 2001 included sales of the Company's products and related accessories and disposable products. The Company completed a sufficient number of cases in its Phase II Clinical Trials relating to the Photon(TM) laser system (many of which were audited by independent parties) to be included in its supplemental submission to the FDA for the existing (510)(k) predicate device application for the Photon(TM) laser system. In December 2001, the Company received a preliminary review from the FDA regarding the supplemental submission. As a result of that preliminary review, the Company submitted additional clinical information to the FDA on February 6, 2002. The application is receiving on-going review by the FDA. If the FDA approves the application, the Company will be able to market its Photon(TM) laser system within the United States. In December 2001, the Company announced a reduction of force of total personnel of approximately 20% (22 employees). The layoff was intended to save costs and to eliminate duplicities in functions that occurred with the acquisition of Dicon. The Company believes that the elimination of headcount will not adversely affect its operations.

The tragic events of September 11, 2001 combined with a recessionary trend in the economy have had a negative effect on the Company's sales. International attendance at the largest trade show of the year in November 2001 was down markedly. The absence of these professionals eliminates many opportunities for the Company to demonstrate and sell its products to this sector. It is difficult to quantify how much an effect that these events have had on the Company, but management believes that the Company has suffered some negative impact due to September 11, 2001 and the downturn in the economy in general which may continue for an indefinite period of time.

On June 5, 2000 the Company purchased under a pooling of interest Vismed Inc. d/b/a Dicon(TM), a California Corporation and manufacturer and distributor of diagnostic instrumentation for the detection of chronic eye diseases. The purchase included the Dicon(TM) perimeter product line consisting of the LD 400, the TKS 4000, the SST(TM), FieldLink(TM), FieldView(TM) and Advanced FieldView and the corneal topographer product line the CT200(TM), the CT50 and an ongoing service and software business. Perimeters are used to determine retinal sensitivity, testing the visual pathway. Corneal topographers are used to determine the shape and integrity of the corneal and anterior surface of the eye. Corneal topographers are used for the refractive surgical applications that eliminate the need for eyeglasses and for optometric applications, including contact lens fitting.

In June of 2000, the Company completed the purchase of Ocular Blood Flow Ltd. ("OBF"). OBF manufactured a blood flow analyzer representing proprietary technology for measuring blood flow to the eye. Many clinicals were performed demonstrating the clinical efficacy of the product in glaucoma. The

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Company received authorization in April 2001 to use a CPT code that provides for a reimbursement to doctors for procedures performed on patients using the Blood Flow Analyzer(TM). In 2001, the manufacturing activities were moved from England to the Company's facilities in San Diego, California.

Results of Operations

Fiscal Year Ended December 31, 2001 Compared to Fiscal Year Ended

December 31, 2000:

Consolidated sales for the twelve months ended December 31, 2001 were \$7,919,000 compared to \$7,989,000 for the same period for 2000, approximately a 1% decrease. The Company restructured its outside sales force during 2001 to provide nationwide coverage. This resulted in a slow down of sales activity due to the time it took to hire and train the new personnel. The Company believes that sales activity was hampered for about a ninety day period. The Company also launched in earnest the sales of the Blood Flow Analyzer(TM) during the second quarter of 2001 after receiving authorization to use a CPT code which provides for a reimbursement to doctors. The Company believes that the investment in

22

time, training and resources in developing the sales force will provide positive results in the future despite a loss of sales activity in 2001.

Sales of the Blood Flow Analyzer(TM) was the single largest contributor to total 2001 revenues generating slightly less than \$2,000,000 (25%) of revenues. Sales in 2000 were not significant as the major marketing efforts did not take place until 2001. Sales of the P45 ultrasonic Biomicroscope workstation accounted for approximately 9% of total 2001 revenues, or \$686,000, compared to approximately a 3% contribution to total 2000 revenues, or \$219,000. The P45 was introduced by the Company in the fall of 2000 resulting in a full year's of selling activity during 2001 as compared to a few months during 2000. The remainder of the ultrasonic product line (UBM, A-Scan, A/B scan and Pachymeter) contributed \$1,543,000 in revenues in 2001 (19%) compared to \$2,027,000 in 2000 (25%).

Sales of the perimeter and corneal topographer decreased by \$1,283,000, from \$3,411,000 in 2000 (43%) to \$2,128,000 (27%). The perimeter and corneal topographer, both mature products, declined in sales in 2000 from those in 1999 by approximately 20%. One of the strategies of the Dicon/Paradigm merger in June of 2000 was to piggyback these products with the phaco surgical line to achieve penetration into the ophthalmic market, in addition to the optometric market, resulting in a growth in the sales of the Dicon products. This anticipated growth has not occurred and may continue to decrease in the future or remain at a lower level than originally expected.

The phaco surgical line and related disposable products accounted for approximately \$641,000 (8%) of total revenues for the twelve months ended December 31, 2001 compared to \$1,144,000 (14%) in revenues for the same period in 2000. The Company concentrated much of its marketing focus on its diagnostic products (Blood Flow Analyzer(TM) and the Ultrasonic Biomicroscope Workstation or P45) during 2001. The Company also continued aggressively in its efforts to obtain FDA approval for its Photon(TM) laser system. The Company did not recognize any sales of its Photon(TM) laser system in 2001. The Photon(TM) cannot be sold within the United States until FDA approval is received. International sales of the Photon(TM) did not occur due in part to the lack of FDA approval. Although not required in the international market, the Company believes many potential customers rely on the FDA approval of products before

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

purchasing.

The gross profit on sales for the fiscal year 2001 was approximately 38% compared to 17% for the same period in 2000. The sharp difference was due principally to an inventory write-down of \$1,596,000 during 2000 to net realizable value. Gross profit on sales for the fiscal year ended December 31, 1999 was 38% which indicates a more consistent trend with the exception of the inventory adjustment that was recognized in 2000.

Marketing and selling expenses increased \$812,000, or 21%, to \$4,762,000 for the twelve months ended December 31, 2001 from \$3,950,000 for the comparable period in 2000. The Company increased costs for enhanced tradeshow participation of \$355,000 due mainly to expenses incurred in relation to the annual meeting of the American Academy of Ophthalmology in November 2001. This is the largest event in the country in which the Company participates. This increase was also partly due to the addition of fifteen direct sales people to cover the United States rather than working through distributors adding approximately \$382,000 of additional expenses. The hiring of the sales force took place during the second and third quarters of 2001 and will result in a higher level of expenses in the form of salaries and travel reimbursements in future operating periods.

General and administrative expenses decreased by \$307,000, or 6%, to \$5,125,000 for the 2001 fiscal year from \$5,432,000 for the comparable period in 2000. The Company had recognized \$1,883,000 in non-cash transactions during 2000 by granting warrants to non-employees as payment for services, stock bonuses granted to officers of the Company and stock granted to non-employees as payment

23

for services. During 2001, the Company recorded \$558,000 of non-cash transactions from granting warrants and stock to non-employees for consulting services. Consulting expenses paid in cash for financial and investor relations services increased by approximately \$165,000 over the comparable period in 2000. The Company initiated procedures to cancel or not to renew outside consulting agreements during the fourth quarter of 2001.

The expenses associated with clinical trials for the FDA approval process for the Photon(TM) increased over the 2000 fiscal year by approximately \$67,000. Payroll and benefits expense increased approximately \$350,000 from 2000 to 2001. The number of personnel decreased over the second half of 2000, due to a shift in responsibilities between the Salt Lake and San Diego facilities and to attrition as a result of the merger. Responsibilities were redistributed between the two facilities at the beginning of 2001, and personnel were rehired. A new Chief Financial Officer was hired in the fourth quarter of 2000, filling a nine-month vacancy. Travel expenses increased by \$84,000 in 2001, largely as a result of travel between the Salt Lake and San Diego facilities and due diligence pertaining to potential international acquisitions. An increase in depreciation expense of \$42,000 in 2001 was due to the acquisition of approximately \$455,000 of additional capital items and a full year of depreciation expense which was recognized on the \$613,000 of capital equipment and software purchased in 2000.

Other increases included general liability and directors' and officers' insurance premiums totaling \$40,000. Amortization expense of the intangible resulting from the OBF acquisition was \$40,000 more than the amortization expense recorded in 2000 because the purchase did not take place until June 2000. Approximately, \$84,000 of expense was contributed by OBF as a result of closing down their physical operations and transferring the manufacturing process to San Diego including travel and shipping costs.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Research and Development expenses (which includes production and manufacturing support and the service department expenses) increased by \$980,000, or 69%, to \$2,405,000 for the twelve months ended December 31, 2001 from \$1,425,000 for the same period in 2000. This increase was due principally to added personnel in engineering, in service and in manufacturing support. As a result, payroll and benefits expense increased by a total of \$692,000 in anticipation of sales demands which did not occur as expected. Personnel in this area, therefore, were affected by the layoffs at the end of December 2001 in a strategic decision to retain and focus resources in the sales and marketing area. Consulting expense and purchases of sample parts and tooling related to new product development increased by \$182,000, and \$145,000, respectively. The main development project in 2001 was postponed to concentrate sales efforts on the Company's existing product line and to aggressively pursue FDA approval for its Photon(TM) laser.

Net interest income was approximately \$6,000 during 2001 compared to \$130,000 for the twelve months ended December 31, 2000 due to increased interest expense incurred by entering into capital leases for the purchase of certain fixed assets and due to smaller amounts of cash on deposit during 2001. Other expense included a charge to expense of \$812,000 representing the value of the 350,000 shares of common stock issued to Mentor Corporation in settlement of a legal action brought against the Company.

The Company incurred a net loss of \$13,044,000, or \$.98 per share based upon 13,245,000 weighted average shares outstanding for the year ended December 31, 2001. This compares to a net loss of \$9,305,000, or \$.81 per share, based on 11,547,000 weighted average shares outstanding for the year ended December 31, 2000. The increase in the net loss attributable to common shareholders was due principally to losses recognized in accordance with Financial Accounting Standards Board Statement Number 123 ("SFAS 123") in connection with two private placements offered by the Company in 2001 of \$2,901,000 (\$2,587,000 was attributable to the beneficial conversion feature included in the Series E and Series F Preferred Stock offerings and \$314,000 represented the computed value of the warrants associated with the Series E Preferred Stock offering). No such

24

expense calculation was included in the net loss for the fiscal year 2000. The Mentor settlement charge of \$812,000 included in the net loss for 2001 was an increase over the comparable period a year ago.

Fiscal Year Ended December 31, 2000 Compared to Fiscal Year Ended

December 31, 1999:

On June 5, 2000, the Company concluded a pooling of interests transaction with Vismed, Inc., d/b/a Dicon. As a result of the pooling, and in accordance with GAAP, the financial results of each organization are reported as though they were one for all periods presented.

Consolidated sales increased by \$515,000, or 7%, to \$7,989,000 for the twelve months ended December 31, 2000, from \$7,474,000 for the comparable period in 1999. Sales of the phaco surgical line, the ultrasonic product line, and related accessories increased \$2,258,000, which were offset by a decrease in sales of the Perimeter, the Corneal Topographer, and the Blood Flow Analyzer.

Sales of the phaco surgical line accounted for approximately \$1,144,000, or 51%, of the \$2,258,000 increase in sales from 1999 to 2000. Of this increase, \$1,057,000 was due to sales of the Mentor SISem and related

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

consumables and accessories. The increase in sales of the Mentor SIStem from 1999 to 2000 was attributed to the fact that the Mentor product line was purchased at the end of October 1999, affording only two months of sales activity in the year 1999, compared to a full year of sales activity in 2000.

Sales of the ultrasonic product line and related accessories accounted for approximately 1,114,000, or 49% of the \$2,258,000 increase. Shipment of the ultrasonic product line did not commence until June 1999, once these products were released for production, affording seven months sales activity in the year 1999, compared to a full year of sales activity in 2000.

Sales of the Perimeter and Corneal Topographer decreased by \$1,717,000 from 1999 to 2000, with approximately 78% of the decrease attributed to sales in the domestic market. The Perimeter and Corneal Topographer, both mature products, have seen a decline in sales over the past two years, both at a rate of approximately 20% per year. The anticipation with the Dicon/Paradigm merger in mid 2000 was that the combination of sales forces and the Pharmacea-Upjohn alliance would piggyback these products with the phaco surgical line to begin their penetration into the ophthalmic market, in addition to the optometric market, resulting in a growth in their sales. Such growth had not taken place as of year-end 2000.

Cost of sales increased by \$2,002,000, or 43%, to \$6,626,000 for the twelve months ended December 31, 2000, from \$4,624,000 for the like period in 1999. The gross profit on sales of 17% for the fiscal year ended December 31, 2000 was 55% lower than the gross profit on sales of 38% for the year ended December 31, 1999. This sharp profit margin decline can be attributed principally to an inventory write-down of \$1,596,000 for the fiscal year 2000 to net realizable value and an increase of \$167,000 in the reserve for obsolete inventory. Many inventory items obtained principally through the acquisition of new product lines were reduced in cost to reflect obsolescence, technological advances and product enhancements.

Of the total inventory write-down amount, \$419,000 in parts and finished goods was utilized for further research and development, \$299,000 was deemed obsolete, and \$878,000 was a cost adjustment. Of the \$878,000 cost adjustment, 74% was for the ultrasonic line, 21% for the Mentor line, and 5% for the Zevex line.

25

The Humphrey ultrasonic product line was purchased in July 1998, the Mentor line in October 1999, and the Zevex inventory in November 1999. Because of engineering redesign, many of the raw material components associated with all three product lines were changed to reflect current technology, and/or were found at lower costs after re-quoting suppliers. In the process of redesigning for production, some components were deemed obsolete. The \$299,000 deemed obsolete consisted of items from all product lines.

Marketing and selling expenses increased by \$994,000, or 34%, to \$3,950,000 for the twelve months ended December 31, 2000, from \$2,956,000 for the comparable period in 1999. This increase was partly the result of the addition of three international area managers in an effort to improve the international distribution system, and employing a United States direct sales force rather than working through distributors. Payroll expenses increased by \$384,000, commissions increased by \$95,000 and travel expenses increased by \$66,000. The increase also included building of additional awareness in the international market, increased tradeshow participation, and updating marketing materials to reflect company integration due to the merger. This resulted in an increase in advertising and tradeshow expenses of \$399,000.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

General and administrative expenses increased by \$2,049,000, or 61%, to \$5,432,000 for the twelve months ended December 31, 2000, from \$3,383,000 for the comparable period in 1999. This increase was mainly due to certain non-cash transactions in the total amount of \$1,883,000, resulting from warrants granted to non-employees as payment for services, stock bonuses granted to officers of the company, and stock granted to non-employees as payment for services. Also included in the increase is \$167,000 paid to Cyndel & Co. for consulting services rendered during the year 2000.

Research and development expenses increased by \$205,000, or 17%, to \$1,425,000 for the twelve months ended December 31, 2000, from \$1,220,000 for the same period in 1999. This increase was due in part as the result of added personnel in engineering and regulatory affairs increasing personnel costs by \$91,000. Expenses related to new product development increased by \$32,000, and FDA clinical expenses increased by \$14,000.

Other income (expense) increased by \$161,000, or 732%, to \$139,000 for the twelve months ended December 31, 2000, from (\$22,000) for the same period in 1999. This was due to interest earned on investment in money market instruments in the year 2000 and a decrease in interest paid on debt in the same year.

The Company had a net loss of \$9,305,000, or \$.81 per share, based on 11,547,000 weighted average shares outstanding for the year ended December 31, 2000. This is compared to a net loss of \$4,731,000, or \$.62 per share, based on 7,655,000 weighted average shares outstanding for the year ended December 31, 1999, an increase of \$4,574,000. The increase in the net loss was partially attributable to the Black-Scholes valuation for warrants granted non-employees in payment for services (\$529,000), the valuation of stock granted non-employees and officers of the company (\$1,404,000), and a write-down of inventory (\$1,596,000) principally for devaluation of certain active inventory items due to technical advances, product enhancements, and obsolescence. The increase was also attributable to an increase in consulting and regulatory fees paid in connection with ISO 9001 and CE Mark certification and FDA compliance of \$195,000, investment banking fees of \$138,000 and in the addition of personnel company-wide for \$389,000.

Liquidity and Capital Resources

The Company used cash in operating activities of \$8,799,000 for twelve months ended December 31, 2001, compared to \$5,424,000 for the twelve months ended December 31, 2000. The Company increased its net inventory balance by

26

\$684,000 during the year in anticipation of building product to meet sales demand, more specifically, for the Blood Flow Analyzer and the P45 ultrasonic Biomicroscope workstation plus. Trade receivables increased mainly due to the increased sales during the fourth quarter 2001 of \$787,000. The Company incurred higher operating expenses during the year related to sales and marketing and product development and service. The company used cash in investing activities of \$246,000 for the twelve months ended December 31, 2001, compared to \$725,000 for the year 2000. The difference was due to investment in property and equipment for production of the Precisionist(TM) system, the move to a larger facility, and cash paid for the acquisition of OBF Labs and the merger with Vismed d/b/a Dicon during 2000. Net cash provided by financing activities for the twelve months ended December 31, 2001, was \$9,553,000, compared to \$7,225,000 for the year ended December 31, 2000. The Company received \$8,964,000 in net proceeds from two private placements, the Series E and Series F Preferred Stock offerings during 2001. The Company also sold 392,000 shares of its common stock under the \$20,000,000 equity line for \$673,000 in 2001 reducing the amount available under the equity line to

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

approximately \$19,000,000. Debt reduction for the year was \$85,000.

As the Company gained regulatory approval of its products, it was aggressive in gaining market presence. The majority of revenues during 2000 were derived from the sales of product in foreign countries. Because of the foreign nature of these revenues and the more liberal acceptance of customers in order to gain market share and product awareness, the Company experienced difficulty in the collection of receivables. As of December 31, 2000, the Company's allowance for doubtful accounts was 19% of total outstanding receivables. The Company has taken measures to reduce the amount of uncollectible accounts receivable such as more thorough and stringent credit approval, improved training and instruction by sales personnel, and frequent direct communication with the customer subsequent to delivery of the system. The allowance for doubtful accounts was 13% of total outstanding receivables as of December 31, 2001. Much of the increase in the outstanding receivable balance occurred during the fourth quarter of 2001 due to the increased sales of primarily the Blood Flow Analyzer(TM) in the United States. The Company has addressed its credit procedures and collection efforts during 2001 and believes that the enhanced procedures will produce positive results. Therefore, the Company believes that the allowance for doubtful accounts is adequate at 13% of total outstanding receivables as of December 31, 2001 compared to 19% of the 2000 year end receivable balance.

The Company carries an allowance for obsolete inventory of \$371,000 as of December 31, 2001, or approximately 7% of total inventory. The Company recorded an allowance for obsolete inventory of \$489,000 which was approximately 10% of total inventory at December 31, 2000 and incurred \$1,596,000 of expenses by adjusting inventory to its net realizable value during 2000. The Company's means of expansion and development of product has been largely from acquisition of businesses, product lines, existing inventory, and the rights to specific products. Through such acquisitions, the Company acquired substantial inventory, some of which the eventual use and recoverability was uncertain.

As of December 31, 2001 the Company had raised approximately \$933,000 through a \$20,000,000 equity line of credit under an investment banking arrangement, which the Company will continue to use, if required. As of December 31, 2001, approximately \$19,000,000 was available under the equity line of credit. Management anticipates that the combination of existing working capital and the private equity line of credit will be sufficient to assure continuation of the Company's operations through December 31, 2002. The Company will also seek funding to meet its working capital requirements through other collaborative arrangements and strategic alliances, additional public offerings and/or private placements of its securities or bank borrowings, if necessary. There can be no assurance, however, that additional funds, if required, will be available from any of the foregoing or other sources on favorable terms.

At December 31, 2001, the Company had net operating loss carry-forwards (NOLs) of approximately \$34,000,000 and research and development tax credit carry-forwards of approximately \$240,000. These carry-forwards are available to offset future taxable income, if any, and began to expire in the year 2001 and

27

extend for twenty years. The Company's ability to use its NOLs to offset future income is dependent upon the tax laws in effect at the time the NOLs can be utilized. The Tax Reform Act of 1986 significantly limits the annual amount that can be utilized for certain of these carry-forwards as a result of changes of ownership.

Effect of Inflation and Foreign Currency Exchange

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

The Company has not realized a reduction in the selling price of the Precisionist phaco system as a result of domestic inflation. Nor has the Company experienced unfavorable profit reductions due to currency exchange fluctuations or inflation with its foreign customers. All sales transactions to date have been denominated in US Dollars.

Impact of New Accounting Pronouncements

In July 2001, the Financial Accounting Standards Board ("FASB") issued Statements of Financial Accounting Standards No. 141 ("SFAS 141"), "Business Combinations." SFAS 141 eliminates the pooling-of-interests method of accounting for business combinations except for qualifying business combinations that were initiated prior to July 1, 2001. In addition, SFAS 141 further clarifies the criteria to recognize intangible assets separately from goodwill. Specifically, SFAS 141 requires that an intangible asset may be separately recognized only if such an asset meets specific criterion. The requirements of Statement 141 are effective for any business combination accounted for by the purchase method that is completed after June 30, 2001. The Company is currently evaluating the impact of SFAS 141 and has not yet determined the impact that adopting SFAS 141 will have on its financial statements. On adoption, the Company will be required to reassess the goodwill and intangible assets previously recorded in acquisitions prior to July 1, 2001 to determine if the new recognition criteria for an intangible asset to be recognized apart from goodwill are met.

In July 2001, the FASB issued Statements of Financial Accounting Standards No. 142 ("SFAS 142"), "Goodwill and Other Intangible Assets." Under SFAS 142, goodwill and indefinite lived intangible assets are no longer amortized but are reviewed annually (or more frequently if impairment indicators arise) for impairment. For intangible assets with indefinite useful lives, the impairment review will involve a comparison of fair value to carrying value, with any excess of carrying value over fair value being recorded as an impairment loss. For goodwill, the impairment test shall be a two-step process, consisting of a comparison of the fair value of a reporting unit with its carrying amount, including the goodwill allocated to each reporting unit. If the carrying amount is in excess of the fair value, the implied fair value of the reporting unit goodwill is compared to the carrying amount of the reporting unit goodwill. Any excess of the carrying value of the reporting unit goodwill over the implied fair value of the reporting unit goodwill will be recorded as an impairment loss. Separable intangible assets that are deemed to have a finite life will continue to be amortized over their useful lives (but with no maximum life). Intangible assets with finite useful lives will continue to be reviewed for impairment in accordance with Statements of Financial Accounting Standards No. 121 ("SFAS 121"), "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of."

The amortization provisions of SFAS 142 apply to goodwill and intangible assets acquired after June 30, 2001. With respect to goodwill and intangible assets acquired prior to July 1, 2001, the Company will apply the new accounting rules beginning July 1, 2002 and will reassess the useful lives of its separately recognized intangible assets in the third quarter of fiscal 2002. The Company will review for impairment previously recognized intangible assets that are deemed to have indefinite lives upon the completion of this analysis in

the first quarter of fiscal 2003. Additionally, upon the adoption of SFAS 142, the Company will perform a transitional impairment review related to the carrying value of goodwill as of July 1, 2002 by the end of the third quarter of fiscal 2002. The Company is currently in the process of determining its

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

reporting units for the purpose of applying the impairment test, analyzing how fair value will be determined for purposes of applying SFAS 142 and quantifying the anticipated impact of adopting the provisions of SFAS 142. Amortization of goodwill was \$80,000 for the twelve months ended December 31, 2001.

In August 2001, the FASB issued Statement of Financial Accounting Standards No. 144 ("SFAS 144"), "Accounting for the Impairment or Disposal of Long-Lived Assets," which supercedes SFAS 121 and the provisions of Accounting Principles Board Opinion (APB 30), "Reporting the Results of Operations -- Reporting the Effects of Disposal of a Segment of a Business, and extraordinary, Unusual and Infrequently Occurring Events and Transactions" with regard to reporting the effects of a disposal of a segment of a business. SFAS 144 retains many of the provisions of FAS 121, but significantly changes the criteria that would have to be met to classify an asset as held for disposal such that long-lived assets to be disposed of other than by sale are considered held and used until disposed of. In addition, SFAS 144 retains the basic provisions of APB 30 for presentation of discontinued operations in the statement of operations but broadens that presentation to a component of an entity. The Company will apply SFAS 144 beginning July 1, 2002. The Company is currently evaluating the potential impact, if any, the adoption of SFAS 144 will have on its financial position and results of operations.

Item 7. Financial Statements

PARADIGM MEDICAL INDUSTRIES, INC.
Index to Financial Statements

	Page

Report of Tanner + Co.	F-2
Balance Sheet	F-3
Statement of Operations	F-4
Statement of Stockholders' Equity	F-5
Statement of Cash Flows	F-6
Notes to Financial Statements	F-7

F-1

INDEPENDENT AUDITORS' REPORT

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

To the Board of Directors of
Paradigm Medical Industries, Inc.

We have audited the balance sheet of Paradigm Medical Industries, Inc. (the Company) as of December 31, 2001, and the related statements of operations, stockholders' equity, and cash flows for the years ended December 31, 2001 and 2000. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Paradigm Medical Industries, Inc. as of December 31, 2001, and the results of its operations and its cash flows for the years ended December 31, 2001 and 2000, in conformity with accounting principles generally accepted in the United States of America.

TANNER + CO.

Salt Lake City, Utah
March 6, 2002

F-2

PARADIGM MEDICAL INDUSTRIES
Balance Sheet

December 31, 2001

Assets	

Current assets:	
Cash	\$
Receivables, net	
Inventories, net	
Prepaid and other assets	

Total current assets	1

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Intangibles, net		
Property and equipment, net		
Other assets		

Total assets		\$ 1

Liabilities and Stockholders' Equity		

Current liabilities:		
Payables		\$
Accrued liabilities		
Current portion of capital lease obligations		

Total current liabilities		-----

Capital lease obligations, net of current portion		-----

Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$.001 par value, 5,000,000 shares authorized, 91,392 shares issued and outstanding (aggregate liquidation preference of \$6,726,000)		
Common stock, \$.001 par value, 20,000,000 shares authorized, 15,072,531 shares issued and outstanding		5
Additional paid-in capital		(4
Accumulated deficit		-----

Total stockholders' equity		-----

Total liabilities and stockholders' equity		\$ 1

See accompanying notes to financial statements.

PARADIGM MEDICAL INDUSTRIES
Statement of Operations

Years Ended December 31

2001 2000

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Sales	\$	7,919,000	\$
Cost of sales		4,912,000	
Gross profit		3,007,000	
Operating expenses:			
General and administrative		5,125,000	
Marketing and selling		4,762,000	
Research and development		2,405,000	
Total operating expenses		12,292,000	1
Operating loss		(9,285,000)	(
Other income (expense):			
Interest income		48,000	
Interest expense		(41,000)	
Other income (expense)		(865,000)	
Total other income (expense)		(858,000)	
Loss before provision for income taxes		(10,143,000)	(
Provision for income taxes		-	
Net loss	\$	(10,143,000)	\$ (
Beneficial conversion feature on Series E preferred stock		(2,587,000)	
Deemed dividend from Series E preferred detachable warrants		(314,000)	
Net loss applicable to common shareholders	\$	(13,044,000)	\$ (
Loss per common share - basic and diluted	\$	(.98)	\$
Weighted average common shares - basic and diluted		13,245,000	1

See accompanying notes to financial statements.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

	Years					
	Preferred Stock (see Note 8)	Common Shares	Stock Amount	Additional Paid-In Capital	Treasury Shares	Sto Amou
Balance at January 1, 2000	\$ -	9,707,078	\$ 10,000	\$ 31,142,000	2,600	\$ (4,0
Treasury stock retired	-	(2,600)	-	(4,000)	(2,600)	4,0
Conversion of preferred stock	-	297,238	-	-	-	-
Issuance of common stock for:						
Cash	-	910,933	1,000	2,571,000	-	-
Exercise of warrants and stock options	-	1,355,646	1,000	4,841,000	-	-
Assets	-	100,000	-	675,000	-	-
Services	-	242,894	1,000	1,403,000	-	-
Issuance of stock options and warrants for services	-	-	-	529,000	-	-
Net loss	-	-	-	-	-	-
Balance at December 31, 2000	-	12,611,189	13,000	41,157,000	-	-
Issuance of Series E preferred stock for cash	-	-	-	4,607,000	-	-
Issuance of Series F preferred stock for cash	-	-	-	4,358,000	-	-
Conversion of preferred stock	-	1,758,617	2,000	(2,000)	-	-
Issuance of common stock for:						
Cash	-	328,725	-	673,000	-	-
Settlement of litigation	-	350,000	-	812,000	-	-
Services	-	24,000	-	48,000	-	-
Compensation	-	-	-	-	-	-
Issuance of stock options and warrants for services	-	-	-	503,000	-	-
Net loss	-	-	-	-	-	-
Balance at December 31, 2001	\$ -	15,072,531	\$ 15,000	\$ 52,156,000	-	\$ -

See accompanying notes to financial statements.

PARADIGM MEDICAL INDUSTRIES
Statement of Cash Flows

Years Ended December 31, 2001

	2001	
<hr/>		
Cash flows from operating activities:		
Net loss	\$ (10,143,000)	\$ (10,143,000)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	671,000	
Issuance of common stock for compensation	8,000	
Issuance of common stock for services	48,000	
Issuance of stock option/warrant for services	503,000	
Common stock issued for settlement	812,000	
Provision for losses on receivables	-	
Provision for losses on inventory	-	
(Gain) loss on disposal of assets	23,000	
(Increase) decrease in:		
Receivables	(787,000)	
Inventories	(684,000)	
Prepaid and other assets	(152,000)	
Increase (decrease) in:		
Payables	530,000	
Accrued liabilities	372,000	
Net cash used in operating activities	(8,799,000)	(8,799,000)
<hr/>		
Cash flows from investing activities:		
Purchase of property and equipment	(220,000)	
Increase in intangibles	(26,000)	
Proceeds from the disposal of assets	-	
Net cash paid in acquisition	-	
Net cash used in investing activities	(246,000)	(246,000)
<hr/>		
Cash flows from financing activities:		
Proceeds from issuance of Series E preferred stock	4,607,000	
Proceeds from issuance of Series F preferred stock	4,358,000	
Proceeds from issuance of common stock	-	
Principal payments on notes payable and long-term debt	(85,000)	
Proceeds from exercise of common stock warrants and options	673,000	
Net cash provided by financing activities	9,553,000	9,553,000

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Net increase in cash	508,000
Cash, beginning of year	2,194,000
Cash, end of year	\$ 2,702,000 \$

See accompanying notes to financial statements.

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements

December 31, 2001 and 2000

1. Organization
and Significant
Accounting
Policies

Organization

Paradigm Medical Industries, Inc. (the Company) is a Delaware Corporation incorporated in October 1989. The Company is engaged in the design, development, manufacture, and sale of high technology surgical and diagnostic eye care products. Its surgical equipment is designed to perform minimally invasive cataract surgery and is comprised of surgical devices and related instruments and accessories, including disposable products. Its diagnostic products include a pachymeter, an A-Scan, an A/B Scan, a biomicroscope, a perimeter, a corneal topographer, and a blood flow analyzer.

Its ultrasound diagnostic products technology were acquired from Humphrey Systems in 1998. In October 1999, the Company purchased the inventory and design and production rights of another line of surgical equipment, also designed to perform minimally invasive cataract surgery. The line includes the Mentor SISTem (TM), the Odyssey (TM), and the Surgitrol (TM). In November 1999, the Company entered into a Mutual Release and Settlement Agreement with the manufacturer of the Precisionist Thirty Thousand (TM) in which the Company purchased the raw materials and finished goods inventory to bring manufacture of this product in-house. The Dicon (TM) perimeter and the Dicon (TM) topographer were acquired when the Company acquired Vismed in June 2000. The blood flow analyzer was acquired when Ocular Blood Flow LTD (OBF) was purchased in June 2000.

F-7

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

1. Organization and Significant Accounting Policies Continued
- Liquidity
- The Company has incurred net losses and negative cash flows from operating activities for the years ended December 31, 2001 and 2000 and has an accumulated deficit. The Company currently has a private equity line of credit agreement with Triton West Group, Inc., (Triton), which allows the Company to sell \$20 million of common stock over a three year period beginning June 30, 2000 to Triton by tendering put notices to purchase shares. The company sold approximately 329,000 shares of common stock for approximately \$674,000 during 2001 (see note 5). Management believes that the combination of existing working capital and the private equity line of credit will be sufficient to assure continuation of the Company's operations through December 31, 2002. In the past, the Company has relied heavily upon sales of its common and preferred stock to fund operations. There can be no assurance that such equity financing will be available on terms acceptable to the Company in the future. If the Company is unable to obtain such financing or secure debt financing, it may be unable to continue development of its products and may be required to substantially curtail operations.

Cash Equivalents

For purposes of the statement of cash flows, cash includes all cash and investments with original maturities to the Company of three months or less.

The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such account and believes it is not exposed to any significant credit risk on cash and cash equivalents.

Inventories

Inventories are stated at the lower of cost or market, cost is determined using the weighted average method.

Property and Equipment

Property and equipment are recorded at cost, less accumulated depreciation. Depreciation on property and equipment is determined using the straight-line method over the estimated useful lives of the assets or terms of the lease. Expenditures for maintenance and repairs are expensed when incurred and betterments are capitalized. Gains and losses on sale of property and equipment are reflected in operations.

F-8

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

1. Organization and Significant
- Intangible Assets
- Intangible assets consist of the purchase price in

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Accounting Policies Continued excess of net assets acquired in the purchase of Ocular Blood Flow, Ltd., product rights, capitalized payments to manufacturers for engineering and design services and patent costs. These costs are being amortized using the straight line method over a three to ten year period.

Evaluation of Intangible and Other Long-Lived Assets
The Company evaluates the carrying value of the unamortized balances of intangible and other long-lived assets to determine whether any impairment of these assets has occurred or whether any revision to the related amortization periods should be made. This evaluation is based on management's projections of the undiscounted future cash flows associated with each asset. If management's evaluation were to indicate that the carrying values of these assets were impaired, such impairment would be recognized by a write down of the applicable asset.

Income Taxes
Deferred income taxes are provided in amounts sufficient to give effect to temporary differences between financial and tax reporting, principally related to depreciation, stock compensation expense, and accrued liabilities.

Earnings Per Share
The computation of basic earnings per common share is based on the weighted average number of shares outstanding during each year.

The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the year. Options and warrants to purchase 6,191,798 and 3,412,181 shares of common stock at prices ranging from \$2.00 to \$12.98 per share were outstanding at December 31, 2001 and 2000, respectively, but were not included in the diluted earnings per share calculation because the effect would have been antidilutive.

F-9

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

1. Organization and Significant Accounting Policies Revenue Recognition
Revenues for sales of products that require specific installation and acceptance by the customer are recognized upon such installation and acceptance by the

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Continued

customer. Revenues for sales of other surgical systems, ultrasound diagnostic devices, and disposable products are recognized when the product is shipped. A signed purchase agreement and a deposit or payment in full from customers are required before a product leaves the premises. Title passes at time of shipment (F.O.B. shipping point).

Research and Development

Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform certain research on behalf of the Company.

Concentration of Risk

The market for ophthalmic lasers is subject to rapid technological change, including advances in laser and other technologies and the potential development of alternative surgical techniques or new pharmaceutical products. Development by others of new or improved products, processes or technologies may make products developed by the Company obsolete or less competitive.

The Company's high technology product line requires the Company to deal with suppliers and subcontractors supplying highly specialized parts, operating highly sophisticated and narrow tolerance equipment and performing highly technical calculations and tasks. Although there are a limited number of suppliers and manufacturers that meet the standards required of a regulated medical device, management believes that other suppliers and manufacturers could provide similar components and services.

The nature of the Company's business exposes it to risk from product liability claims. The Company maintains product liability insurance providing coverage up to \$2 million per claim with an aggregate policy limit of \$2 million. Any losses that the Company may suffer from any product liability litigation could have a material adverse effect on the Company.

F-10

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

1. Organization and Significant Accounting Policies Continued

Concentration of Risk - Continued
A significant portion of the Company's product sales are in foreign countries. The economic and political instability of some foreign countries may affect the ability of medical personnel to purchase the Company's products and the ability of the customers to pay for the

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

procedures for which the Company's products are used. Such circumstances could cause a possible loss of sales, which would affect operating results adversely.

During the years ended December 31, 2001 and 2000, no single customer represented more than 10 percent of total net sales.

Accounts receivable are due from medical distributors, surgery centers, hospitals, optometrists and ophthalmologists located throughout the U.S. and a number of foreign countries. The receivables are generally due within thirty days for domestic customers with extended terms offered for some international customers. The Company maintains an allowance for estimated potentially uncollectible amounts.

Warranty

The Company provides product warranties on the sale of certain products that generally extend for one year from the date of sale. The Company maintains a reserve for estimated warranty costs based on historical experience and management's best estimates.

Stock-Based Compensation

For stock options and warrants granted to employees the Company employs the footnote disclosure provisions of Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based Compensation. SFAS No. 123 encourages entities to adopt a fair-value based method of accounting for stock options or similar equity instruments. However, it also allows an entity to continue measuring compensation cost for stock-based compensation using the intrinsic-value method of accounting prescribed by Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees (APB 25). The Company has elected to continue to apply the provisions of APB 25 and provide pro forma footnote disclosures required by SFAS No. 123. The appropriate disclosures required by SFAS No. 123 are included in note 10.

F-11

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

-
- | | |
|---|---|
| 1. Organization and Significant Accounting Policies Continued | Stock-Based Compensation - Continued
Stock options and warrants granted to non-employees for services are accounted for in accordance with SFAS 123 which requires expense recognition based on the fair value of the options/warrants granted. The Company calculates the fair value of options and warrants granted by use of the Black-Scholes pricing model. |
| | Use of Estimates in the Preparation of Financial |

Statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Reclassifications

Certain amounts in the 2000 financial statements have been reclassified to conform with the presentation of the current year financial statements.

2. Acquisitions

In June 2000, the Company acquired Vismed, Inc. dba Dicon in exchange for 921,500 shares of common stock. The business combination has been accounted for by the pooling-of-interest method in accordance with APB 16. Accordingly, the historical financial statements have been restated to reflect the combination with Vismed as if it had occurred as of January 1, 1999. Vismed was founded in 1989 and manufactures and distributes Dicon branded diagnostic products. These products include a perimeter used to detect retinal sensitivity and a corneal topographer used to measure the curvature of the cornea which is useful in the fitting of contact lenses and refractive surgery.

In June 2000, the Company completed the purchase of Ocular Blood Flow, Ltd. (OBF) for \$100,000 and 100,000 shares of common stock. This transaction has been accounted for using the purchase method of accounting. OBF manufactures a blood flow analyzer representing proprietary technology for measuring blood flow to the eye. Pro forma results of operations as if the companies had been combined have not been presented since OBF operations were not significant.

F-12

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

3. Detail of
Certain
Balance
Sheet
Accounts

Receivables:	
Trade receivables	\$ 2,750,000
Other	14,000
Allowance for doubtful accounts	(370,000)

	\$ 2,394,000

Inventories:		
Finished goods	\$	2,318,000
Raw materials		2,896,000
Work in process		288,000
Reserve for obsolescence		(371,000)
	\$	5,131,000
Accrued liabilities:		
Warranty and return allowance	\$	596,000
Customer deposits		41,000
Payroll and employee benefits		306,000
Royalties		145,000
Commissions		100,000
Deferred revenue		220,000
Other		164,000
	\$	1,572,000

F-13

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

3.	Detail of Certain Balance Sheet Accounts Continued	Intangible assets:	
		Purchase price in excess of net asset	\$ 799,000
		Product and technology rights	773,000
		Engineering and design costs	482,000
		Patents	169,000
			2,223,000
		Accumulated amortization	(1,065,000)
		Net intangible assets	\$ 1,158,000

Amortization expense for the years ended December 31, 2001 and 2000 was \$341,000 and \$260,000, respectively.

4. Property and Equipment Property and equipment consists of the following:

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Office equipment	\$	770,000
Computer equipment		707,000
Automobile		52,000
Furniture and fixtures		264,000
Leasehold improvements		227,000

		2,020,000
Accumulated depreciation and amortization		(1,180,000)

	\$	840,000

F-14

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

5. Equity Line of Credit

The Company currently has a private equity line of credit agreement with Triton West Group, Inc., (Triton), which allows the Company to sell \$20 million of common stock over a three year period beginning June 30, 2000 to Triton by tendering put notices to purchase shares. The put notices may be tendered by the Company at the Company's discretion. Upon the put notice Triton is obligated to purchase shares at 88% of the lowest closing bid price on the trading day immediately following a five day period commencing two days prior to put notice and ending two days after such put notice date. The total amount per put is determined based on the stock closing bid price and the 30 trading day volume, with a maximum put amount of \$2 million.

The Company sold approximately 329,000 shares of common stock for approximately \$674,000 during 2001 under the equity line of credit with Triton West Group, Inc. in five different transactions dating from February 16, 2001 to June 21, 2001.

6. Lease Obligations

During the years ended December 31, 2001 and 2000, the Company leased certain equipment under noncancellable capital leases. These leases provide the Company the option to purchase the leased assets at the end of the initial lease term. Assets under capital leases included in fixed assets and are as follows:

Computer and other equipment	\$	291,000
Less accumulated depreciation		(74,000)

\$ 217,000

Depreciation expense on assets under capital leases during the years ended December 31, 2001 and 2000 was \$54,000 and \$10,000, respectively.

F-15

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

6. Lease Obligations Continued Capital lease obligations have imputed interest rates of approximately 15% to 22%. The leases are secured by equipment. Future minimum payments on the capital lease obligations are as follows:

	2002	\$	87,000
	2003		61,000
	2004		45,000
	2005		37,000
	2006		15,000

			245,000
	Less amount representing interest		(62,000)

	Present value of future minimum lease payments		183,000
	Less current portion		(59,000)

	Long-term portion	\$	124,000

The Company leases office and warehouse space under an operating lease agreement. Future minimum rental payments under the noncancellable operating lease as of December 31, 2001 are approximately as follows:

	Year Ending December 31,		Amount
	-----		-----
	2002	\$	340,000
	2003		51,000

	Total future minimum rental payments	\$	391,000

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Rent expense related to noncancelable operating leases was approximately \$435,000 and \$362,000 for the years ended December 31, 2001 and 2000, respectively.

F-16

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

7. Income Taxes
- The provision for income taxes is different than amounts which would be provided by applying the statutory federal income tax rate to loss before provision for income taxes for the following reasons:

	Years Ended December 31,	
	2001	2000
Federal income tax benefit at Statutory rate	\$ 3,753,000	\$ 3,443,000
Expiration of research and development tax credit carryforwards	(181,000)	(107,000)
Tax credits	-	44,000
Amortization of goodwill	(30,000)	(15,000)
Other	(28,000)	(20,000)
Change in valuation allowance	(3,514,000)	(3,345,000)
	\$ -	\$ -

Deferred tax assets (liabilities) are comprised of the following:

Net operating loss carryforward	\$ 12,791,000
Depreciation and amortization	106,000
Allowance and reserves	557,000
Research and development tax credit carryforwards	59,000
	13,513,000
Valuation allowance	(13,513,000)
	\$ -

A valuation allowance has been established for the net

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

deferred tax asset due to the uncertainty of the Company's ability to realize such asset.

F-17

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

7. Income Taxes Continued
At December 31, 2001, the Company had net operating loss carryforwards of approximately \$34,000,000 and research and development tax credit carryforwards of approximately \$240,000. These carryforwards are available to offset future taxable income and began to expire in 2001 and extend to 2020. The utilization of the net operating loss carryforwards is dependent upon the tax laws in effect at the time the net operating loss carryforwards can be utilized. The Tax Reform Act of 1986 significantly limits the annual amount that can be utilized for certain of these carryforwards as a result of the change in ownership.

8. Capital Stock
The Company has established a series of preferred stock with a total of 5,000,000 authorized shares and a par value of \$.001, and one series of common stock with a par value of \$.001 and a total of 20,000,000 authorized shares.

Series A Preferred Stock

On September 1, 1993, the Company established a series of non-voting preferred shares designated as the 6% Series A Preferred Stock, consisting of 500,000 shares with \$.001 par value. The Series A Preferred Stock has the following rights and privileges:

1. The holders of the shares are entitled to dividends at the rate of twenty-four cents (\$.24) per share per annum, payable in cash only from surplus earnings of the Company or in additional shares of Series A Preferred Stock. The dividends are non-cumulative and therefore deficiencies in dividend payments from one year are not carried forward to the next year.
2. Upon the liquidation of the Company, the holders of the Series A Preferred Stock are entitled to receive, prior to any distribution of any assets or surplus funds to the holders of shares of common stock or any other stock, an amount equal to \$1.00 per share, plus any accrued and unpaid dividends related to the fiscal year in which such liquidation occurs. Total liquidation preference at December 31, 2001 was \$6,000.
3. The shares are convertible at the option of the

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

holder at any time into common shares, based on an initial conversion rate of one share of Series A Preferred Stock for 1.2 common shares.

F-18

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

8. Capital Stock
Continued

Series A Preferred Stock - Continued

4. The holders of the shares have no voting rights.
5. The Company may, at its option, redeem all of the then outstanding shares of the Series A Preferred Stock at a price of \$4.50 per share, plus accrued and unpaid dividends related to the fiscal year in which such redemption occurs.

Series B Preferred Stock

On May 9, 1994, the Company established a series of non-voting preferred shares designated as 12% Series B Preferred Stock, consisting of 500,000 shares with \$.001 par value. The Series B Preferred Stock have the following rights and privileges:

1. The holders of the shares are entitled to dividends at the rate of forty-eight cents (\$.48) per share per annum, payable in cash only from surplus earnings of the Company or in additional shares of Series B Preferred Stock. The dividends are non-cumulative and therefore deficiencies in dividend payments from one year are not carried forward to the next year.
 2. Upon the liquidation of the Company, the holders of the Series B Preferred Stock are entitled to receive, prior to any distribution of any assets or surplus funds to the holders of shares of common stock or any other stock, an amount equal to \$4.00 per share, plus any accrued and unpaid dividends related to the fiscal year in which such liquidation occurs. Such right, however, is subordinate to the rights of the holders of Series A Preferred Stock to receive a distribution of \$1.00 per share plus accrued and unpaid dividends. Total liquidation preference at December 31, 2001 was \$36,000.
 3. The shares are convertible at the option of the holder at any time into common shares, based on an initial conversion rate of one share of Series B Preferred Stock for 1.2 common shares.
 4. The holders of the shares have no voting rights.
-

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

8. Capital Stock
Continued

Series B Preferred Stock - Continued

5. The Company may, at its option, redeem all of the then outstanding share of the Series B Preferred Stock at a price of \$4.50 per share, plus accrued and unpaid dividends related to the fiscal year in which such redemption occurs.

Series C Preferred Stock

In January 1998, the Company authorized the issuance of a total of 30,000 shares of Series C Preferred Stock, \$.001 par value, \$100 stated value. The Series C Preferred Stock have the following rights and privileges:

1. The holders of the shares are entitled to dividends at the rate of 12% per share per annum of the aggregate stated value. The dividends are non-cumulative and, therefore, deficiencies in dividend payments from one year are not carried forward to the next year.
2. Upon the liquidation of the Company, the holders of the Series C Preferred Stock are entitled to receive an amount per share equal to the greater of (a) the amount they would have received if they had converted the shares into shares of Common Stock immediately prior to such liquidation plus declared but unpaid dividends; or (b) the stated value, subject to adjustment.
3. Each share is convertible, at the option of the holder at any time until January 1, 2002, into approximately 57.14 shares of common stock at an initial conversion price, subject to adjustments for stock splits, stock dividends and certain combination or recapitalization of the common stock, equal to \$1.75 per share of common stock.
4. The holders of the shares have no voting rights.

8. Capital Stock
Continued

Series D Preferred Stock

In January 1999, the Company's Board of Directors authorized the issuance of a total of 1,140,000 shares of Series D Preferred Stock \$.001 par value, \$1.75 stated value. The Series D Preferred Stock has the following rights and privileges:

1. The holders of the shares are entitled to dividends at the rate of 10% per share per annum of the aggregate stated value. The dividends are non-cumulative and, therefore, deficiencies in dividend payments from one year are not carried forward to the next year.
2. Upon the liquidation of the Company, the holders of the Series D Preferred Stock are entitled to receive an amount per share equal to the greater of (a) the amount they would have received had they converted the shares into Common Stock immediately prior to such liquidation plus all declared but unpaid dividends; or (b) the stated value, subject to adjustment. Total liquidation preference at December 31, 2001 was \$18,000.
3. Each share is convertible, at the option of the holder at any time until January 1, 2002, into one share of Common Stock at an initial conversion price, subject to adjustment. The Series D Preferred Stock shall be converted into one share of the Common Stock subject to adjustment (a) on January 1, 2002 or (b) upon 30 days written notice by the Company to the holders of the Shares, at any time after (i) the 30-day anniversary of the registration statement on which the shares of Common Stock issuable upon conversion of the Series D Preferred Stock were registered and (ii) the average closing price of the Common Stock for the 20-day period immediately prior to the date on which notice of redemption is given by the Company to the holders of the Series D Preferred Stock is at least \$3.50 per share. The Company in 1999 recorded \$872,000 as a beneficial conversion feature related to the differences in the conversion price of the preferred stock to common stock.
4. The holders of the shares have no voting rights.

F-21

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

8. Capital Stock
Continued

Series E Preferred Stock

In May 2001, the Company authorized the issuance of a

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

total of 50,000 shares of Series E Preferred Stock \$.001 par value, \$100 stated value. The Series E Preferred Stock has the following rights and privileges:

1. The holders of the shares are entitled to dividends at the rate of 8% per share per annum of the aggregate stated value. The dividends are non-cumulative and, therefore, deficiencies in dividend payments from one year are not carried forward to the next year.
2. Upon the liquidation of the Company, the holders of the Series E Preferred Stock are entitled to receive an amount per share equal to the greater of (a) the amount they would have received had they converted the shares into Common Stock immediately prior to such liquidation plus all declared but unpaid dividends; or (b) the stated value, subject to adjustment. Total liquidation preference at December 31, 2001 was \$1,930,000.
3. Each share is convertible, at the option of the holder at any time until January 1, 2005, into approximately 53.33 shares of Common Stock at an initial conversion price, subject to adjustment for stock splits, stock dividends and certain combination or recapitalization of the common stock, equal to \$1.875 per share of common stock. The Series E Preferred Stock shall be converted into Common Stock subject to adjustment (a) on January 1, 2005 or (b) upon 30 days written notice by the Company to the holders of the Shares, at any time after (i) the 30-day anniversary of the registration statement on which the shares of Common Stock issuable upon conversion of the Series E Preferred Stock were registered and (ii) the average closing price of the Common Stock for the 20-day period immediately prior to the date on which notice of redemption is given by the Company to the holders of the Series E Preferred Stock is at least \$3.50 per share. The Company in 2001 recorded \$1,482,000 as a beneficial conversion feature related to the differences in the conversion price of the preferred stock to common stock.

F-22

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

-
- | | |
|-------------------------------|---|
| 8. Capital Stock
Continued | Series E Preferred Stock - Continued
4. The holders of the shares have no voting rights.

5. The holders of the shares also were issued warrants to purchase shares of common stock equal to 1,000 warrants for every 200 shares purchased at an |
|-------------------------------|---|

exercise price of \$4.00 per share. Each warrant is exercisable until May 23, 2006.

Series F Preferred Stock

In August 2001, the Company authorized the issuance of a total of 50,000 shares of Series F Preferred Stock \$.001 par value, \$100 stated value. The Series F Preferred Stock has the following rights and privileges:

1. The holders of the shares are entitled to dividends at the rate of 8% per share per annum of the aggregate stated value. The dividends are non-cumulative and, therefore, deficiencies in dividend payments from one year are not carried forward to the next year.
2. Upon the liquidation of the Company, the holders of the Series F Preferred Stock are entitled to receive an amount per share equal to the greater of (a) the amount they would have received had they converted the shares into Common Stock immediately prior to such liquidation plus all declared but unpaid dividends; or (b) the stated value, subject to adjustment. Total liquidation preference at December 31, 2001 was \$4,736,000.

F-23

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

8. Capital Stock
Continued

Series F Preferred Stock - Continued

3. Each share is convertible, at the option of the holder at any time until January 1, 2005, into approximately 53.33 shares of Common Stock at an initial conversion price, subject to adjustment for stock splits, stock dividends and certain combination or recapitalization of the common stock, equal to \$1.875 per share of common stock. The Series F Preferred Stock shall be converted into Common Stock subject to adjustment (a) on January 1, 2005 or (b) upon 30 days written notice by the Company to the holders of the Shares, at any time after (i) the 30-day anniversary of the registration statement on which the shares of Common Stock issuable upon conversion of the Series F Preferred Stock were registered and (ii) the average closing price of the Common Stock for the 20-day period immediately prior to the date on which notice of redemption is given by the Company to the holders of the Series F Preferred Stock is at least \$3.50 per share. The Company in 2001 recorded \$1,105,000 as a beneficial conversion feature related to the differences in the conversion price of the preferred stock to common stock.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

4. The holders of the shares have no voting rights.

F-24

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

8. Capital Stock Continued The following table summarizes preferred stock activity during the years ended December 31, 2001 and 2000:

	Series A		Series B		Series C		Series D	
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount
Balance at January 1, 2000	8,077	\$ -	19,236	\$ -	500	\$ -	313,644	\$ -
Conversion of preferred stock	(2,120)	-	(4,000)	-	(500)	-	(261,144)	-
Balance at December 31, 2000	5,957	-	15,236	-	-	-	52,500	-
Issuance of Series E preferred stock for cash	-	-	-	-	-	-	-	-
Issuance of Series F preferred stock for cash	-	-	-	-	-	-	-	-
Conversion of preferred stock	(210)	-	(6250)	-	-	-	(42,500)	-
Balance at December 31, 2001	5,747	\$ -	8,986	\$ -	-	\$ -	10,000	\$ -
Authorized	500,000		500,000		30,000		1,140,000	
Liquidation preference		\$6,000		\$36,000		\$ -		\$18,000

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

9. Stock Option Plan and Warrants The Company has a Stock Option Plan (the Option Plan), which reserves shares of the Company's authorized but unissued common stock for the granting of stock options. Amendments to the Option Plan increased the number of shares of common stock reserved for issuance thereunder to an aggregate of 2,700,000 shares.

The Option Plan provides for the grant of incentive stock options and non-qualified stock options to employees and directors of the Company. Incentive stock options may be granted only to employees. The Option Plan is administered by the Board of Directors or a Compensation Committee, which determines the terms of options granted including the exercise price, the number of shares subject to the option, and the exercisability of the option.

During the year 2001, the Company granted options and warrants to non-employees. These options and warrants were nonforfeitable, vested and fully exercisable at the time of grant. The exercise prices of these options were not issued at a discount to the then market price of the common stock. The options and warrants were valued according to the Black-Scholes pricing model.

The Company granted warrants to purchase 100,000 shares of common stock at an exercise price of \$4.00 per share, warrants to purchase 35,000 shares of common stock at an exercise price of \$2.00 per share, and warrants to purchase 100,000 shares of common stock at \$3.00 per share in return for consulting services. As a result of these warrants granted the Company recorded approximately \$342,000 of general and administrative expense.

Warrants to purchase 50,000 shares of common stock at an exercise price of \$4.00 that vested in November 2001 were issued to a consultant as an extension of the consulting agreement. The Company recognized \$133,000 of general and administrative expense in connection with these warrants.

In connection with the Series E Preferred Stock offering, the Company issued warrants to purchase in aggregate 231,095 shares of common stock at an exercise price of \$4.00 per share.

F-26

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

9. Stock Option Plan and Warrants Continued In addition, the Company granted the following options and warrants to non-employees during the year ended December 31, 2000:

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

The Company granted warrants to purchase 300,000 shares of common stock in connection with private placement offerings of common stock, the pooling of interests merger with Dicon, and other equity raising activities. The warrants were immediately fully vested, nonforfeitable, and fully exercisable at the date of grant. The exercise price of such warrants was equal to or in excess of the market price of the Company's common stock on the date of grant. Because these warrants were granted in connection with equity transactions they were recorded as a direct offset to capital rather than as an expense to operations.

The Company also granted warrants to purchase 120,000 shares of common stock as consideration for consulting and other services rendered. 70,000 of the warrants were immediately fully vested, nonforfeitable, and fully exercisable at the date of grant and the remaining 50,000 vest in May of 2001. The exercise price of such warrants was equal to or in excess of the market price of the Company's common stock on the date of grant. These warrants were valued using the Black-Scholes Option Pricing Model and an expense of \$396,000 was recorded and is included in general and administrative expense in the statement of operations. An expense of \$28,000 related to the warrants vesting in May 2001 will be recorded upon vesting.

F-27

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

9. Stock Option Plan and Warrants Continued A schedule of the options and warrants is as follows:

	Number of		Exercise Price Per Share
	Options	Warrants	
Outstanding at January 1, 2000	1,048,232	2,636,758	\$ 2.30 - 12.98
Granted	746,000	400,000	4.00 - 7.27
Exercised	(162,490)	(1,100,056)	2.38 - 8.13
Expired	(18,488)	(137,775)	3.33 - 6.49
Outstanding at December 31, 2000	1,613,254	1,798,927	2.30 - 12.98
Granted	2,790,000	516,095	2.00 - 4.00
Exercised	-	-	-
Expired	(236,626)	-	4.87 - 5.00
Forfeited	(289,852)	-	2.75 - 5.00

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Outstanding at				
December 31, 2001	3,876,776	2,315,022	\$	2.00 - 12.98

10. Stock-Based Compensation

The Company adopted the disclosure only provisions of Statement of Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based Compensation." Accordingly, no compensation expense has been recognized for stock options granted to employees. Had compensation expense for the Company's stock options been determined based on the fair value at the grant date consistent with the provisions of SFAS No. 123, the Company's results of operations would have been reduced to the pro forma amounts indicated below:

	Years Ended December 31,	
	2001	2000
Net loss - as reported	\$ (10,143,000)	\$ (9,305,000)
Net loss - pro forma	\$ (11,575,000)	\$ (10,180,000)
Loss per share - as reported	\$ (.77)	\$ (.81)
Loss per share - pro forma	\$ (.87)	\$ (.88)

F-28

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

10. Stock-Based Compensation Continued

The fair value of each option grant is estimated at the date of grant using the Black-Scholes option pricing model with the following assumptions:

	December 31,	
	2001	2000
Expected dividend yield	\$ -	\$ -
Expected stock price volatility	106%-107%	106%
Risk-free interest rate	4-5%	6.0%
Expected life of options	3-5 years	2-5 years

The weighted average fair value of options granted

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

during the years ended December 31, 2001 and 2000 are \$1.71 and \$2.69, respectively.

The following table summarizes information about stock options and warrants outstanding at December 31, 2001:

Range of Exercise Prices	Outstanding			Exercisable		
	Number Outstanding	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Exercise Price	
\$ 2.00 - 5.00	4,578,890	5.58	\$ 3.35	3,584,128	\$ 1.95	
6.00 - 8.13	1,587,025	.84	7.21	1,359,900	7.15	
12.98	25,883	N/A	12.98	25,883	12.98	
<hr/>						
\$ 2.30 -12.98	6,191,798	4.37	\$ 4.34	4,969,911	\$ 4.54	

F-29

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

11. Related Party Transactions

On October 1, 1999, the Company entered into a consulting agreement with Cyndel & Company, Inc. ("Cyndel"), an entity owned by former directors of the Company, in which Cyndel agreed to perform unspecified investment banking services for the Company for a one-year period, for which the Company agreed to pay Cyndel a monthly retainer of \$8,333, plus reimburse Cyndel for any expenses incurred in connection with such investment banking services.

The October 1, 1999 consulting agreement was terminated when the Company entered into a new consulting agreement with Cyndel on April 1, 2000. Under the terms of the April 1, 2000 consulting agreement, Cyndel agreed to perform unspecified investment banking services for the Company for a one-year period, for which the Company agreed to pay Cyndel a monthly retainer of \$16,667, plus reimburse Cyndel for any expenses incurred in connection with such investment banking services.

Besides a monthly retainer, the Company has agreed in the April 1, 2000 consulting agreement to pay Cyndel additional compensation of an unspecified amount to be mutually agreed upon if Cyndel brings to the Company a candidate for merger, acquisition, joint venture or other combination or relationship, and the Company

enters into a business relationship with such entity. The April 1, 2000 consulting agreement is automatically renewable for additional, successive one-year periods through March 31, 2003, unless either party delivers to the other party on or before January 1 of the contract year written notice of its intent not to renew the agreement.

F-30

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

11. Related
Party
Transactions
Continued

Under the terms of the April 1, 2000 consulting agreement, the Company paid Cyndel approximately \$182,000 in consulting fees during 2000. In addition, the Company paid \$500,000 and issued warrants to purchase 150,000 shares of common stock at an exercise price of \$4.00 per share as commission for the private placement transaction in which 750,000 shares of common stock were sold for net proceeds of approximately \$1,974,000. The warrants issued and the commissions paid were considered direct costs of capital, therefore no expense was recorded but such amounts were recorded as a direct reduction of capital.

The April 1, 2000 consulting agreement was renewed for an additional one-year period through March 2002. However, on December 26, 2001, the Company provided written notification to Cyndel of its intension not to renew the agreement after March 31, 2002. The total amount paid to Cyndel for services under the agreement from April 1, 2000 to February 28, 2002 was \$383,333. Final payment of \$16,667, which was due on March 1, 2002, has not yet been paid.

Thomas F. Motter, Chairman of the Board and Chief Executive Officer of the Company, leased his former residence, which he still owns, to the Company for \$2,500 per month. The primary use of the residential property was for housing accommodations for the Company's employees living outside of Utah while they were working at the Company's corporate headquarters in Salt Lake City. The Company has obtained an appraisal from an independent appraiser, which has concluded that the monthly rate of \$2,500 represents the fair market rate for leasing the residential property. This lease agreement was terminated on October 31, 2000.

On January 21, 2000 the Board of Directors granted Thomas F. Motter, CEO and President, 100,000 shares of the Company's Common Stock. 61,111 shares of this total amount were considered repayment for 61,111 shares Mr. Motter issued to Douglas A. MacLeod prior to the

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Company's initial public offering in July 1996, under a settlement agreement to terminate certain anti-dilution rights granted Mr. MacLeod by the Company. The balance of 38,889 shares was deemed by the Board as a bonus for work done by Mr. Motter since the initial public offering. The market price on the date of grant was \$12.50 per share, and compensation expense in the amount of \$486,000 was recognized.

F-31

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

11. Related Party Transactions Continued
On January 21, 2000 the Board of Directors granted Michael W. Stelzer, a former officer of the Company, 20,000 shares of the Company's Common Stock as part of a severance agreement, and as part of settlement of Mr. Stelzer's employment agreement. The market price on the date of grant was \$12.50 per share, and compensation expense in the amount of \$250,000 was recognized.

On June 5, 2000 the Company issued Mark Miehle 28,500 shares of the Company's Common Stock for a signing bonus as part of Mr. Miehle's employment agreement. The market price on the date of the grant was \$6.8125 per share, and compensation expense in the amount of \$194,000 was recognized.

A law firm, of which a director of the Company is a shareholder, has rendered legal services to the Company. The Company paid this firm \$159,000 and \$167,000, for the years ended December 31, 2001 and 2000, respectively. As of December 31, 2001, the Company owed this firm \$40,000 which is included in accounts payable.

12. Supplemental Cash Flow Information
During the year ended December 31, 2001 the Company acquired approximately \$235,000 of property and equipment in exchange for capital lease agreements.

F-32

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

12. Supplemental
During the year ended December 31, 2000 the Company

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Cash Flow Information Continued acquired the assets and liabilities of Ocular Blood Flow, Ltd. (OBF) in a purchase transaction. The transaction required the payment of \$100,000 and 100,000 shares of common stock. The Company recorded the following:

Accounts receivable	\$	22,000
Prepays		18,000
Inventory		28,000
Intangibles		799,000
Property, plant and equipment		25,000
Accounts payable		(48,000)
Accrued liabilities		(8,000)
Debt		(66,000)
Common stock issued		(675,000)

Net cash	\$	95,000

Actual amounts paid for interest and income taxes are as follows:

	Years Ended December 31,	
	2001	2000
	-----	-----
Interest	\$ 41,000	\$ 16,000
	-----	-----
Income taxes	\$ -	\$ -
	-----	-----

F-33

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

13. Export Sales Total sales include export sales by major geographic area as follows:

	Years Ended December 31,	
Geographic Area	2001	2000
	-----	-----
Far East	\$ 1,416,000	\$ 2,428,000
South America	301,000	408,000
Middle East	287,000	200,000

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Europe	1,323,000	1,219,000
Canada	200,000	138,000
Mexico	31,000	7,000
	-----	-----
	\$ 3,558,000	\$ 4,400,000
	-----	-----

14. Savings Plan In November 1996, the Company established a 401(k) Retirement Savings Plan for the Company's officers and employees. The Plan provisions include eligibility after six months of service, a three year vesting provision and 100% matching contribution by the Company up to 3% of a participant's compensation. During the years ended December 31, 2001 and 2000, the Company contributed approximately \$68,000 and \$49,000 to the Plan, respectively.

15. Commitments and Contingencies Consulting Agreements
 During the year ended December 31, 1999 the Company entered a consulting agreement with a former officer of the Company, which expires in 2004 and requires annual payments of \$25,000 through 2003 and a payment of \$12,500 in 2004.

During the year ended December 31, 2000, in connection with the acquisition of OBF, the Company entered a consulting agreement with the former owner of OBF which requires monthly payments of \$6,000 through June 2003.

 F-34

PARADIGM MEDICAL INDUSTRIES, INC.
 Notes to Financial Statements
 Continued

15. Commitments and Contingencies Continued Employment Agreements
 The Company has employment agreements with two officers which expire between June 2003 and December 2003. The agreements provide for aggregate annual compensation of \$350,000. In addition, the Company has entered into agreements which provide for additional payments to be made to the officer in the event the Company has a change of control.

Litigation
 An action was brought against the Company in March 2000 by George Wiseman, a former employee, in the Third District Court of Salt Lake County, State of Utah. The complaint alleges that the Company owes Mr. Wiseman 6,370 shares of its common stock plus costs, attorney's fees and a wage penalty (equal to 1,960 additional shares of Paradigm common stock) pursuant to Utah law.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

The Company believes the complaint is without merit and intends to vigorously defend against the action.

An action was brought against the Company in September 2000 by PhotoMed International, Inc. and Daniel M. Eichenbaum in the Third District Court of Salt Lake County, State of Utah. The action involves an amount of royalties that are allegedly due and owing to PhotoMed International, Inc. and Dr. Eichenbaum with respect to the sales of certain equipment plus attorney's fees. Discovery has taken place and the Company has paid royalties of \$15,000 to bring all required payments up to date through June 30, 2001. However, the legal action has not been dismissed as a result of the payments. The Company is in the process of working with Photomed International and Dr. Eichenbaum to ensure that the calculations have been correctly made on the royalties paid as well as the proper method of calculation in the future. It is anticipated that once the parties can agree on the correct calculations on the royalties, the legal action will be dismissed. The Company believes that any additional royalty payments that may be required as settlement of the action will not have a material impact on the financial statements.

An action has been brought against the Company by Merrill Corporation that alleges that the Company owes the plaintiff approximately \$20,000 together with interest thereon at the rate of 10% per annum from August 30, 1999, plus costs and attorney's fee. The Company has filed an answer to the complaint and discovery is proceeding. The Company believes that the complaint against the Company is without merit and intends to vigorously defend against the action.

F-35

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

-
- | | |
|--|--|
| 15. Commitments and Contingencies
Continued | Litigation - Continued
The Company received demand letters dated September 14, 2000 and October 17, 2000 from Mentor Corporation ("Mentor") claiming that the Company failed to register 485,751 shares of common stock issued to Mentor under the Asset Purchase Agreement dated October 15, 1999, among the Company, Mentor, Mentor Ophthalmics, Inc. and Mentor Medical, Inc. The Asset Purchase Agreement related to the Company's purchase of Mentor's phacoemulsification product line in consideration for the issuance by the Company to Mentor of 485,751 shares of its common stock, valued at the sum of \$1,500,000 at the time of closing. |
|--|--|

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

On July 2, 2001, the Company entered into a settlement agreement with Mentor Corporation in which the Company agreed to pay 350,000 shares of common stock to the Mentor Corporation in exchange for release of all claims against the Company in connection with the registration of certain shares of the Company's common stock previously issued. This settlement resulted in a litigation settlement expense of \$812,000 based on the market price of the Company's common stock on the date of settlement.

The Company may become or is subject to other investigations, claims or lawsuits ensuing out of conduct of its business, including those related to environmental safety and health, product liability, commercial transactions etc. The Company is currently not aware of any other such items, which it believes could have a material adverse effect on the financial statements.

Royalty Agreements

The Company has a royalty agreement with the president of OBF. The agreement provides for the payment of 10% royalty of the net sales related to the Blood Flow Analyzer. The agreement terminates in 2020. As of December 31, 2001, the Company paid \$133,000 of royalties under this agreement and \$94,000 was accrued at the end of the year.

F-36

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

15. Commitments and
Contingencies
Continued

Royalty Agreements - Continued

The Company has an amended exclusive patent license agreement with a company which owns the patent for the laser-probe used on the Photon machine. The agreement provides for the payment of a 1% royalty on all sales proceeds related directly or indirectly, to the Photon machine. The agreement terminates on July 7, 2003. Through December 31, 2001, no significant royalties have been paid under this agreement.

The Company has an agreement with a company that provides for the payment of royalties related to the sales of the corneal topography instrument referred to as the CT. During the years ended December 31, 2001 and 2000 payments were made of approximately \$146,000 and \$173,000, respectively. In addition, \$28,350 was accrued at the end of 2001.

The Company has an agreement with a Canadian corporation that provides for the payment of royalties related to

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

the sales of UBM (Ultrasonic Bio-Microscopy). The agreement outlines payments of 150 Canadian Dollars for each licensed product sold for a period of 12 years that ends in September of 2002. No significant royalties were due under this agreement during the years ended December 31, 2001 and 2000.

The Company has a royalty agreement with another company that developed a promotional CD for the Company. Through the promotion of the CD, the Company hopes to increase sales in the Autoperimeter and assist doctors currently using the unit with the interpretation of visual fields. The royalty base will be 50% each until the Company's share equals the production costs related to development of the disk. Thereafter, the developer will receive 70% and the Company will receive 30% of the royalty base. Royalties paid during the year relating to this agreement were not considered material.

16. Fair Value
of Financial
Instruments

The Company's financial instruments consist of cash, receivables, payables, and notes payable. The carrying amount of cash, receivables and payables approximates fair value because of the short-term nature of these items. The carrying amount of the notes payable approximates fair value as the individual borrowings bear interest at market interest rates.

F-37

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

17. Recent
Accounting
Pronounce-
ments

In July 2001, the Financial Accounting Standards Board ("FASB") issued Statements of Financial Accounting Standards No. 141 ("SFAS 141"), "Business Combinations." SFAS 141 eliminates the pooling-of-interests method of accounting for business combinations except for qualifying business combinations that were initiated prior to July 1, 2001. In addition, SFAS 141 further clarifies the criteria to recognize intangible assets separately from goodwill. Specifically, SFAS 141 requires that an intangible asset may be separately recognized only if such an asset meets specific criterion. The requirements of Statement 141 are effective for any business combination accounted for by the purchase method that is completed after June 30, 2001. The Company is currently evaluating the impact of SFAS 141 and has not yet determined the impact that adopting SFAS 141 will have on its financial statements. On adoption, the Company will be required to reassess the goodwill and intangible assets previously recorded in acquisitions prior to July 1, 2001 to determine if the new recognition criteria for an intangible asset to

be recognized apart from goodwill are met.

F-38

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

17. Recent
Accounting
Pronounce-
ments
Continued

In July 2001, the FASB issued Statements of Financial Accounting Standards No. 142 ("SFAS 142"), "Goodwill and Other Intangible Assets." Under SFAS 142, goodwill and indefinite lived intangible assets are no longer amortized but are reviewed annually (or more frequently if impairment indicators arise) for impairment. For intangible assets with indefinite useful lives, the impairment review will involve a comparison of fair value to carrying value, with any excess of carrying value over fair value being recorded as an impairment loss. For goodwill, the impairment test shall be a two-step process, consisting of a comparison of the fair value of a reporting unit with its carrying amount, including the goodwill allocated to each reporting unit. If the carrying amount is in excess of the fair value, the implied fair value of the reporting unit goodwill is compared to the carrying amount of the reporting unit goodwill. Any excess of the carrying value of the reporting unit goodwill over the implied fair value of the reporting unit goodwill will be recorded as an impairment loss. Separable intangible assets that are deemed to have a finite life will continue to be amortized over their useful lives (but with no maximum life). Intangible assets with finite useful lives will continue to be reviewed for impairment in accordance with Statements of Financial Accounting Standards No. 121 ("SFAS 121"), "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of." The amortization provisions of SFAS 142 apply to goodwill and intangible assets acquired after June 30, 2001. With respect to goodwill and intangible assets acquired prior to July 1, 2001, the Company will apply the new accounting rules beginning July 1, 2002 and will reassess the useful lives of its separately recognized intangible assets in the third quarter of fiscal 2002. The Company will review for impairment previously recognized intangible assets that are deemed to have indefinite lives upon the completion of this analysis in the first quarter of fiscal 2003. Additionally, upon the adoption of SFAS 142, the Company will perform a transitional impairment review related to the carrying value of goodwill as of July 1, 2002 by the end of the third quarter of fiscal 2002. The Company is currently in the process of determining its reporting units for the purpose of applying the impairment test, analyzing how fair value will be determined for purposes of applying SFAS 142 and quantifying the anticipated

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

impact of adopting the provisions of SFAS 142. Amortization of goodwill was \$80,000 for the year ended December 31, 2001.

F-39

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

17. Recent Accounting Pronouncements Continued
- In August 2001, the FASB issued Statement of Financial Accounting Standards No. 144 ("SFAS 144"), "Accounting for the Impairment or Disposal of Long-Lived Assets," which supercedes SFAS 121 and the provisions of Accounting Principles Board Opinion (APB 30), "Reporting the Results of Operations -- Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions" with regard to reporting the effects of a provisions of FAS 121, but significantly changes the criteria that would have to be met to classify an asset as held for disposal such that long-lived assets to be disposed of other than by sale are considered held and used until disposed of. In addition, SFAS 144 retains the basic provisions of APB 30 for presentation of discontinued operations in the statement of operations but broadens that presentation to a component of an entity. The Company will apply SFAS 144 beginning July 1, 2002. The Company is currently evaluating the potential impact, if any, the adoption of SFAS 144 will have on its financial position and results of operations.
18. Subsequent Event
- On January 31, 2002, Paradigm Medical Industries, Inc., a Delaware corporation (the "Company") completed the purchase of certain assets of Innovative Optics, Inc. ("Innovative Optics"), pursuant to the terms of the Asset Purchase Agreement (the "Agreement") which the Company entered into on January 31, 2002 with Innovative Optics and Barton Dietrich Investments, L.P., the majority shareholder of Innovative Optics. Innovative Optics is a Georgia domiciled corporation which manufactures and sells the Innovatome(TM), a software driven microkeratome that provides ophthalmic surgeons a means of cutting a corneal flap in refractive surgery, and microkeratome blades.

F-40

-
18. Subsequent Event Continued
- As consideration for the purchase of certain assets of Innovative Optics, the Company paid \$100,000 and issued an aggregate of 1,272,825 shares of its common stock and warrants to purchase 250,000 shares of the Company's common stock at \$5.00 per share, exercisable over a period of three years from the closing date. The Company is required to file a registration statement with the Securities and Exchange Commission within five months of the closing date to register the shares of common stock for resale that Innovative Optics received as purchase consideration and the shares that Innovative Optics will receive upon the exercise of the warrants. The assets purchased included but were not limited to patents, inventory, work in process and finished goods relating to the Innovatome(TM), a microkeratome, and microkeratome blades.
- Of the 1,272,825 shares of the Company's common stock issued to Innovative Optics at closing, one-half the number of these shares, or 636,412 shares, remained in an escrow account maintained at the law firm of Mackey Price & Thompson (the "Disbursing Agent") pursuant to the terms of an Escrow Agreement. The Company is required to use its best efforts to implement, within 90 days of the closing, Phase I of a Blade Price Reduction Program as prepared by Igor Gradov, a consultant. Immediately after such 90 day period, the Disbursing Agent will distribute three-fourths of the shares held in escrow, or 477,309 shares, to Innovative Optics, unless the Company has certified that it has implemented Phase I of the Blade Price Reduction Program and, despite best efforts, is unable to manufacture microkeratome blades at a materials cost of \$29.25 or less per blade. If the Company certifies that implementation of Phase I of the Blade Price Reduction Program has resulted in materials cost that exceeds \$29.25 per blade and such certification is not disputed by Innovative Optics, the number of escrow shares disbursed to Innovative Optics will be reduced by 300 shares for every cent that the materials cost per blade exceeds \$29.25. If Innovative Optics disputes the Company's certification, the dispute will be resolved by arbitration by submitting the matter for resolution to the accounting firm of KPMG LLP.

F-41

18. Subsequent
Event
Continued

The Company is also required to use its best efforts to implement, within six months after closing, Phase II of the Blade Price Reduction Program. Immediately after such six month period, the Disbursing Agent shall disburse the remaining shares in escrow to Innovative Optics unless the Company has certified that it has implemented Phase II of the Blade Price Reduction Program and, despite best efforts, is unable to manufacture the microkeratome blades at a materials cost of \$17.25 or less per blade. If Paradigm certifies that implementation of Phase II of the Blade Price Reduction Program has resulted in a materials cost that exceeds \$17.25 per blade and such certification is not disputed by Innovative Optics, the number of escrow shares disbursed to Innovative Optics will be reduced by 300 shares for every cent that the materials cost per blade exceeds \$17.25. If Innovative Optics disputes the Company's certification, the dispute will be resolved by arbitration by submitting the matter for resolution to the accounting firm of KPMG LLP.

The Company acquired from Innovative Optics, the raw materials, work in process and finished goods inventories. Additionally, it acquired the furniture and equipment of Innovative Optics used in the manufacturing process of the microkeratome console and the inspection and packaging of the disposable blades. The Company assumed the remaining life of the lease of the office-warehouse facility at \$3,000 per month, which expires in August 2002. The Company did not continue to lease employees per the arrangement in place at the time of purchase. The Company assumed an agreement to purchase the raw blades from Medical Sterile Products, Inc., Puerto Rico, extending through December 2003. The pricing of the raw blades is based upon annual minimum purchase commitments, but the Company is not required to purchase the quantities contained in the pricing model. The Company did not assume any other liabilities.

F-42

PARADIGM MEDICAL INDUSTRIES, INC.
Notes to Financial Statements
Continued

18. Subsequent
Event
Continued

The total purchase price recorded in January 2002 consisted of the number of issued shares of 636,413 at the market price of the common stock as of the acquisition date (\$2.85 per share) of \$1,814,000, the value of the warrants to purchase 250,000 shares of common stock using the Black-Scholes pricing model of \$295,000 and \$100,000 in cash. The escrowed shares will be issued when the conditions of the Agreement have been

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

met, which value will be recorded at the date (s) of issue. The Company valued inventories and equipment purchased at fair market value. The intangible assets of patents, rights and trade names were valued based upon a discounted cash flow analysis of potential and estimated revenues from product and disposable blade sales. None of the purchase price was allocated to the monthly facility lease agreement, which expires in August 2002. Final allocations among goodwill and the separable intangible assets of patents, rights and trade names will be determined when the final number of escrowed shares is issued.

The Company recorded the following:

Inventory	\$	225,000
Property, plant and equipment		35,000
Intangibles:		
Patents, rights, trade name		530,000
Goodwill		1,419,000
Equity:		
Common stock issued		(1,814,000)
Warrants issued		(295,000)

Net cash paid	\$	100,000
		=====

F-43

Item 8. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

None.

PART III

Item 9. Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the Exchange Act.

The executive officers and directors of the Company, their ages and their positions are set forth below:

Name	Age	Position
Thomas F. Motter	53	Chairman of the Board and Chief Executive Officer
Mark R. Miehle	49	President and Chief Operating Officer
Heber C. Maughan	50	Vice President of Finance, Treasurer and Chief Financial
John W. Hemmer	74	Senior Vice President
Randall A. Mackey, Esq.	55	Secretary and Director
David M. Silver, PhD.	59	Director
Keith D. Ignatz	53	Director

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

The directors are elected for one-year terms that expire at the next annual meeting of shareholders. Executive officers are elected annually by the Board of Directors to hold office until the first meeting of the Board following the next annual meeting of shareholders and until their successors have been elected and qualified.

29

Thomas F. Motter has served as Chairman of the Board of the Company since April 1993. Since December 12, 1997 and from May 1994 to August 1997, he has served as President and Chief Executive Officer of the Company. From June 1989 to April 1993, Mr. Motter served as Chief Executive Officer of Paradigm Medical, Inc. which merged with the Company in May 1994. From September 1990 to April 1992, he was employed by HGM Medical Laser Systems as general manager of their International Division. From October 1978 to June 1989, Mr. Motter was employed by SmithKline Beckman's Humphrey Instruments Division, which developed and manufactured advanced ophthalmic diagnostic instruments, serving last as National Sales Manager overseeing all domestic sales in its ophthalmic computer division. Mr. Motter received a B.A. degree in English from Stephen's College in 1970 and an M.B.A. degree from Pepperdine University in 1975.

Mark R. Miehle has served as President and Chief Operating Officer of the Company since June 5, 2000. From December 1997 to June 2000, Mr. Miehle served as President and Chief Executive Officer of Vismed, Inc., d/b/a Dicon, a start-up company. In 1982, Dicon was acquired by CooperVision diagnostics. From 1982 to 1985, Mr. Miehle was the Vice President of Sales and Marketing of CooperVision Diagnostics. Mr. Miehle received a B.S. degree in Organic Chemistry from Tulane University in 1975. He is a member of the Young Presidents' Organization (YPO) and the Vision Industry Council of America (VICA).

Heber C. Maughan has served as Vice President of Finance, Treasurer and Chief Financial Officer since October 2001. From July 1997 to October 2001, Mr. Maughan served as Controller for Peterbilt of Utah, which sells and services heavy duty trucks. From 1989 to 1997, he was employed by First Health Strategies, Inc, where he served as Vice President of Finance from 1995 to 1997. From 1987 to 1989, Mr. Maughan was the Chief Financial Officer at Standard Optical Company, a regional retail eye care chain. Mr. Maughan received a B.S. degree in Accounting from Oklahoma State University in 1976 and an M.A. degree in Accounting from Brigham Young University in 1977.

John W. Hemmer has served as Senior Vice President since September 2001. He previously served as Vice President of Finance, Treasurer and Chief Financial Officer of the Company from September 20, 2000 to September 30, 2001. Mr. Hemmer previously served as Vice President of Finance, Treasurer, Chief Financial Officer and a director of the Company from November 1995 to June 1999. Mr. Hemmer has served as a director and consultant since 1989 and Chief Financial Officer since February 2000 of Bio Marine Technologies, Inc. in Gulf Breeze, Florida, which develops offshore marine production systems licensed and permitted for use in the Gulf of Mexico. He was the President and Chief Executive Officer of John W. Hemmer, Inc., a registered broker/dealer firm from 1987 to 1989, which subsequently changed its name to Westfalia Investments Inc. Prior thereto he was Vice President of Bankers Trust Company in charge of venture capital and a member of the research and investment management committees. Mr. Hemmer was also Vice President of Corporate Finance at Dempsey, Tegler & Company, Inc., a Senior Analyst at Lazard Freres & Company and an Investment Officer of the Chase Manhattan Bank. Mr. Hemmer received a B.A. degree in Economics from Queens College in 1951 and a M.S. degree in Banking and Finance from Columbia University Graduate School of Business in 1952.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Randall A. Mackey, Esq. has been a director of the Company since January 2000. He had served as a director of the Company from November 1995 to September 1998. Mr. Mackey has been president of the Salt Lake City law firm of Mackey Price & Williams since 1992, and a shareholder and director of the firm and its predecessor firms since 1989. Mr. Mackey received a B.S. degree in Economics from the University of Utah in 1968, an M.B.A. degree from Harvard University in 1970, a J.D. degree from Columbia University in 1975 and a B.C.L. degree from Oxford University in 1977. Mr. Mackey has served as Chairman of the Board since June 2001 and a director since 1998 of Cimetrix Incorporated, a software development company. Mr. Mackey has also served as Chairman of the Board since July 2000 and as a trustee since 1993 of Salt Lake Community College.

30

David M. Silver, Ph.D. has been a director of the Company since January 2000. He had served as a director of the Company from November 1995 to September 1998. Dr. Silver is a Principal Senior Scientist in the Milton S. Eisenhower Research and Technology Development Center at the Johns Hopkins University Applied Physics Laboratory, where he has been employed since 1970. He served as the J. H. Fitzgerald Dunning Professor of Ophthalmology in the Johns Hopkins Wilmer Eye Institute in Baltimore during 1998-99. He received a B.S. degree from Illinois Institute of Technology, an M.A. degree from Johns Hopkins University and a Ph.D. degree from Iowa State University before holding a postdoctoral fellowship at Harvard University and a visiting scientist position at the University of Paris.

Keith D. Ignatz was elected as director in November 2000. He has been President and Chief Operating Officer of SpectRx, Inc., a medical technology company that he founded in 1992, which develops, manufactures and markets alternatives to traditional blood-based medical tests. From 1986 to 1992, Mr. Ignatz was Senior Vice President of Allergan Humphrey, Inc., a medical electronics company. From 1985 to 1986, he was President of Humphrey Instruments Limited - SKB, a medical electronics company, and from 1980 to 1985, Mr. Ignatz was President of Humphrey Instruments GmbH, also a medical electronics company. Mr. Ignatz also served on the Board of Directors of Vismed, Inc., d/b/a Dicon from 1992 to June 2000. Mr. Ignatz received a B.A. degree in Sociology and Political Science from San Jose University and an M.B.A. degree from Pepperdine University. Mr. Ignatz has served as a trustee of Pennsylvania College of Optometry since 1990, as a director for FluoRx, Inc. since 1997, and as a member of the American Marketing Association of the American Association of Diabetes Education.

Technical and Medical Advisory Personnel

The Company utilizes an informal Clinical Advisory Board of recognized practicing ophthalmic surgeons in technical and medical advisory capacities. Outside consultants are generally used on an ad hoc basis and such individuals do not meet together as a group and are not compensated. The Members of the Company's Clinical Advisory Board are as follows:

Paul L. Archambeau, M.D. -- Dr. Archambeau is an ophthalmologist in Santa Rosa, California and a faculty member at the University of California at San Francisco. He received his medical degree at the University of Buffalo Medical School in 1959 and performed his residency at the Mayo Clinic in Rochester, Minnesota.

Daniele S. Aron-Rosa, Ph.D, M.D. -- Dr. Aron-Rosa is a faculty member

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

at the Rothschild Eye Institute in Paris, France. She received a doctorate degree in physics from the University of Paris in 1957 and received her medical degree there in 1962 and performed her residency at the University of Paris Hospital.

Richard G. Bowe, M.D. - Dr. Bowe is an ophthalmologist practicing in Tacoma, Washington. He received his medical degree at the University of Washington in 1964 and performed his residency at Brooke Army Medical Center.

J. Charles Casebeer, M.D. - Dr. Casebeer is an ophthalmologist practicing in Divide, Montana. He received his medical degree at the University of Southern California in 1964 and performed his residency at Stanford University.

Jonathan Cress, M.D. - Dr. Cress is an ophthalmologist practicing in Santa Cruz, California.

31

Roger F. Husted, M.D. - Dr. Husted is an ophthalmologist practicing in Monterey, California. He received his medical degree at George Washington University in 1970 and performed his residency at Letterman Army Medical Center.

Stephane P. Ganem, M.D. -- Dr. Ganem is chairman of the ophthalmology department at the Rothschild Eye Institute in Paris, France.

Michael B. Limberg, M.D. -- Dr. Limberg is an ophthalmologist practicing in San Luis Obispo, California. He received his medical degree at the University of Utah Medical School in 1982 and performed his residency at Louisiana State University.

Lawrence E. Noble, M.D. -- Dr. Noble is an ophthalmologist in Provo, Utah. He received his medical degree at the University of Oregon in 1964, and performed his residency at the Good Samaritan Hospital.

Sheldon Rabin, M.D. - Dr. Rabin is an ophthalmologist practicing in Flushing, New York. He received his medical degree at Northwestern University in 1969 and performed his residency at New York University.

David M. Schneider, M.D. -- Dr. Schneider is an ophthalmologist in Cincinnati, Ohio. He received his medical degree at the University of Cincinnati in 1975, and performed his residency at the University of Cincinnati.

David Silver, Ph.D. -- Dr. Silver is a Principal Senior Scientist in the Milton S. Eisenhower Research and Technology Development Center at the Johns Hopkins University Applied Physics Laboratory. He received a Ph.D. degree from Iowa State University.

Gerald Zelman, M.D. -- Dr. Zelman is an Ophthalmologist in Manhasset, New York. He received his medical degree at the University of Lausanne in 1964, and performed his residency at the Brooklyn Eye and Ear facility in Brooklyn, New York.

Board Meetings and Committees

The Board of Directors held a total of six meetings during the fiscal year ended December 31, 2001. The Audit Committee of the Board of Directors consists of directors Dr. David M. Silver, Randall A. Mackey and Keith D. Ignatz. The Audit Committee met twice during the fiscal year. The Audit Committee is primarily responsible for reviewing the services performed by the Company's independent public accountants and internal audit department and

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

evaluating the Company's accounting principles and its system of internal accounting controls. The Compensation Committee of the Board of Directors consists of directors Thomas F. Motter, Dr. David M. Silver, and Randall A. Mackey. The Compensation Committee met three times during the fiscal year. The Compensation Committee is primarily responsible for reviewing compensation of executive officers and overseeing the granting of stock options. No director attended fewer than 75% of all meetings of the Board of Directors during the 2001 fiscal year.

Pursuant to Nasdaq corporate governance requirements recently made applicable to Nasdaq SmallCap Market companies, the Company must have (i) a minimum of two independent directors; (ii) an audit committee with a majority of independent directors; and (iii) an annual stockholders meeting. The Company has and can presently satisfy each of these requirements. Messrs. Ignatz, Silver, and Mackey qualify as independent directors.

32

Item 10. Executive Compensation

The following table sets forth, for each of the last three fiscal years, the compensation received by Thomas F. Motter, Chairman of the Board, and Chief Executive Officer of the Company and other executive officers (collectively, the "Named Executive Officers") whose salary and bonus for all services in all capacities exceed \$100,000 for the fiscal years ended December 31, 2001, 2000 and 1999.

Summary Compensation Table

Name and Principal Position	Period	Annual Compensation		Other Annual Compensation (\$)(6)	Restricted Stock Awards(\$)	Long Term Awards	Lo In Pa
		Salary(\$)	Bonus(\$)			Securities Underlying Options/SARs (8#)	
Thomas F. Motter Chairman of the Board and Chief Executive Officer	2001(1)	\$ 200,000	\$ 22,380(7)	0	0	925,000(9)	
	2000(2)	\$ 178,357	\$ 486,113(6)	0	0		
	1999(3)	\$ 141,208		0	0	50,000(10)	
Mark R. Miehle President and Chief Operating Officer	2001(1)	\$ 150,000	\$ 0	0	0	110,000(9)	
	2000(2)	\$ 235,201	\$ 194,000(8)	0	0	150,000(8)	

(1) For the fiscal year ended December 31, 2001

(2) For the fiscal year ended December 31, 2000

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

(3) For the fiscal year ended December 31, 1999

(4) The amounts under "Other Annual Compensation" for 2001, 2000 and 1999 consist of payments related to the operation of automobiles and/or automobiles and insurance by the named executives.

(5) The amounts under "Other Annual Compensation" for 2000 and 1999 consist of payments related to the residential housing accommodations for the Company's employees, living outside of Utah while they are working at the Company's Corporate headquarters in Salt Lake City, leased from Mr. Motter at \$2,500 per month.

(6) On January 21, 2000, the Board of Directors approved a bonus to Mr. Motter in the form of 38,889 shares of the Company's Common Stock. The bonus was valued at \$486,113 on the basis of the closing bid price of the Company's Common Stock of \$12.50 per share on January 21, 2000, the date the board approved the bonus.

(7) The Company awarded Mr. Motter a cash bonus in June 2001.

(8) On June 5, 2000, the Board of Directors issued Mr. Miehle 28,500 shares of the Company's Common Stock as a initial bonus as part of his employment agreement. The market price on the date of grant as \$6.8125 per share, and compensation expense in the amount of \$194,000 was recognized. Mr. Miehle

33

was also granted options to purchase 150,000 shares of the Company's Common Stock at an exercise price of \$6.00 per share.

(9) On September 11, 2001, the Company granted options to purchase the respective number of shares of the Company's Common Stock at an exercise price of \$2.75 per share.

(10) On September 10, 1999, the Company granted Mr. Motter options to purchase 50,000 shares of the Company's Common Stock at an exercise price of \$4.00 per share.

The following table sets forth information concerning the exercise of options to acquire shares of the Company's Common Stock by the Named Executive Officers during the fiscal year ended December 31, 2001 as well as the aggregate number and value of unexercised options held by the Named Executive Officers on December 31, 2001.

Name	Shares Acquired On Exercise (#)	Value Realized (\$)	Number of Securites Underlying Unexercised Options/SARs At December 31, 2001 (#)		Value In-the- At Dec
			Exercisable	Unexercisable	
Thomas F. Motter	-	-	787,450	225,000	
Mark R. Miehle	-	-	62,500	342,000	

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Director Compensation

On September 11, 2001, Messrs. Randall A. Mackey, Dr. David M. Silver and Keith D. Ignatz, directors of the Company, were each granted options to purchase 125,000 shares of the Company's Common Stock at an exercise price of \$2.75 per share. On September 11, 2001, Messrs. Mackey and Silver were each granted options to purchase 200,000 shares of the Company's Common Stock at an exercise price of \$2.75 per share in consideration for past services as directors of the Company from November 1995 to September 1998 and since January 2000. In addition, outside directors are also reimbursed for their expenses in attending board and committee meetings. Directors are not precluded from serving the Company in any other capacity and receiving compensation therefore. The options were not issued at a discount to the then market price.

Employee 401(k) Plan

In October 1996, the Company's Board of Directors adopted a 401(k) Retirement Savings Plan. Under the terms of the 401(k) plan, effective as of November 1, 1996, the Company may make discretionary employer matching contributions to its employees who choose to participate in the plan. The plan allows the Board to determine the amount of the contribution at the beginning of each year. The Board adopted a contribution formula specifying that such discretionary employer matching contributions would equal 100% of the participating employee's contribution to the plan up to a maximum discretionary employee contribution of 3% of a participating employee's compensation, as defined by the plan. All persons who have completed at least six months' service with the Company and satisfy other plan requirements are eligible to participate in the 401(k) plan.

34

1995 Stock Option Plan

The Company adopted a 1995 Stock Option Plan (the "Plan"), for officers, employees, directors and consultants of the Company on November 7, 1995. The Plan authorized the granting of stock options ("Plan Options") to purchase an aggregate of not more than 300,000 shares of the Company's Common Stock. On February 16, 1996, options for substantially all 300,000 shares were granted. On June 9, 1997, the Company's shareholders approved an amendment to the Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 300,000 shares to 600,000 shares. On September 3, 1998, the Company's shareholders approved an amendment to the Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 600,000 shares to 1,200,000 shares. On November 29, 2000, the Company's shareholders approved an amendment to the Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 1,200,000 shares to 1,700,000 shares. On September 11, 2001, the Company's shareholders approved an amendment to the Plan to increase the number of shares of Common Stock reserved for issuance thereunder from 1,700,000 shares to 2,700,000 shares.

The Plan is administered by the Compensation Committee. In general, the Compensation Committee will select the person to whom options will be granted and will determine, subject to the terms of the Plan, the number, exercise, and other provisions of such options. Options granted under the Plan will become exercisable at such times as may be determined by the Compensation Committee. Plan Options granted may be either incentive stock options ("ISOs"), as such term is defined in the Internal Revenue Code, or non-ISOs. ISOs may only be granted to persons who are employees of the Company. Non-ISOs may be granted to any person, including, but not limited to, employees of the Company, independent agents, consultants as the Compensation Committee believes has contributed, or

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

will contribute, to the success of the Company as the Compensation Committee believes has contributed, or will contribute, to the success of the Company. The Compensation Committee shall determine the exercise price of options granted under the Plan, provided that, in the case of ISOs, such price may not be less than 100% (110% in the case of ISOs granted to holders of 10% of voting power of the Company's stock) of the fair market value (as defined in the Plan) of the Common Stock on the date of grant. The aggregate fair market value (determined at the time of option grant) of stock with respect to which ISOs become exercisable for the first time in any year cannot exceed \$100,000.

The term of each Option shall not be more than 10 years (five years in the case of ISOs granted to holders of 10% of the voting power of the Company's stock) from the date of grant. The Board of Directors has a right to amend, suspend or terminate the Plan at any time; provided, however, that unless ratified by the Company's shareholders, no amendment or change in the Plan will be effective which would increase the total number of shares which may be issued under the Plan, materially increase the benefits accruing to persons granted under the Plan or materially modify the requirements as to eligibility and participation in the Plan. No amendment, supervision or termination of the Plan shall, without the consent of an employee to whom an option shall heretofore have been granted, affect the rights of such employee under such option.

Employment Agreements

The Company entered into an employment agreement with Thomas F. Motter, which commenced on January 1, 1998 and expires on December 31, 2003. The agreement requires Mr. Motter to devote substantially all of his working time to the Company, provided that he may be terminated for "cause" (as provided in the agreements) and prohibits him from competing with the Company for two years

35

following the termination of his employment agreement. The agreement provides for the payment of an initial base salary of \$135,000, effective as of January 1, 1998. The agreement also provides for salary increases and bonuses as shall be determined at the discretion of the Board of Directors. Effective as of October 1, 1999, the Board of Directors approved an increase in Mr. Motter's annual base salary to \$160,000, and effective as of July 1, 2000, the board approved an increase in his annual base salary to \$200,000 which remained in effect at the end of 2001.

The Company entered into an employment agreement with Mark R. Miehle, which commenced on June 5, 2000 and will expire on June 4, 2003. The agreement requires Mr. Miehle to devote substantially all of his working time to the Company, provided that he may be terminated for "cause" (as provided in the agreement) and prohibits him from competing with the Company for two years following the termination of his employment agreement. The agreement provides for the payment of an initial annual base salary of \$150,000, effective as of June 5, 2000, and the issuance of stock options to purchase 150,000 shares of the Company's Common stock at \$6.00 per share, to be vested in equal annual amounts over a three year period. The agreement also provides for salary increases and bonuses as shall be determined at the discretion of the Board of Directors. Mr. Miehle exceeded the annual base in 2000 due to compensation received prior to the effective date of the agreement. The stated annual compensation remained in effect through December 31, 2001.

Limitation of Liability and Indemnification

The Company re-incorporated in Delaware in February 1996, in part, to take advantage of certain provisions in Delaware's corporate law relating to

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

limitations on liability of corporate officers and directors. The Company believes that the re-incorporation into Delaware, the provisions of its Certificate of Incorporation and Bylaws and the separate indemnification agreements outlined below are necessary to attract and retain qualified persons as directors and officers. The Company's Certificate of Incorporation limits the liability of directors to the maximum extent permitted by Delaware law. This provision is intended to allow the Company's directors the benefit of Delaware General Corporation Law which provides that directors of Delaware corporations may be relieved of monetary liabilities for breach of their fiduciary duties as directors, except under certain circumstances, including breach of their duty of loyalty, acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, unlawful payments of dividends or unlawful stock repurchases or redemption's or any transaction from which the director derived an improper personal benefit. The Company's Bylaws provide that the Company shall indemnify its officers and directors to the fullest extent provided by Delaware law. The Bylaws authorize the use of indemnification agreements and the Company has entered into such agreements with each of its directors and executive officers.

There is no pending litigation or proceeding involving a director, officer, employee or other agent of the Company as to which indemnification is being sought, nor is the Company aware of any threatened litigation that may result in claims for indemnification by any director, officer, employee or other agent.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

36

Compliance with Section 16(a) of the Securities and Exchange Act of 1934

Section 16(a) of the Securities Exchange Act of 1934 requires the Company's executive officers, directors and persons who own more than 10% of any class of the Company's Common Stock to file initial reports of ownership and reports of changes of ownership of the Company's Common Stock. For fiscal 2001, Thomas F. Motter, Chairman and Chief Executive Officer, through an oversight, filed one late stock transaction report covering one transaction, and Dr. David M. Silver, a director of the Company, through an oversight, filed one late stock transaction report covering two transactions. In addition, Keith D. Ignatz, a director of the Company, through an oversight, filed late an initial statement of beneficial ownership of securities. No other late filings occurred during 2001.

Item 11. Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information with respect to beneficial ownership of the Company's Common Stock as of March 31, 2002 for (i) each executive officer of the Company (ii) each director, (iii) each person known to the Company to be the beneficial owner of more than 5% of the outstanding shares, and (iv) all directors and officers as a group.

Name and Address(1)	Number of Shares	Percent of Ownership
Thomas F. Motter(2)	1,413,020	8.3%

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Mark R. Miehle(3)	338,966	2.0
John W. Hemmer(4)	106,013	*
Dr. David M. Silver(5)	505,666	3.0
Randall A. Mackey(5)	495,000	2.9
Keith D. Ignotz(6)	204,560	1.2
Heber C. Maughan(7)	30,000	*
Mentor Corporation	761,651	4.5
Executive officers and directors as a group (7 persons)	3,854,876	22.7%

*Less than 1%.

(1) The address for Messrs. Motter and Maughan is c/o Paradigm, 2355 South 1070 West, Salt Lake City, UT, 84119. The address for Mr. Miehle is 10373 Roselle Street, San Diego, California 92121. The address for Mr. Hemmer is 88 Meadow Road, Briarcliff Manor, New York 10510. The address for Dr. Silver is 17 Avalon Court, Bethesda, Maryland 20816. The address for Mr. Mackey is 1474 Harvard Avenue, Salt Lake City, Utah 84105. The address for Mr Ignotz is 6025-A Unity Dr., Norcross, Georgia 30071.

(2) Includes options to purchase 312,450 shares of Common Stock granted to Mr. Motter under the 1995 Option Plan and options to purchase 700,000 shares of Common Stock granted to Mr. Motter by the Company on September 11, 2001.

(3) Includes options to purchase 260,000 shares of Common Stock granted to Mr. Miehle under the Company's 1995 Option Plan.

(4) Includes options to purchase 100,000 shares of Common Stock granted to Mr. Hemmer.

37

(5) Includes options to purchase 495,000 shares of Common Stock granted to each of Dr. Silver and Mr. Mackey.

(6) Includes options to purchase 203,851 shares of Common Stock granted to Mr. Ignotz.

(7) Includes options to purchase 30,000 shares of Common Stock granted to Mr. Maughan.

Item 12. Certain Relationships and Related Transactions

The information set forth herein describes certain transactions between the Company and certain affiliated parties. Future transactions, if any, will be approved by a majority of the disinterested members of the Company and will be on terms no less favorable to the Company than those that could be obtained from unaffiliated parties.

On October 1, 1999, the Company entered into a consulting agreement with Cyndel & Company, Inc. ("Cyndel"), in which Cyndel agreed to perform unspecified investment banking services for the Company for a one-year period, for which the Company agreed to pay Cyndel a monthly retainer of \$8,333, plus reimburse Cyndel for any expenses incurred in connection with such investment banking services. Patrick M. Kolenick, a director of the Company from November 1977 to January 21, 2000, and Steven J. Bayern, a director of the Company from July 1999 to January 21, 2000, are each an officer, a director and a 50% shareholder of Cyndel. The Company paid \$33,333 in fees to Cyndel during 1999.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

The October 1, 1999 consulting agreement was terminated when the Company entered into a new consulting agreement with Cyndel on April 1, 2000. Under the terms of the April 1, 2000 consulting agreement, Cyndel agreed to perform unspecified investment banking services for the Company for a one-year period, for which the Company agreed to pay Cyndel a monthly retainer of \$16,667, plus reimburse Cyndel for any expenses incurred in connection with such investment banking services.

Besides a monthly retainer, the Company has agreed in the April 1, 2000 consulting agreement to pay Cyndel additional compensation of an unspecified amount to be mutually agreed upon if Cyndel brings to the Company a candidate for merger, acquisition, joint venture or other combination or relationship, and the Company enters into a business relationship with such entity. The April 1, 2000 consulting agreement is automatically renewable for additional, successive one-year periods through March 31, 2003, unless either party delivers to the other party on or before January 1 of the contract year written notice of its intent not to renew the agreement.

Under the terms of the April 1, 2000 consulting agreement, the Company paid Cyndel approximately \$182,000 in consulting fees during 2000. In addition, the Company paid \$500,000 and issued warrants to purchase 150,000 shares of common stock at an exercise price of \$4.00 per share as commission for the private placement transaction in which 750,000 shares of common stock were sold for net proceeds of approximately \$1,974,000. The warrants issued and the commissions paid were considered direct costs of capital, therefore no expense was recorded but such amounts were recorded as a direct reduction of capital.

The April 1, 2000 consulting agreement was renewed for an additional one-year period through March 2002. However, on December 26, 2001, the Company provided written notification to Cyndel of its intention not to renew the agreement after March 31, 2002. The total amount paid to Cyndel for services under the agreement from April 1, 2000 to February 28, 2002 was \$383,333. Final payment of \$16,667, which was due on March 1, 2002, has not yet been paid.

38

Thomas F. Motter, Chairman of the Board and Chief Executive Officer of the Company, leased his former residence, which he still owns, to the Company for \$2,500 per month. The primary use of the residential property was for housing accommodations for the Company's employees living outside of Utah while they were working at the Company's corporate headquarters in Salt Lake City. The Company has obtained an appraisal from an independent appraiser, which has concluded that the monthly rate of \$2,500 represents the fair market rate for leasing the residential property. This lease agreement was terminated on October 31, 2000.

On January 21, 2000, the Board of Directors granted Mr. Motter, Chairman and Chief Executive Officer of the Company, 100,000 shares of the Company's common stock. Of these total shares, 61,111 shares were considered repayment for 61,111 shares Mr. Motter that previously issued to Dr. Douglas A. MacLeod prior to the Company's initial public offering in July 1996 under a settlement agreement to terminate certain anti-dilution rights that the Company granted Dr. MacLeod. The balance of 38,889 shares was deemed by the Board as a bonus for work done by Mr. Motter since the initial public offering. The market price on the date of grant was \$12.50 per share, and compensation expense in the amount of \$486,000 was recognized.

On January 21, 2000 the Board of Directors granted Michael W. Stelzer, formerly the Vice President of Operations and Chief Operating Officer of the Company, 20,000 shares of Paradigm common stock as severance under the terms of

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

a settlement of Mr. Stelzer's employment agreement. The market price on the date of grant was \$12.50 per share, and compensation expense in the amount of \$250,000 was recognized.

On June 5, 2000 the Company issued Mark Miehle 28,500 shares of Paradigm common stock as a bonus for entering into an employment agreement with the Company. The market price of the Paradigm common stock on the day the shares were granted to Mr. Miehle was \$6.81 per share, and compensation expense in the amount of \$194,000 was recognized.

Randall A. Mackey, a director of the Company since January 21, 2000, and a former director of the Company from September 1995 to September 3, 1998, is President and a shareholder of the law firm of Mackey Price & Williams, which rendered legal services to the Company in connection with various corporate matters. Legal fees and expenses paid to Mackey Price & Williams for the fiscal years ended December 31, 2001 and 2000 totaled \$158,990 and \$167,022, respectively.

PART IV

Item 13. Exhibits and Reports on Form 8-K

(a) Exhibits

The following Exhibits are filed herewith pursuant to Rule 601 of Regulation S-B or are incorporated by reference to previous filings.

Table No. -----	Document -----
2.1	Amended Agreement and Plan of Merger between Paradigm Medical Industries, Inc., a California corporation and Paradigm Medical Industries, Inc., a Delaware corporation(1)
3.1	Certificate of Incorporation(1)
3.2	Amended Certificate of Incorporation(16)
39	
3.3	Bylaws(1)
4.1	Warrant Agency Agreement with Continental Stock Transfer & Trust Company (3)
4.2	Specimen Common Stock Certificate (2)
4.3	Specimen Class A Warrant Certificate(2)
4.4	Form of Class A Warrant Agreement(2)
4.5	Underwriter's Warrant with Kenneth Jerome & Co., Inc.(3)
4.6	Warrant to Purchase Common Stock with Note Holders re bridge financing (1)
4.7	Warrant to Purchase Common Stock with Mackey Price & Williams (1)
4.8	Specimen Series C Convertible Preferred Stock Certificate(4)
4.9	Certificate of the Designations, Powers, Preferences and Rights of the Series Convertible Preferred Stock(4)
4.10	Specimen Series D Convertible Preferred Stock Certificate (7)
4.11	Certificate of the Designations, Powers, Preferences and Rights of the Series D Convertible Preferred Stock (10)
4.12	Warrant to Purchase Common Stock with Cyndel & Co. (7)
4.13	Warrant Agreement with KSH Investment Group, Inc. (7)
4.14	Warrant to Purchase Common Stock with R.F. Lafferty & Co., Inc.

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

- (7)
- 4.15 Warrant to Purchase Common Stock with Dr. David B. Limberg (10)
 - 4.16 Warrant to Purchase Common Stock with John W. Hemmer (10)
 - 4.17 Stock Purchase Warrant with Triton West Group, Inc.(12)
 - 4.18 Warrant to Purchase Common Stock with KSH Investment Group, Inc. (12)
 - 4.19 Warrants to Purchase Common Stock with Consulting for Strategic Growth, Ltd.(12)
 - 10.1 Exclusive Patent License Agreement with Photomed(1)
 - 10.2 Consulting Agreement with Dr. Daniel M. Eichenbaum(1)
 - 10.3 Lease with Eden Roc (4)
 - 10.4 1995 Stock Option Plan and forms of Stock Option Grant Agreement (1)
 - 10.5 Form of Promissory Note with Note Holders re bridge financing (1)
 - 10.6 Co-Distribution Agreement with Pharmacia & Upjohn Company and National Healthcare Manufacturing Corporation (5)
 - 10.7 Agreement for Purchase and Sale of Assets with Humphrey Systems Division of Carl Zeiss, Inc. (5)
 - 10.8 Employment Agreement with Thomas F. Motter (6)
 - 10.9 Asset Purchase Agreement with Mentor Corp., Mentor Ophthalmics, Inc. and Mentor or Medical, Inc. (8)
 - 10.10 Transition Services Agreement with Mentor Corp., Mentor Ophthalmics, Inc., and Mentor Medical, Inc. (8)
 - 10.11 Severance Agreement and General Release with Michael W. Stelzer (8)
 - 10.12 Consulting Agreement with Dr. Michael B. Limberg (8)
 - 10.13 Renewed Consulting Agreement with Dr. Michael B. Limberg (10)
 - 10.14 Mutual Release and Settlement Agreement with Zevex International, Inc. (8)
 - 10.15 Consulting Agreement with Douglas Adams (8)
 - 10.16 Agreement and Plan of Reorganization with Paradigm Subsidiary, Inc., and Vismed, Inc. d/b/a Dicon (9)
 - 10.17 Agreement and Plan of Merger with Paradigm Subsidiary, Inc. and Vismed Inc. d/b/a Dicon (9)
 - 10.18 Registration Rights Agreement with Paradigm Subsidiary, Inc. and certain shareholders of Vismed, Inc. d/b/a Dicon (9)
 - 10.19 Indemnification Agreement with Paradigm Subsidiary, Inc. and certain shareholders of Vismed, Inc. d/b/a Dicon (9)
 - 10.20 Consulting Agreement with Cyndel & Co., Inc. (10)
 - 10.21 Stock Purchase Agreement with Occular Blood Flow, Ltd. and Malcolm Redman (10)
 - 10.22 Consulting Agreement with Malcolm Redman (10)
 - 10.23 Royalty Agreement with Malcolm Redman (10)
- 40
- 10.24 Registration Rights with Malcolm Redman (10)
 - 10.25 Agreements with Steven J. Bayern and Patrick M. Kolenik (11)
 - 10.26 Employment Agreement with Mark R. Miehle (12)
 - 10.27 Employment Agreement with John W. Hemmer (12)
 - 10.28 Private Equity Line of Credit Agreement with Triton West Group, Inc. (12)
 - 10.29 Renewed Consulting Agreement with Dr. Michael B. Limberg (12)
 - 10.30 Agreement with KSH Investment Group, Inc. (12)
 - 10.31 Renewed Consulting Agreement with Dr. Michael B. Limberg (13)
 - 10.32 Settlement Agreement with Mentor Corporation (13)
 - 10.33 Consulting Agreement with Rodman & Renshaw, Inc. (13)
 - 10.34 Consulting Agreement with Barry Kaplan Associates (14)
 - 10.35 Asset Purchase Agreement with Innovative Optics, Inc. and Barton Dietrich Investments, L.P. (15)
 - 10.36 Escrow Agreement with Innovative Optics, Inc. and Barton Dietrich

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

- Investments, L.P. (15)
- 10.37 Assignment and Assumption Agreement with Innovative Optics, Inc. (15)
- 10.38 General Assignment and Bill of Sale with Innovative Optics, Inc. (15)
- 10.39 Non-competition and Confidentiality Agreement with Mario F. Barton (15)

- (1) Incorporated by reference from Registration Statement on Form SB-2, as filed on March 19, 1996.
- (2) Incorporated by reference from Amendment No. 1 to Registration Statement on Form SB-2, as filed on May 14, 1996.
- (3) Incorporated by reference from Amendment No. 2 to Registration Statement on Form SB-2, as filed on June 13, 1996.
- (4) Incorporated by reference from Annual Report on Form 10-KSB, as filed on April 16, 1998.
- (5) Incorporated by reference from Quarterly Report on Form 10-QSB, as filed on August 1, 1998.
- (6) Incorporated by reference from Quarter Report on Form 10-QSB, as filed on November 12, 1998.
- (7) Incorporated by reference from Registration Statement on Form SB-2, as filed on April 29, 1999.
- (8) Incorporated by reference from Annual Report on Form 10-KSB, as filed on March 30, 2000.
- (9) Incorporated by reference from Form 8-K, as filed on June 5, 2000.
- (10) Incorporated by reference from Report on Form 10-QSB, as filed on August 16, 2000.
- (11) Incorporated by reference from Report on Form 10-QSB, as filed on November 1, 2000.
- (12) Incorporated by reference from Report on Form 10-KSB, as filed on April 16, 2001.
- (13) Incorporated by reference from Report on Form 10-QSB, as filed on August 14, 2001.
- (14) Incorporated by reference from Report on Form 10-QSB, as filed on November 14, 2001.
- (15) Incorporated by reference from Current Report on Form 8-K, as filed on March 5, 2002.
- (16) Incorporated by reference from Amendment No. 1 to Registration Statement on Form S-3, as filed on March 20, 2002.

(b) Reports on Form 8-K

No reports on Form 8-K were filed by the Company during the quarter ended December 31, 2001.

41

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PARADIGM MEDICAL INDUSTRIES, INC.

Dated: June 4, 2002

By: /s/ Thomas F. Motter

Edgar Filing: PARADIGM MEDICAL INDUSTRIES INC - Form PRE 14A

Thomas F. Motter, Chairman of the
Board and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed by the following persons in counterpart on behalf of
the Company on the dates indicated.

Signature	Title	Date
/s/Thomas F. Motter -----	Chairman of the Board and Chief Executive Officer (Principal Executive Officer)	June 4, 2002
/s/Heber C. Maughan -----	Vice President of Finance, Treasurer and Chief Financial Officer (Principal Financial and Accounting Officer)	June 4, 2002
/s/Randall A. Mackey, Esq. -----	Secretary and Director	June 4, 2002
/s/David M. Silver, Ph.D -----	Director	June 4, 2002
/s/Keith D. Igotz -----	Director	June 4, 2002